WO1999029693A1 - Imidazonaphthyridines and their use in inducing cytokine biosynthesis - Google Patents

Imidazonaphthyridines and their use in inducing cytokine biosynthesis Download PDF

Info

Publication number
WO1999029693A1
WO1999029693A1 PCT/US1998/026473 US9826473W WO9929693A1 WO 1999029693 A1 WO1999029693 A1 WO 1999029693A1 US 9826473 W US9826473 W US 9826473W WO 9929693 A1 WO9929693 A1 WO 9929693A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclyl
group
Prior art date
Application number
PCT/US1998/026473
Other languages
French (fr)
Other versions
WO1999029693A8 (en
Inventor
Kyle J. Lindstrom
John F. Gerster
Original Assignee
Minnesota Mining And Manufacturing Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA2000074070A priority Critical patent/UA67760C2/en
Priority to EP98963888A priority patent/EP1040112B1/en
Priority to PL98341159A priority patent/PL193915B1/en
Priority to NZ504776A priority patent/NZ504776A/en
Priority to SK5035-2007A priority patent/SK286304B6/en
Priority to HU0101155A priority patent/HUP0101155A3/en
Priority to IL13655698A priority patent/IL136556A0/en
Priority to KR1020037016102A priority patent/KR100642702B1/en
Priority to JP2000524286A priority patent/JP4283438B2/en
Priority to EEP200000349A priority patent/EE04314B1/en
Priority to AU19123/99A priority patent/AU753864B2/en
Priority to AT98963888T priority patent/ATE277046T1/en
Priority to KR1020007006369A priority patent/KR100642703B1/en
Priority to BR9814275-5A priority patent/BR9814275A/en
Application filed by Minnesota Mining And Manufacturing Company filed Critical Minnesota Mining And Manufacturing Company
Priority to DE69826518T priority patent/DE69826518T2/en
Priority to DK04022441T priority patent/DK1512686T3/en
Priority to DK98963888T priority patent/DK1040112T3/en
Priority to KR1020037016103A priority patent/KR100563175B1/en
Priority to SK835-2000A priority patent/SK285872B6/en
Priority to SI9830711T priority patent/SI1040112T1/en
Priority to CA2311456A priority patent/CA2311456C/en
Publication of WO1999029693A1 publication Critical patent/WO1999029693A1/en
Priority to NO20002663A priority patent/NO316687B1/en
Priority to HR20000363A priority patent/HRP20000363B1/en
Priority to IL136556A priority patent/IL136556A/en
Priority to NO20035719A priority patent/NO20035719D0/en
Priority to NO20035718A priority patent/NO328045B1/en
Publication of WO1999029693A8 publication Critical patent/WO1999029693A8/en
Priority to IL178092A priority patent/IL178092A/en
Priority to IL178091A priority patent/IL178091A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Definitions

  • This invention relates to imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds, processes for making these compounds and intermediates used in their preparation.
  • This invention additionally relates to pharmaceutical compositions containing imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds.
  • a further aspect of this invention relates to the use of these compounds as inimunomodulators and for inducing cytokine biosynthesis in animals.
  • this invention provides imidazonaphthyridine compounds of Formula I:
  • R t and R 2 are as defined hereinafter.
  • the invention also provides tetrahydroimidazonaphthyridine compounds of Formula II:
  • the compounds of Formula I and Formula II are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune reponse when administered to animals. This ability makes the compounds useful in the treatment of a variety of conditions, e.g. viral diseases and tumors that are responsive to such changes in the immune response.
  • the invention further provides pharmaceutial compositions containing a compound of Formula I or Formula II and methods of inducing cytokine biosynthesis in an animal and/or treating a viral infection in an animal by administering a compound of Formula I or Formula II to the animal.
  • the invention provides a method of inducing interferon biosynthesis in an animal comprising the step of administering to said animal a compound of Formula I or Formula II in an amount effective to induce said interferon biosynthesis, and a method of treating a viral infection in an animal comprising the step of administering to said animal a compound of Formula I or Formula II in an amount effective to inhibit the viral infection.
  • Ri is selected from the group consisting of: - hydrogen;
  • Q is -CO- or - SO 2 -;
  • X is a bond, -O- or -NR 3 - and
  • R 4 is aryl; heteroaryl; heterocyclyl; or -C 1-20 alkyl or C 2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
  • Y is -N- or -CR-;
  • R 2 is selected from the group consisting of: -hydrogen; -C ⁇ -10 alkyl; -C 2- ⁇ o alkenyl;
  • each R 3 is independently selected from the group consisting of hydrogen and C 1-10 alkyl; .and each R is independently selected from the group consisting of hydrogen, Ci-io alkyl, C MO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
  • This invention also provides compounds of Formula II
  • B is -NR-C(R) 2 -C(R) 2 -C(R) 2 -; -C(R) 2 -NR-C(R) 2 -C(R) 2 -;
  • Ri is selected from the group consisting of: - hydrogen;
  • X is a bond, -O- or -NR 3 - and R4 is aryl; heteroaryl; heterocyclyl; or -C ⁇ -2 o alkyl or C 2-2 o alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
  • Y is -N- or -CR-;
  • R 2 is selected from the group consisting of: -hydrogen;
  • each R 3 is independently selected from the group consisting of hydrogen and C M O alkyl; and each R is independently selected from the group consisting of hydrogen, Ci-io alkyl, C MO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
  • alkyl As used herein, the terms “alkyl”, “alkenyl”, and the prefix “-alk” are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. These cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopentyl, cyclohexyl and adamantyl.
  • aryl as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl .and indenyl.
  • heteroaryl includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, tetrazolyl, imid.azo, .and so on.
  • Heterocyclyl includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N).
  • exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thi-azolidinyl, and imidazolidinyl.
  • the aryl, heteroaryl and heterocyclyl groups may be unsubstituted or substituted by one or more substituents selected from the group consisting of C 1-2 0 alkyl, hydroxy, halogen, N(R 3 ) 2 , NO , C 1-2 o alkoxy, C ⁇ - 0 alkylthio, trihalomethyl, C ⁇ -20 acyl, arylcarbonyl, heteroarylcarbonyl, (C ⁇ -10 alkyl)o- ⁇ -aryl, (C ⁇ - ⁇ oalkyl)o- ⁇ -heteroaryl, nitrile, C ⁇ - 2 o alkoxycarbonyl, oxo, arylalkyl wherein the alkyl group has from 1 to 10 carbon atoms, and heteroarylalkyl wherein the alkyl group has from 1 to 10 carbon atoms.
  • the invention is inclusive of the compounds described herein in .any of their ph.armaceutically acceptable forms, including isomers such as diastereomers and enantiomers, salts, solvates, polymorphs, and the like. Preparation of the Compounds
  • Reaction Scheme I a 2-aminonicotinic acid of Formula III is reacted with acetic anhydride by heating to provide a 2-methyl-4H-pyrido[2,3--i][l,3]oxazin-4-one of Formula IV.
  • R is hydrogen
  • the compound of Formula IV where R is hydrogen is known and its preparation has been disclosed in U.S. Patent No. 3,314,941 (Littell), the disclosure of which is incorporated herein by reference.
  • step (2) of Reaction Scheme I a compound of Formula IV is reacted with sodium .azide in a suitable solvent such as acetic acid to provide a tetrazolyl nicotinic acid of Formula V.
  • the reaction conveniently may be run at ambient conditions.
  • step (3) of Reaction Scheme I an acid of Formula V is esterified to provide a compound of Formula VI.
  • the esterification may be carried out using conventional methods.
  • the acid may be esterified in acetone using potassium carbonate and ethyl iodide.
  • a compound of Formula VI is cyclized to provide a tetrazolo[l,5- ⁇ ][l,8]naphthyridin-5-ol of Formula VII.
  • the reaction may be carried out by reacting the compound of Formula VI with an alkoxide in a suitable solvent, e.g., potassium ethoxide in N,N-dimethylformamide, at ambient conditions.
  • step (5) of Reaction Scheme I a compound of Formula VII is nitrated using a suitable nitrating agent such as nitric acid to provide a 4-nitrotetrazolo[l,5 ⁇ ⁇ ][l,8]naphthyridin-5-ol of Formula VIII.
  • step (6) of Reaction Scheme I a compound of Formula VIII is converted to a triflate of Formula IX.
  • the reaction is preferably carried out by combining a compound of Formula VIII with a base, preferably a tertiary amine such as triethyl amine, in a suitable solvent such as dichloromethane and then adding trifluoromethanesulfonic anhydride.
  • the addition is preferably carried out in a controlled manner, e.g., adding dropwise at a reduced temperature such as, for example, at about 0°C.
  • the product can be isolated by conventional methods or it can be carried on without isolation as described below in connection with step (7).
  • step (7) of Reaction Scheme I a compound of Formula IX is reacted with an amine of formula R ⁇ NH 2 where Ri is as defined above to provide a 4-nitrotetrazolo[l,5- ⁇ ][l,8]naphthyridin-5-amine of Formula X.
  • the reaction can be carried out by adding the amine to the reaction mixture resulting from step (6).
  • the reaction can also be carried out by adding the amine to a solution of the compound of Formula IX and a tertiary amine in a suitable solvent such as dichloromethane.
  • step (8) of Reaction Scheme I a compound of Formula X is reduced to provide a tetrazolo[l,5- ⁇ ][l,8]naphthyridin-4,5-diamine of Formula XL
  • the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon.
  • the reaction can conveniently be carried out on a Pan apparatus in a suitable solvent such as ethanol.
  • a compound of Formula XI is reacted with a carboxylic acid or an equivalent thereof to provide a 7H-tetrazolo[l,5- ⁇ ]imidazo[4,5- c][l,8]naphthyridine of Formula XII.
  • Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates.
  • the carboxylic acid or equivalent is selected such that it will provide the desired R 2 substituent in a compound of Formula XII. For example, diethoxymethylacetate will provide a compound where R 2 is hydrogen and valeryl chloride will provide a compound where R 2 is butyl.
  • the reaction can be run in the absence of solvent, in a carboxylic acid such as acetic acid, or in an inert solvent in the presence of a carboxylic acid.
  • the reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
  • step (10) of Reaction Scheme I a compound of Formula XII is reacted with triphenylphosphine to provide a N-triphenylphosphinyl-iH-imidazo[4,5- c][l,8]naphthyridin-4- .amine of Formula XIII.
  • the reaction can be carried out by combining a compound of Formula XII with triphenylphosphine in a suitable solvent such as 1 ,2-dichlorobenzene and heating.
  • step (11) of Reaction Scheme I a compound of Formula XIII is hydro lyzed to provide a 7H-imidazo[4,5-c][l,8]naphthyridin-4-amine of Formula XIV which is a subgenus of Formula I.
  • the hydrolysis can be carried out by conventional methods such as by heating in a lower alkanol in the presence of an acid.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (12) of Reaction Scheme I a compound of Formula XIV is reduced to provide a 6,7,8,9-tetrahydro-77J-imidazo[4,5-c][l,8]naphthyridin-4-amine of Formula XV which is a subgenus of Formula II.
  • the reduction is carried out by suspending or dissolving a compound of Formula XIV in trifluoroacetic acid, adding a catalytic amount of platinum (IV)oxide, and then subjecting the mixture to hydrogen pressure.
  • the reaction can be conveniently carried out in a Pan apparatus.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • amine of Formula XV can be prepared by reduction of a compound of Formula XII. The reduction is carried out by suspending or dissolving a compound of Formula XII in trifluoroacetic acid, adding a catalytic amount of platinum (IV)oxide, and then subjecting the mixture to hydrogen pressure. The reaction can be conveniently carried out in a Pan apparatus. As above, the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • R, R ⁇ and R 2 are as defined above can be prepared according to Reaction Scheme II.
  • step (1) of Reaction Scheme II a 3-aminoisonicotinic acid of Formula XVI is reacted with acetic anhydride by heating to provide a 2-methyl- H-pyrido[3,4- £tj[l,3]oxazin-4-one of Formula XVII.
  • R is hydrogen
  • step (2) of Reaction Scheme II a compound of Formula XVII is reacted with sodium azide in a suitable solvent such as acetic acid to provide a tetrazolyl isonicotinic acid of Formula XVIII.
  • the reaction conveniently may be run at ambient conditions.
  • step (3) of Reaction Scheme II an acid of Formula XVIII is esterified to provide a compound of Formula XIX.
  • the esterification may be carried out using conventional methods.
  • the acid may be esterified in acetone using potassium carbonate and ethyl iodide or by reacting with dimethylformamide diethyl acetal in a suitable solvent such as dichloromethane.
  • step (4) of Reaction Scheme II a compound of Formula XIX is cyclized to provide a tetrazolo[l,5- ⁇ ][l,7]naphthyridin-5-ol of Formula XX.
  • the reaction may be carried out by reacting the compound of Formula XIX with an alkoxide in a suitable solvent, e.g., potassium ethoxide in N,N-dimethylformamide, at ambient conditions.
  • a compound of Formula XX is chlorinated using a suitable chlorinating agent such as thionyl chloride, oxalyl chloride, phosphorus pentachloride or preferably phosphorus oxychloride to provide a 5-chlorotetrazolo[l,5- fl][l,7]naphthyridine of Formula XXI.
  • a suitable chlorinating agent such as thionyl chloride, oxalyl chloride, phosphorus pentachloride or preferably phosphorus oxychloride to provide a 5-chlorotetrazolo[l,5- fl][l,7]naphthyridine of Formula XXI.
  • the reaction can be carried out in an inert solvent or if appropriate in neat chlorinating agent.
  • Preferred reaction conditions involve reaction in neat phosphorus oxychloride with heating at about 90°C.
  • step (6) of Reaction Scheme II a compound of Formula XXI is reacted with an amine of formula R1NH 2 where Rj is as defined above to provide a tetrazolo[l,5- ⁇ ][l,7]naphthyridin-5-amine of Formula XXII.
  • the reaction can be carried out by heating with an excess of the amine.
  • step (7) of Reaction Scheme II a compound of Formula XXII is nitrated using a suitable nitrating agent such as nitric acid to provide a 4-nitrotetrazolo[l,5- ⁇ ][l,7]naphthyridin-5-amine of Formula XXIII.
  • the reaction is carried out in acetic acid with mild heating and .an excess of nitric acid.
  • step (8) of Reaction Scheme II a compound of Formula XXIII is reduced to provide a tetrazolo[ 1 ,5-a] [ 1 ,7]naphthyridin-4,5-diamine of Formula XXIV.
  • the reduction is carried out using an excess of sodium hydrogensulfide in a suitable solvent such as acetic acid.
  • step (9) of Reaction Scheme II a compound of Formula XXIV is reacted with a carboxylic acid or an equivalent thereof to provide a 7H-tetrazolo[l,5- ⁇ ]imidazo[4,5- c][l,7]naphthyridine of Formula XXV.
  • Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R substituent in a compound of
  • diethoxymethylacetate will provide a compound where R 2 is hydrogen and valeryl chloride will provide a compound where R 2 is butyl.
  • the reaction can be run in the absence of solvent, in a carboxylic acid such as acetic acid, or in an inert solvent in the presence of a carboxylic acid. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
  • step (10) of Reaction Scheme II a compound of Formula XXV is reacted with triphenylphosphine to provide a N-triphenylphosphinyl-7H-imidazo[4,5- c][l,7]naphthyridin-4-amine of Formula XXVI.
  • the reaction can be carried out by combining a compound of Formula XXV with triphenylphosphine in a suitable solvent such as 1 ,2-dichlorobenzene and heating.
  • step (11) of Reaction Scheme II a compound of Formula XXVI is hydro lyzed to provide a 7H-imidazo[4,5-c][l,7]naphthyridin-4-amine of Formula XXVII which is a subgenus of Formula I.
  • the hydrolysis can be carried out by conventional methods such as by heating in a lower alkanol in the presence of an acid.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (12) of Reaction Scheme II a compound of Formula XXVII is reduced to provide a 6,7,8,9-tetrahydro-77J-imidazo[4,5-c][l,7]naphthyridin-4- .
  • amine of Formula XXVIII which is a subgenus of Formula II.
  • the reduction is carried out by suspending or dissolving a compound of Formula XXVII in trifluoroacetic acid, adding a catalytic amount of platinum (IV)oxide, and then subjecting the mixture to hydrogen pressure.
  • the reaction can be conveniently carried out in a Pan apparatus.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • a 6,7,8,9- tetrahydro-77/-imidazo[4,5-c][l,7]naphthyridin-4-amine of Formula XXVIII can be prepared by reduction of a compound of Formula XXV.
  • the reduction is carried out by suspending or dissolving a compound of Formula XXV in trifluoroacetic acid, adding a catalytic amount of platinum (IV)oxide, and then subjecting the mixture to hydrogen pressure.
  • the reaction can be conveniently carried out in a Parr apparatus.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (1) of Reaction Scheme III a 3-nitro[l,5]naphthyridin-4-ol of Formula XXIX is chlorinated using a suitable chlorinating agent such as phosphorus oxychloride to provide a 4-chloro-3-nitro[l,5]naphthyridine of Formula XXX.
  • the reaction can be carried out by reacting a compound of Formula XXIX with phosphorus oxychloride in a suitable solvent such as N,N-dimethylformamide with mild heating (-55° C).
  • the compound may be isolated by conventional methods or it can be carried on without isolation as described below in connection with step (2).
  • the compound of Formula XXIX where R is hydrogen is known and its preparation has been disclosed in Hart,
  • XXX is reacted with an amine of Formula R 1 NH 2 where Ri is as defined above to provide a 3-nitro[l ,5]naphthyridin-4-amine of Formula XXXI.
  • the reaction can be carried out by adding water then excess amine to the reaction mixture resulting from step (1) then heating on a steam bath.
  • the reaction can also be carried out by adding excess amine to a solution of a compound of Formula XXX in a suitable solvent such as dichloromethane and optionally heating.
  • Rj is hydrogen
  • XXXI is reduced to provide a [l,5]naphthyridine-3,4-diamine of Formula XXXII.
  • the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon.
  • the reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as ethyl acetate.
  • step (4) of Reaction Scheme III a compound of Formula XXXII is reacted with a carboxylic acid or an equivalent thereof to provide a IH- imidazo[4,5-c][l,5]naphthyridine of Formula XXXIII.
  • Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R 2 substituent in a compound of Formula
  • XXXIII diethoxymethylacetate will provide a compound where R 2 is hydrogen and trimethylorthovalerate will provide a compound where R 2 is butyl.
  • the reaction can be run in the absence of solvent, in a carboxylic acid such as acetic acid, or in an inert solvent in the presence of an acid. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
  • step (4) may be carried out by (i) reacting a compound of Formula
  • Part (i) involves reacting a compound of Formula XXXII with an acyl halide of formula R2C(O)X wherein R 2 is as defined above and X is chloro or bromo.
  • the reaction can be carried out by adding the acyl halide in a controlled fashion (e.g. dropwise) to a solution of a compound of Formula XXXII in a suitable solvent such as dichloromethane at a reduced temperature (e.g., 0°C).
  • a suitable solvent such as dichloromethane
  • Part (ii) involves cyclizing the product of part (i) by reacting it with methanolic ammonia at an elevated temperature (e.g. 150°C) and pressure.
  • step (5) of Reaction Scheme III a compound of Formula XXXIII is oxidized to provide a IH- imidazo[4,5-c][l,5]naphthyridine-5N-oxide of Formula XXXIV using a conventional oxidizing agent that is capable of forming N-oxides.
  • Prefened reaction conditions involve reacting a solution of a compound of Formula XXXIII in chloroform with 3-chloroperoxybenzoic acid at ambient conditions.
  • step (6) of Reaction Scheme III a compound of Formula XXXIV is aminated to provide a IH- imidazo[4,5-c][l,5]naphthyridin-4-amine of Formula XXXV which is a subgenus of Formula I.
  • Step (6) involves (i) reacting a compound of formula XXXIV with an acylating agent; and then (ii) reacting the product with an aminating agent.
  • Part (i) of step (6) involves reacting an N-oxide with an acylating agent.
  • Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benzenesulfonyl chloride, methanesulfonyl choride, p-toluenesulfonyl chloride).
  • Arylsulfonyl chlorides are prefened.
  • p- Toluenesulfonyl chloride is most prefened.
  • Part (ii) of step (6) involves reacting the product of part (i) with an excess of an aminating agent.
  • Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate).
  • Ammonium hydroxide is prefened.
  • the reaction is preferably carried out by dissolving the N-oxide of Formula XXXIV in an inert solvent such as dichloromethane, adding the aminating agent to the solution, and then adding the acylating agent. Preferred conditions involve cooling to about 0°C to about 5°C during the addition of the acylating agent.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (6) may be carried out by (i) reacting a compound of Formula XXXFV with an isocyanate; and then (ii) hydrolyzing the product.
  • Part (i) involves reacting the N-oxide with an isocyanate wherein the isocyanato group is bonded to a carbonyl group.
  • Prefened isocyanates include trichloroacetyl isocyanate and aroyl isocyanates such as benzoyl isocyanate.
  • the reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as dichloromethane. The resulting product can be isolated by removal of the solvent.
  • Part (ii) involves hydrolysis of the product from part (i).
  • the reaction can be carried out by conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide.
  • step (7) of Reaction Scheme III a compound of Formula XXXV is reduced to provide a 6,7,8,9-tetrahydro-777- imidazo[4,5-c][l,5]naphthyridin-4-amine of Formula XXXVI which is a subgenus of Formula II.
  • the reduction is carried out by suspending or dissolving a compound of Formula XXXV in trifluoroacetic acid, adding a catalytic amount of platinum (IV) oxide, and then subjecting the mixture to hydrogen pressure.
  • the reaction can be conveniently carried out in a Pan apparatus.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Certain functional groups recited in connection with Ri and R 2 may be incompatible with some of the reagents of Reaction Schemes I, II and III.
  • Compounds containing such functional groups can be prepared by those skilled in the art using well known methods of functional group protection and manipulation. For example, amine groups may be protected when necessary by derivatizing with di-tert-butyl dicarbonate.
  • Some compounds of Formula I or Formula II containing certain functional groups may be readily prepared from other compounds of Formula I or Formula II.
  • compounds wherein the Ri substituent contains an amide group may conveniently be prepared by reacting an acid chloride with a compound of Formula I or Formula II wherein the R] substituent contains a primary amine.
  • compounds wherein the Ri substituent contains a urea group may be prepared by reacting an isocyanate with a compound of Formula I or Formula II wherein the Ri substituent contains a primary amine.
  • compounds wherein the R] substituent contains a carbamate group may be prepared by reacting a chloro formate with a compound of Formula I or Formula II wherein the Ri substituent contains a primary amine.
  • R 1 ⁇ R2 and A are as defined above for compounds of Formula I and Formula II.
  • R, Ri, and R 2 are as defined above for compounds of Formula I and Formula II.
  • R, Ri and R 2 are as defined above for compounds of Formula I and Formula II.
  • R 7 is OH, halogen or NHR t (.and A and Ri are as defined above for compounds of Formula I) and R 8 is H, NO2 or NH2.
  • A is as defined above for compounds of Formula I and R is H or Ci-io alkyl.
  • R and Ri are as defined above for compounds of Formula I and Formula II with the proviso that Ri is other than hydrogen, and R 10 is NO 2 or NH2.
  • compositions of the invention contain a therapeutically effective amount of a compound of Formula I or Formula II as defined above in combination with a pharmaceutically acceptable carrier.
  • a therapeutically effective amount means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction or antiviral activity.
  • compositions of the invention will contain sufficient active ingredient to provide a dose of about lOOng/kg to about 50mg/kg, preferably about lO ⁇ g/kg to about 5mg/kg of the compound to the subject.
  • Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and so on.
  • the compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the Test Method set forth below. This ability indicates that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
  • Cytokines that are induced by the administration of compounds according to the invention generally include interferon (IFN) and tumor necrosis factor (TNF) as well as certain interleukins (IL).
  • IFN interferon
  • TNF tumor necrosis factor
  • IL interleukins
  • the compounds induce IFN- ⁇ , TNF- ⁇ , IL-1, 6, 10 .and 12, and a variety of other cytokines.
  • cytokines inhibit virus production and tumor cell growth, making the compounds useful in the treatment of tumors and viral diseases.
  • the compounds affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction.
  • the compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
  • Compounds of the invention also have an effect on the acquired immune response.
  • the production of the T helper type 1 (Thl) cytokine LFN- ⁇ is induced indirectly and the production of the Th2 cytokine IL-5 is inhibited upon administration of the compounds.
  • This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired.
  • the compounds are expected to be useful in the treatment of atopy, e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
  • the immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce cytokines such as IFN- ⁇ and TNF- ⁇ , the compounds are particularly useful in the treatment of viral diseases and tumors.
  • This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to viral diseases e.g. genital warts, common warts, plantar warts, Hepatitis B, Hepatitis C, Herpes Simplex Type I and Type II, molluscum contagiosm, HIV, CMV, VZV, cervical intraepithelial neoplasia, human papillomavirus and associated neoplasias; fungal diseases, e.g.
  • Candida aspergillus, cryptococcal meningitis
  • neoplastic diseases e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers
  • parasitic diseases e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers
  • parasitic diseases e.g.
  • Additional diseases or conditions that can be treated using the compounds of the invention include eczema, eosinophilia, essential thrombocythaemia, leprosy, multiple sclerosis, Ommen's syndrome, rheumatoid arthritis, systemic lupus erythematosis, discoid lupus, Bowen's disease and Bowenoid papulosis.
  • the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective .amount of a compound of Formula I or Formula II to the animal.
  • An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, INF- , TNF- ⁇ , IL-1,6,10 and 12 that is increased over the background level of such cytokines.
  • the precise amount will vary according to factors known in the art but is expected to be a dose of about lOOng/kg to about 50mg/kg, preferably about lO ⁇ g/kg to about 5mg/kg.
  • the invention further provides a method of treating a viral infection in .an animal comprising administering an effective amount of a compound of Formula I or Formula II to the animal.
  • An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals.
  • the precise amount will vary according to factors known in the art but is expected to be a dose of lOOng/kg to about 50mg/kg, preferably about lO ⁇ g/kg to about 5mg/kg.
  • the invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way.
  • 2-Aminonicotinic acid (5 g, 36 mmole) was suspended in acetic anhydride (25 mL) then heated at reflux for 2 hours. The reaction mixture was concentrated under vacuum.
  • the material from Part A was covered with acetic acid (75 mL), sodium azide (2 g) was added and the reaction mixture was stined at ambient temperature over the weekend.
  • Nitric acid (1.33 mL of 16M) was added to a suspension of tetrazolo[l,5- ⁇ ][l,8]naphthyridin-5-ol (4 g, 21 mmole) in acetic acid (50 mL).
  • the reaction mixture was heated on a steam bath for 5 minutes then cooled to ambient temperature.
  • Sodium acetate (0.3 eq) in a small amount of water was added to the reaction mixture.
  • the resulting solid was isolated by filtration and dried to provide 5 g of 4-nitrotetrazolo[l,5- ⁇ ][l,8]naphthryidin-5-ol as a solid, m.p. 278°C (decomposition).
  • Example 6 Compound of Formula X N 5 -(2-Methylpropyl)-4-nitrotetrazolo [1 ,5- ⁇ ] [1 ,8] naphthyridin-5-amine 4-Nitrotetrazolo[l,5- ⁇ ][l,8]naphthryidin-5-ol (3 g, 13 mmole) was suspended in dichloromethane (3.8 mL), triethylamine (1.8 mL) was added, and the reaction mixture was cooled in an ice bath. Trifiuoromethanesulfonic anhydride (2.2 mL) was added dropwise. Isobutylamine (3.8 mL) was added in a single aliquot and the reaction mixture exothermed.
  • N 5 -(2-methylpropyl)tetrazolo[ 1 ,5-a] [ 1 ,8]naphthyridin-4,5-diamine from Example 7 was combined with diethoxymethylacetate (2 mL) and heated on a steam bath for 3 hours. The reaction mixture was allowed to stand at ambient temperature overnight and then it was diluted with dichloromethane and methanol. The resulting solution was heated to remove the dichloromethane and reduce the volume of methanol to 50 mL and then cooled.
  • Triphenylphosphine (1.0 g, 3.7 mmole) was added to a solution of l-(2- methylpropyl)-7H-tetrazolo[l,5- ⁇ ]imid ⁇ o[4,5-c][l,8]naphthyridine (0.5 g, 1.87 mmole) in 1 ,2-dichlorobenzene (15 mL). The reaction mixture was heated at reflux for 2 hours then concentrated under vacuum to remove the majority of the 1 ,2-dichlorobenzene. The residue was slurried with hexanes for 30 minutes.
  • the solution was refluxed to remove the methanol then cooled to ambient temperature.
  • the resulting precipitate was isolated by filtration then coated onto silica gel.
  • the silica gel was eluted with 10-20% methanol in ethyl acetate.
  • the eluant was concentrated to dryness.
  • the resulting material was recrystallized from methanol and water to provide 0.35 g l-(2-methylpropyl)-7H-imidazo[4,5- c][l,8]naphthyridin-4-amine hydrate as a solid, m.p. 325-330°C (decomposition).
  • Triphenylphosphine (0.9 g, 3.7 mmole) was added to a solution of 2-butyl-l-(2- methylpropyl)-7H-tetrazolo[l,5- ⁇ ]imid ⁇ o[4,5-c][l,8]naphthyridine (0.6 g, 1.8 mmole) in 1,2-dichlorobenzene (15 mL). The resulting mixture was heated at reflux for 2 hours then concentrated under vacuum to remove most of the 1,2-dichlorobenzene. The residue was slurred with hexanes then taken up in dichloromethane and filtered through a layer of silica gel.
  • silica gel was eluted initially with dichloromethane to remove the 1,2- dichlorobenzene and then with 10% methanol in dichloromethane to recover 2-butyl-l-(2- methylpropyl)-N-triphenylphosphinyl-7H-imid.azo[4,5-c] [ 1 ,8]naphthyridin-4- amine.
  • Example 14 Compound of Formula XVIII 3-(5-Methyl-2 -tetrazol-l-yl)pyridine-4-carboxylic acid 3-Aminopyridine-4-carboxylic acid (50.0 g, 0.36 mol) was suspended in acetic anhydride (250 mL) then heated at reflux for 2 hours. The reaction mixture was concentrated under vacuum. The solid residue was slurried with heptane then concentrated under vacuum. The resulting solid was covered with acetic acid (300 mL), then sodium azide (23.5 g, 0.36 mol) was added. The reaction exothermed to 50°C. The reaction mixture was allowed to stir at ambient temperature overnight. The precipitate was isolated by filtration then slurried with methanol and filtered. The solid was dissolved in 10% sodium hydroxide. The solution was heated on a steam bath for 30 minutes, allowed to cool to ambient temperature then neutralized with 6N hydrochloric acid. The resulting precipitate was isolated by filtration, washed with water and dried to
  • Nitric acid (2 equivalents of 16M) was added to a solution of N 5 -(2- methylpropyl)tetrazolo[l,5- ⁇ ][l,7]naphthyridin-5-amine (2.0 g, 8.26 mmol) in acetic acid.
  • the reaction mixture was heated on a steam bath for about an hour then concentrated under vacuum. The residue was poured into ice water and the resulting mixture was neutralized with sodium bicarbonate. The resulting precipitate was extracted with dichloromethane. The dichloromethane extracts were combined, washed with water, and dried over magnesium sulfate. Thin layer chromatography indicated a mixture so the material was filtered through a layer of silica gel eluting with 5% ethyl acetate in dichloromethane. The reaction was rerun on 4 g of starting material but using only one equivalent of nitric acid. The resulting material was also a mixture.
  • N 5 -(2-Methylpropyl)-4-nitrotetrazolo[l,5- ⁇ ][l,7]naphthyridin-5-amine (1.5 g, 5.22 mmol) was suspended in acetic acid (75 mL). An excess of sodium hydrogen sulfide was dissolved in a minimum of water and added to the suspension. The reaction mixture turned red and all of the material went into solution. The reaction mixture was extracted twice with dichloromethane (150 mL).
  • N 5 -(2-Methylpropyl)tetrazolo[l,5- ⁇ ][l,7]naphthyridin-4,5-diamine (1.1 g, 4.3 mmol) was combined with diethoxymethylacetate (2 mL) and heated on a steam bath overnight. The reaction mixture was partitioned between dichloromethane and ammonium hydroxide. The dichloromethane layer was separated, washed with water, dried over magnesium sulfate and concentrated under vacuum.
  • Example 22 Compound of Formula I l-(2-Methylpropyl)-7/ -imidazo[4,5-c] [l,7]naphthyridin-4-amine
  • Triphenylphosphine (0.49 g, 1.8 mmol) was added to a suspension of l-(2- methylpropyl)-777-tetrazolo[l,5- ⁇ ]imidazo[4,5-c][l,7]naphthyridine (0.24 g, 0.9 mmol) in dichlorobenzene (15 mL). The reaction mixture was heated at reflux overnight then concentrated under vacuum. The residue was slurried with hexane and the resulting solid 1 -(2-methylpropyl)-N-triphenylphosphinyl-7H-imidazo[4,5-c] [ 1 ,7]naphthyridin-4-amine was isolated by filtration.
  • Part B The 1 -(2-methylpropyl)-N-triphenylphosphinyl-7H-imidazo[4,5- c][l,7]naphthyridin-4-amine from Part A was dissolved in methanol (30 mL). Hydrochloric acid (3 mL of 3N) was added to the solution and the reaction mixture was heated at reflux overnight before being concentrated under vacuum to remove the methanol. The aqueous residue was neutralized with sodium bicarbonate then extracted with dichloromethane. The extract was dried over magnesium sulfate then concentrated under vacuum.
  • the aqueous layer was made basic with 10% sodium hydroxide then the dichloromethane layer was separated, dried over magnesium sulfate and concentrated under vacuum.
  • the residue was purified by flash chromatography (silica gel eluting with 2-5% methanol in dichloromethane) to provide 0.25 g of 2-methyl-l-(2-methylpropyl)- 7H-tetrazolo[l,5- ⁇ ]imidazo[4,5-c][l,7]naphthyridine as a solid, m.p. 157-158°C.
  • Triphenylphosphine (2.5 g, 9.6 mmol) was added to a suspension of 2-methyl-l- (2-methylpropyl)-777-tetrazolo[l,5- ⁇ ]imidazo[4,5-c][l,7]naphthyridine (1 g, 4 mmol) in dichlorobenzene. The reaction mixture was heated at reflux overnight then concentrated under vacuum. The residue was slurried with hexane and the
  • a catalytic amount of platinum oxide was added to a solution of 2-methyl- 1 -(2- methylpropyl)-777-imidazo[4,5-c][l,7]naphthyridin-4-amine (0.1 g, 0.4 mol) in trifluoroacetic acid.
  • the reaction mixture was reduced on a Parr apparatus at 50 psi (3.5 Kg/cm 2 ) hydrogen pressure overnight.
  • the reaction mixture was filtered and washed with methanol to remove the catalyst, and the filtrate was concentrated under vacuum. The residue was combined with dichloromethane and aqueous sodium bicarbonate was added until the mixture was basic.
  • dichloromethane layer was separated, and the aqueous layer was extracted three times with dichloromethane (100 mL).
  • the combined dichloromethane extracts were dried over magnesium sulfate and concentrated under vacuum.
  • the resulting residue was recrystallized from toluene to provide 6,7,8,9- tetrahydro-2-methyl-l-(2-methylpropyl)-7H-imidazo[4,5-c][l,7]naphthyridin-4-amine as a solid, m.p. 226-230°C.
  • Valeryl chloride (0.76 mL, 6.4 mmol) was added to a solution of N 5 -(2- methylpropyl)tetrazolo[l,5- ⁇ ][l,7]naphthyridin-4,5-diamine (1.5 g, 5.8 mmol) in acetonitrile (15 mL). The reaction mixture was allowed to stir at ambient temperature for several hours. The resulting precipitate was isolated by filtration. Thin layer chromatography indicated that the material contained two components. The solid was dissolved in acetic acid and heated at reflux overnight. The reaction mixture was concentrated under vacuum, and the residue extracted with dichloromethane.
  • the crude solid from Part A was combined with diethoxymethylacetate (2 mL) then heated on a steam bath overnight.
  • the reaction mixture was taken up in dichloromethane, washed with water, dried over magnesium sulfate then filtered through a layer of silica gel.
  • the silica gel was eluted with dichloromethane to remove excess diethoxymethylacetate then with 5% methanol in dichloromethane to recover the product.
  • the eluant was concentrated to provide an oil which was purified by flash chromatography (silica gel eluting with 50% ethyl acetate/hexane then with ethyl acetate) to provide 0.25 g of 1 -(2-methylpropyl)-77/-imidazo[4,5-c] [ 1 ,5]naphthyridine as a solid m.p. 82-84°C.
  • a catalytic amount of platinum oxide was added to a solution of l-(2- methylpropyl)-777-imidazo[4,5-c][l,5]naphthyridin-4-amine (0.46 g) in trifluoroacetic acid (10 mL).
  • the reaction mixture was reduced on a Parr apparatus under 45 psi (3.15 Kg/cm 2 ) hydrogen pressure for 4 hours.
  • the reaction mixture was filtered to remove the catalyst and the filtrate was concentrated under vacuum.
  • the residue was combined with aqueous sodium bicarbonate then a small amount of 10% sodium hydroxide was added.
  • the resulting precipitate was extracted with dichloromethane.
  • the dichloromethane extract was dried over magnesium sulfate then concentrated under vacuum.
  • 3-Chloroperoxybenzoic acid (4.5 g of 50%, 13.1 mmol) was added in small portions over a period of 30 minutes to a solution of 2-methyl- 1 -(2-methylpropyl)-7H- imidazo[4,5-c][l,5]naphthyridine (2.1 g, 8.7 mmole) in chloroform at ambient temperature. After 3 hours the reaction mixture was diluted with chloroform, washed twice with 2.0 M sodium hydroxide, once with water, and once with brine, dried over magnesium sulfate then concentrated under vacuum.
  • Phosphorus oxychloride (4 mL, 0.31 mole) was combined with N,N- dimethylform.amide (100 mL) while cooling in .an ice bath. The resulting mixture was added to a solution of 3-nitro[l,5]naphthyridin-4-ol (50 g, 0.26 mole) in N,N- dimethylformamide (500 mL). The reaction mixture was stined at ambient temperature for 6 hours. The reaction mixture was poured into ice water and then extracted with dichloromethane (1800 mL). The organic layer was separated and then combined with triethylamine (45 mL).
  • Example 43 Compound of Formula XXXIII 1,1-Dimethylethyl N-[4-(2-Butyl-l/J-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate
  • Ammonium hydroxide (20 mL) was added to a solution of l- ⁇ 4-[(l,l- dimethylethylcarbonyl)amino]butyl ⁇ -2-butyl- 177-imidazo[4,5-c] [ 1 ,5 ]naphthyridine-5N- oxide (19.4 g) in chloroform.
  • Tosyl chloride (9 g) was slowly added. Thin layer chromatography indicated that the reaction was proceeding slowly. Additional tosyl chloride was added twice. After thin layer chromatography indicated that the reaction was complete, the layers were separated. The organic layer was washed with dilute aqueous sodium carbonate, dried over magnesium sulfate and then concentrated under vacuum.
  • phenyl isocyanate 52 ⁇ L, 0.48 mmol
  • 4-(4-amino-2-butyl- lH-imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)butaneamine (0.15 g, 0.48 mmole) in anhydrous tetrahydrofuran (60 mL).
  • the reaction mixture was stined for 20 minutes at which time it had turned homogeneous and thin layer chromatography indicated no starting material remained.
  • Aminomethyl resin (280 mg of 1% cross linked, 100-200 mesh available from BACHEM, Torrance, California) was added and the reaction mixture was allowed to stir for 0.5 hr.
  • Silica gel (0.4 g) was added and the mixture was concentrated under vacuum to provide a solid.
  • the solid was purified by flash chromatography eluting with 95/5 dichloromethane/methanol to give a white solid which was dried under vacuum at 60°C to provide 0.12 g of N-[4-(4-amino-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]- N'-phenylurea.
  • cyclohexyl isocyanate (61 ⁇ L, 0.48 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.15 g, 0.48 mmole) to provide 0.14 g of N-[4-(4-amino-2 -butyl- 177- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]- N'- cyclohexylurea as a white solid.
  • Benzyl isocyanate (59 ⁇ L, 0.48 mmol) was added at ambient temperature to a suspension of 4-(4-amino-2-butyl-177-imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)but.aneamine (0.15 g, 0.48 mmol) in tetrahydrofuran (60 mL).
  • a solution was obtained in less than 30 minutes and thin layer chromatography (9:1 dichloromethane:methanol) showed one major new spot with a higher R f and only a trace of starting material.
  • Aminomethyl resin (280 mg) was added and the reaction mixture was stined for 15 minutes. The solvent was removed under vacuum.
  • Phenylacetyl chloride (21 ⁇ L, 0.16 mmol) was added to a suspension of 4-(4- amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butaneamine (0.050 g, 0.16 mmol) in tetrahydrofuran (30 L). The reaction mixture was stirred at ambient temperature for 1 hour by which time a solution was obtained. Thin layer chromatography (9:1 dichloromethane :methanol) showed one major new spot with a higher R f and only a trace of starting material. Aminomethyl resin (100 mg) was added and the reaction mixture was stined for 5 minutes.
  • benzyl chloroformate (83 ⁇ L, 0.58 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.15 g, 0.48 mmol) to provide 0.18 g of benzyl N-[4-(4-amino-2-butyl- lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate as a white powder.
  • 9-fluorenylmethyl chloroformate (0.085 g, 0.33 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin- l-yl)butaneamine (0.105 g, 0.33 mmol) to provide 0.125 g of 9H-9-fluorenylmethyl N-[4- (4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate as a white powder.
  • Trimethylorthovalerate (3.6 mL, 20 mmol) was added to a suspension of 1,1 - dimethyl-2-[(3-amino[l,5]naphthyridin-4-yl)amino]ethanol 3.5 g, 13 mmol) in xylene (100 mL).
  • the reaction mixture was heated at reflux for two days.
  • the mixture was diluted with methanolic ammonia, placed in a Pan vessel and then heated at 110°C for 4 hours.
  • the reaction mixture was concentrated under vacuum.
  • the residue was partitioned between dichloromethane and water. The layers were separated. The organic layer was washed with water, dried over magnesium sulfate and then concentrated under vacuum to provide an oil.
  • Phenylacetyl chloride (2.0 mL, 20 mmol) was added to a suspension of 1,1- dimethyl-2-[(3-amino[l,5]naphthyridin-4-yl)amino]ethanol 3.5 g, 13 mmol) in dichlorometha. ne (100 mL). The reaction mixture was heated at reflux until thin layer chromatography indicated that the reaction was complete. The reaction mixture was taken on to the next step.
  • Example 66 Compound of Formula XXXI N-PhenylmethyI-3-nitro [1 ,5] naphthyridin-4-amine Phosphorus oxychloride (3.5 mL, 37.7 mmol) was reacted with N,N- dimethylformamide (15 mL) while chilling in an ice bath. This mixture was added to a solution of 3-nitro[l,5]naphthyridin-4-ol (6.0 g, 31.4 mmol) in N,N-dimethylformamide (60 mL). The reaction mixture was warmed in an oil bath to 60°C. After 3 hours the reaction mixture was poured into ice water. The resulting precipitate was isolated by filtration and then washed with water.
  • N-(4-Phenylmethylamino[l,5]naphthyridin-3-yl)-ethoxyacetamide hydrochloride (5.8 g, 15.5 mmol) was combined with a 7 % solution of ammonia in methanol (100 mL), placed in a sealed Parr vessel and then heated at 150°C for 6 hours. The reaction mixture was concentrated under vacuum. The residue was partitioned between water and dichloromethane. The dichloromethane layer was separated, washed with water, dried over magnesium sulfate and then concentrated under vacuum.
  • Valeryl chloride (1.53 mL, 12.9 mmol) was added dropwise over a 15 minute period to a chilled (ice bath) solution of N 4 -(3-isopropoxypropyl)[l,5]naphthyridine-3,4- diamine (3.2 g, 12.3 mmol) in dichloromethane (40 mL). The cooling bath was removed and the reaction mixture was maintained at ambient temperature for 1 hour. The solvent was removed under vacuum to provide a dark tan solid. Part B
  • the material from Part A and a 7.5% solution of ammonia in methanol (100 mL) were placed in a pressure vessel. The vessel was sealed and then heated at 150°C for 6 hours. After the mixture was cooled to ambient temperature it was concentrated under vacuum. The residue was partitioned between dichloromethane (150 mL) and water (150 mL). The fractions were separated and the aqueous fraction was extracted with dichloromethane (100 mL). The organic fractions were combined, dried over magnesium sulfate, filtered and then concentrated under vacuum to provide a brown oil.
  • N 4 -(3-butoxypropyl)-3-nitro[l,5]naphthyridin-4- amine (4.9 g, 16 mmol) was reduced to provide 4.3 g of N 4 -(3- butoxypropyl)[l,5]naphthyridine-3,4-diamine as a bright yellow oil.
  • N 4 -(3- butoxypropyl)[l,5]naphthyridine-3,4-diamine (3.7 g, 13.5 mmol) was reacted with valeryl chloride (1.7 mL, 14.3 mmol) and the resulting amide intermediate was cyclized to provide 2.9 g of l-(3-butoxypropyl)-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridine as a colorless oil.
  • Example 75 l-(3-butoxypropy ⁇ )-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridine-5N-oxide (1.2 g, 3.4 mmol) was reacted with trichloroacetyl isocyanate (0.6 mL, 5.0 mmol) and the resulting intermediate was hydrolyzed to provide 0.86 g of l-(3-butoxypropyl)-2 -butyl- lH-imidazo[4,5- c][l,5]naphthyridin-4-amine as a white powder, m.p. 101.0-101.5°C.
  • N 4 -(2-Phenoxyethyl)-3-nitro[l,5]naphthyridin-4-amine Using the general method of Example 76, 4-chloro-3 -nitro [ 1 ,5]naphthyridine (5.0 g, 24 mmol) was reacted with 2-phenoxyethylamine (3.5 mL, 27 mmol) to provide 6.6 g of N 4 -(2-phenoxyethyl)-3-nitro[l,5]naphthyridin-4-amine as a yellow solid, m.p. 107-108°C.
  • N 4 -(2-Phenoxyethyl)[l,5]naphthyridine-3,4-diamine Using the general method of Example 77, N 4 -(2-phenoxyethyl)-3- nitro[l,5]naphthyridin-4-amine (5.4 g, 17.4 mmol) was reduced to provide 4.6 g of N 4 -(2- phenoxyethyl)[l,5]naphthyridine-3,4-diamine as a bright yellow oil.
  • Example 84 Compound of Formula XXXTV 2-Butyl-l-(2-phenoxyethyl)-li -imidazo[4,5-c][l,5]naphthyridine-5N-oxide Using the general method of Example 74, 2-(2-butyl-17J-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl phenyl ether (0.6 g, 1.7 mmol) was oxidized to provide 0.44 g of 2-butyl-l-(2-phenoxyethyl)-177-imidazo[4,5-c][l,5]naphthyridine-5N-oxide as a yellow powder.
  • This solid was purified by flash chromatography (silica gel eluting with dichloromethane) to provide 24.8 g of 1,1 -dimethylethyl N- ⁇ 2-[(3-nitro[l,5]naphthyridin-4-yl)amino]ethylcarbamate as a canary yellow solid.
  • a portion (0.3 g) was recrystallized from toluene (10 mL) and heptane (10 mL) to provide 0.2 g of canary yellow needles, m.p. 149-151°C.
  • Example 87 Compound of Formula XXXII 1,1-Dimethylethyl N- ⁇ 2- [(3- Amino [1 ,5]naphthyridin-4-yl)amino] ethyl ⁇ carbamate
  • Trichloroacetyl isocyanate (4.8 mL, 40 mmol) was added via a syringe to a solution of l- ⁇ 2-[(l, l-dimethylethoxycarbonyl)amino]ethyl ⁇ -2-butyl-lH-imidazo[4,5- c][l,5]naphthyridine-5N-oxide (10.4 g, 27 mmol) in dichloromethane (75 mL). The reaction mixture was stined at ambient temperature for 1 hour. Sodium methoxide (9 mL of 25% sodium methoxide in methanol) was added and the reaction mixture was stined at ambient temperature overnight.
  • Trifluoroacetic acid (5 mL) was added to a solution of 1,1 -dimethylethyl N-[2-(4- amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]carbamate (5.7 g, 15 mmol) in dichloromethane (10 mL). The reaction mixture was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with dichloromethane and then extracted with 10% hydrochloric acid. The hydrochloric acid extract was washed twice with dichloromethane and then it was made basic with ammonium hydroxide.
  • This material was purified by column chromatography (silica gel eluting with dichloromethane) to provide 0.2 g of a solid.
  • This solid was recrystallized from acetonitrile (30 mL) to provide 0.18 g of N 1 -[2-(4-amino-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl]acetamide as a white powder, m.p.228-230°C.
  • crotonyl chloride (68 ⁇ L, 0.7 mmol) was reacted with 2-(4-amino-2-butyl-lH-imidazo[4,5-c] [ 1 ,5 jnaphthyridin- 1 -yl)ethaneamine (0.2 g, 0.7 mmol) to provide 0.2 g of N 1 -[2-(4-amino-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl]-(E)-2-butenamide as a white powder, m.p. 198-200°C.
  • reaction mixture was stirred at ambient temperature for 30 minutes and then a solution of l-[3-(dimethoxyamino)propyl]-3- ethylcarbodiimide hydrochloride (0.37 g, 1.9 mmol) in anhydrous dichloromethane (50 mL) was added dropwise.
  • the reaction mixture was stined at ambient temperature overnight and then filtered to remove solids. The filtrate was washed twice with 10% sodium hydroxide and then with brine, dried, and then concentrated under vacuum to provide 0.3g of crude product.
  • citronellic acid 0.3 g, 1.7 mmole
  • 2-(4-amino-2 -butyl- lH-imidazo[4,5 -c] [ 1 ,5]naphthyridin- 1 -yl)ethaneamine 0.5 g, 1.7 mmol
  • 2-(4-amino-2-butyl-177-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl]-3,7-dimethyl-6-octenamide as a white whispy solid, m.p. 163-164°C.
  • 6-morpholinonicotinic acid (0.12 g, 64 mmol) was reacted with 4-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.2 g, 0.64 mmol) to provide N 1 -[4-(4-.amino-2 -butyl -lH-imid ⁇ o[4,5- c][l,5]naphthyridin-l-yl)butyl]-6-morpholmonicotinamide as a white solid, m.p. 95- 100°C.
  • Example 105 6-quinolinecarboxylic acid (0.11 g, 64 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.2 g, 0.64 mmol) to provide N -[4-(4-amino-2-butyl -lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)butyl]-6-quinolinecarboxamide as a white solid, m.p. 190-191°C.
  • Example 105 (4-pyridylthio)acetic acid (0.11 g, 64 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yDbutaneamine (0.2 g, 0.64 mmol) to provide 0.1 g of N 1 -[4-(4-amino-2-butyl -177- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-2-(4-pyridylsulfanyl)acetamide as a solid, m.p. 127.5-129°C.
  • the toluene supernatant was decanted off and concentrated under vacuum to provide 1.1 g of 1,1- dimethylethyl N-[4-(177-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate.
  • the oil was identified as 4-(177-imidazo[4,5-c][l,5]naphthyridin-l-yl)butaneamine.
  • Tosyl chloride (0.64 g, 3.37 mmol) was slowly added in small portions to a solution of the material from Part B (1.2 g, 3.37 mmol) in dichloromethane (20 mL).
  • reaction mixture was partitioned between diethyl ether and saturated aqueous sodium bicarbonate (the aqueous layer was basic). The aqueous layer was extracted with an additional lOOmL of diethyl ether. The combined organic layers were dried and then concentrated under vacuum. The residue was purified by flash chromatography (silica gel eluting with 5%, then 10% methanol in dichloromethane) to provide 2.49 g of methyl 4- [ -(2-N,N-dimethylaminoethoxy)benzyl]benzoate as a colorless oil.
  • Example 112 Part B D-desthiobiotin (151 mg, 0.70 mmole) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yDethaneamine (200 mg, 0.70 mmol) to provide 231 mg of N 1 -[4-(4-amino-2-butyl-lH- imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)ethyl]-
  • Examples 118-152 shown in the table below were prepared according to the following method. 4-(4-Amino-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethaneamine (50 ⁇ mol) was dissolved in dichloromethane (5 mL) in a screw-capped test tube and the solution was cooled in an ice-water bath. An acid chloride (50 ⁇ mol) of the formula R A COCI was added as a solution in 100 ⁇ L of dichloromethane (Acid chlorides that are solids were either dissolved or suspended in -400 ⁇ L of dichloromethane and then added).
  • the mixture was vortexed for 15 seconds to 1 minute, becoming cloudy, and then -80 mg of an aminomethyl polystyrene resin (0.62 meq/g, 100-200 mesh, 1% crosslink, Bachem #D-2100, lot # FM507) was added, and the mixture was vortexed for another 30 seconds.
  • the mixture was applied to a short column (3 x 1 cm ) of silica gel conditioned with dichloromethane.
  • the product was eluted with 10:1 dichloromethane:methanol, collecting -2 mL fractions. Thin layer chromatography of the fractions was performed, and fractions with the product spot were pooled and stripped to dryness in a Savant SpeedVac.
  • Examples 153-190 shown in the table below were prepared according to the following method. 4-(4-Amino-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)butaneamine (25 ⁇ mol) was dissolved in dichloromethane (10 mL) in a screw-capped test tube and the solution was cooled in an ice-water bath. An acid chloride (25 ⁇ mol) of the formula R A COCl was added as a solution in 100 ⁇ L of dichloromethane (Acid chlorides that are solids were added directly.).
  • the mixture was vortexed for 15 seconds to 1 minute, becoming cloudy, and then -80 mg of an aminomethyl polystyrene resin (0.62 meq/g, 100-200 mesh, 1% crosslink, Bachem #D- 2100, lot # FM507) was added, and the mixture was vortexed for another 30 seconds.
  • the mixture was applied to a short column (3 x 1 cm ) of silica gel conditioned with dichloromethane.
  • the product was eluted with 10:1 dichloromethane methanol, collecting -2 mL fractions. Thin layer chromatography of the fractions was performed, and fractions with the product spot were pooled and stripped to dryness in a Savant SpeedVac.
  • the coupling agent, l-(3-dimethylaminopropyl)-3- ethyl carbodiimide hydrochloride (-10.5 mg, 55 ⁇ mol) was added and the mixture was vortexed at 400 rpm for 1-2 h at ambient temperature, giving a clear solution in most cases.
  • the mixture was applied to a short column (3 x 1 cm ) of silica gel conditioned with dichloromethane.
  • the product was eluted with 10:1 dichloromethane:methanol, collecting -2 mL fractions. Thin layer chromatography of the fractions was performed, and fractions with the product spot were pooled and stripped to dryness in a Savant SpeedVac. Purity was checked by reversed phase-HPLC
  • Gradient elution linear gradient from 100% water +0.1% trifluoroacetic acid to 100% acetonitrile + 0.1% trifluoroacetic acid over 5 min. at 1 mL per minute. Detection is at 220 nm and 254 nm).
  • APCI-mass spectral data confirmed presence of the expected molecular ion, and proton nmr data supported the expected structure.
  • CYTOKINE INDUCTION IN HUMAN CELLS An in vitro human blood cell system was used to assess cytokine induction by compounds of the invention. Activity is based on the measurement of interferon and tumor necrosis factor ( ⁇ *) (IFN and TNF, respectively) secreted into culture media as described by Testerman et. al. In "Cytokine Induction by the Inimunomodulators
  • PBMCs Peripheral blood mononuclear cells
  • Histopaque®-1077 Sigma Chemicals, St. Louis, MO
  • the PBMCs are suspended at 1.5-2 x 10 6 cells/mL in RPMI 1640 medium containing 10 % fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin solution (RPMI complete). 1 mL portions of PBMC suspension are added to 24 well flat bottom sterile tissue culture plates.
  • the compounds are solubilized in dimethyl sulfoxide (DMSO).
  • DMSO concentration should not exceed a final concentration of 1 % for addition to the culture wells.
  • the compounds are generally tested in a concentration range of from 0.1 to 100 ⁇ M. Incubation
  • test compound is added to the wells containing 1 mL of PBMCs in media.
  • the plates are covered with plastic lids, mixed gently and then incubated for 18 to
  • Interferon Analysis/Calculation Interferon is determined by bioassay using A549 human lung carcinoma cells challenged with encephalomyocarditis.
  • the details of the bioassay method have been described by G. L. Brennan and L. H. Kronenberg in "Automated Bioassay of Interferons in Micro-test Plates", Biotechniques, June/July, 78, 1983, incorporated herein by reference. Briefly stated the method is as follows: A549 cells are incubated with samples and standard interferon dilutions at 37°C for 24 hours. The incubated cells are then infected with an inoculum of encephalomyocarditis virus.
  • the infected cells are incubated for an additional 24 hours at 37°C before quantifying for viral cytopathic effect.
  • the viral cytopathic effect is quantified by staining followed by visual scoring of the plates. Results are expressed as alpha reference units/mL based on the value obtained for NTH Human
  • Tumor necrosis factor ( «) (TNF)concentration is determined using an ELISA kit available from Genzyme, Cambridge, MA. The results are expressed as pg/mL. In the table below, a "+” indicates that the compound induced the indicated cytokine at that particular concentration, a “-” indicates that the compound did not induce the indicated cytokine at that particular concentration, and a “ ⁇ ” indicates that the results were equivocal at that particular concentration.
  • Peripheral blood mononuclear cells were separated from whole blood by using either LeucoPREPTM Brand Cell Separation Tubes (available from Becton Dickinson) or Ficoll-Paque® solution (available from Pharmacia LKB Biotechnology Inc, Piscataway, NJ).
  • the PBM's were suspended at 1 x 10 6 /mL in RPMI 1640 media (available from GIBCO, Grand Island, NY) containing 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2- eth.anesulfonic acid) and L-glutamine (1% penicillin-streptomycin solution added) with
  • the compounds were solubilized in ethanol, dimethyl sulfoxide or tissue culture water then diluted with tissue culture water, 0.01N sodium hydroxide or 0.01N hydrochloric acid (The choice of solvent will depend on the chemical characteristics of the compound being tested.). Ethanol or DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells. Compounds were initially tested in a concentration range of from about 0.1 ⁇ g/mL to about 5 ⁇ g/mL. Compounds which show induction at a concentration of 0.5 ⁇ g/mL were then tested in a wider concentration range.
  • test compound was added in a volume (less than or equal to 50 ⁇ L) to the wells containing 200 ⁇ L of diluted whole blood or of PBM's in media. Solvent and/or media was added to control wells (wells with no test compound) and as needed to adjust the final volume of each well to 250 ⁇ L.
  • the plates were covered with plastic lids, vortexed gently and then incubated for 48 hours at 37°C with a 5% carbon dioxide atmosphere.
  • Interferon was determined by bioassay using A549 human lung carcinoma cells challenged with encephalomyocarditis. The details of the bioassay method have been described by G. L. Brennan and L. H. Kronenberg in "Automated Bioassay of Interferons in Micro-test Plates", Biotechniques. June/July, 78, 1983, incorporated herein by reference. Briefly stated the method is as follows: interferon dilutions and A549 cells are incubated at 37°C for 12 to 24 hours. The incubated cells are infected with an inoculum of encephalomyocarditis virus.
  • the infected cells are incubated for an additional period at 37°C before quantifying for viral cytopathic effect.
  • the viral cytopathic effect is quantified by staining followed by spectrophotometric absorbance measurements. Results are expressed as alpha reference units/mL based on the value obtained for NTR HU IF-L standard.
  • the interferon was identified as essentially all interferon alpha by testing in checkerboard neutralization assays against rabbit anti-human interferon (beta) and goat anti-human interferon (alpha) using A549 cell monolayers challenged with encephalomyocarditis virus.

Abstract

Imidazonaphthyridine (I) and tetrahydroimidazonaphthyridine (II) compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed. R1 and R2 and A are as defined in the application.

Description

IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS
Field of the Invention
This invention relates to imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds, processes for making these compounds and intermediates used in their preparation. This invention additionally relates to pharmaceutical compositions containing imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds. A further aspect of this invention relates to the use of these compounds as inimunomodulators and for inducing cytokine biosynthesis in animals.
Background of the Invention
The first reliable report on the l//-imidazo[4,5-r]quinoline ring system, Backman etal., J. Ore. Chem. 15, 1278-1284 (1950) describes the synthesis of l-(6- methoxy-8-quinolinyl)-2-methyl- 1 //-imidazo[4,5-c jquinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted l/ -imidazo[4,5-r] quinolines were reported. For example, Jain et al., J. Med. Chem. 1 1, pp. 87-92 (1968), synthesized the compound l -f2-(4-piperidyl)ethyl]-l //-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al., Chem. Abs. 85, 94362 (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al.,
Heterocvclic Chem. 18, 1537-1540 (1981 ), have reported certain 2-oxoimidazo[4,5- cjquinolines.
Certain lH-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, inter alia, U.S. Patent Nos. 4,689,338;
4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640, all of which are incorporated herein by reference. Although there continues to be interest in the imidazoquinoline ring system, as seen for example in WO 98/30562, there is a continuing need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other mechanisms. Summary of the Invention
We have found a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Accordingly, this invention provides imidazonaphthyridine compounds of Formula I:
Figure imgf000004_0001
wherein A, Rt and R2 are as defined hereinafter.
The invention also provides tetrahydroimidazonaphthyridine compounds of Formula II:
Figure imgf000004_0002
π
wherein B, Ri and R2 are as defmed hereinafter.
The compounds of Formula I and Formula II are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune reponse when administered to animals. This ability makes the compounds useful in the treatment of a variety of conditions, e.g. viral diseases and tumors that are responsive to such changes in the immune response. The invention further provides pharmaceutial compositions containing a compound of Formula I or Formula II and methods of inducing cytokine biosynthesis in an animal and/or treating a viral infection in an animal by administering a compound of Formula I or Formula II to the animal.
In addition, methods of synthesizing compounds of Formula I and Formula II, and intermediates useful in the synthesis of these compounds are provided.
Further the invention provides a method of inducing interferon biosynthesis in an animal comprising the step of administering to said animal a compound of Formula I or Formula II in an amount effective to induce said interferon biosynthesis, and a method of treating a viral infection in an animal comprising the step of administering to said animal a compound of Formula I or Formula II in an amount effective to inhibit the viral infection.
Detailed Description of the Invention
As mentioned earlier, the invention provides compounds of Formula I:
Figure imgf000005_0001
I wherein
A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;
Ri is selected from the group consisting of: - hydrogen;
-Cj- o alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -aryl;
-heteroaryl; -heterocyclyl; -O-Cι-20 -alkyl,
-O-(Cι-2oalkyl)0-ι-aryl;
-O-(C i -2oalkyl)o-ι -heteroaryl;
-O-(Cι-2oalkyl)0-1 -heterocyclyl; -Cι-2o alkoxycarbonyl;
-S(O)0-2 -C1-20 alkyl;
-S(O)0.2-(C,-2o alkyl)o-1-aryl;
-S(O)0-2 -(Cι-20 alkyl)0-ι -heteroaryl;
-S(O)0-2 -(Cι-20 alkyl)0-ι -heterocyclyl; -N(R3)2;
-N3; oxo;
-halogen;
-NO2; -OH; and
-SH; and
-C1-20
Figure imgf000006_0001
wherein Q is -CO- or - SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl; -O-Cι-20 alkyl,
-O-(Cι-20alkyl)0-1-aryl;
-O-(C1-2oalkyl)0-1 -heteroaryl;
-O-(C 1 -2oalkyl)0- 1 -heterocyclyl ;
-Cι-2o alkoxycarbonyl; -S(O)0-2 -C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-,-aryl;
-S(O)0-2 -(Cι-20 alkyl)0-1 -heteroaryl; -S(O)0-2 -(Ci -20 alkyl)0-ι -heterocyclyl;
-N(R3)2;
-NR3-CO-O-Cι-20alkyl;
-N3; oxo;
-halogen;
-NO2;
-OH; and
Figure imgf000007_0001
wherein Y is -N- or -CR-; R2 is selected from the group consisting of: -hydrogen; -Cι-10 alkyl; -C2-ιo alkenyl;
-aryl;
-Ci-io alkyl -O-Cι-10-alkyl; -Cμio alkyl-O-C2-ιo alkenyl; and
-C1-10 alkyl or C20 alkenyl substituted by one or more substituents selected from the group consisting of:
-OH; -halogen; -N(R3)2; -CO-N(R3)2; -CO-d-io alkyl;
-N3; -aryl; -heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; each R3 is independently selected from the group consisting of hydrogen and C1-10 alkyl; .and each R is independently selected from the group consisting of hydrogen, Ci-io alkyl, CMO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
This invention also provides compounds of Formula II
Figure imgf000008_0001
π
wherein B is -NR-C(R)2-C(R)2-C(R)2-; -C(R)2-NR-C(R)2-C(R)2-;
-C(R)2-C(R)2-NR-C(R)2- or -C(R)2-C(R)2-C(R)2-NR-; Ri is selected from the group consisting of: - hydrogen;
-C1-2o alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl; -heterocyclyl; -O-C1-20 alkyl; -O-(C1-20alkyl)0-1-aryl;
-O-(C 1 -20alkyl)0-ι -heteroaryl; -O-(Cι-2oalkyl)o-ι-heterocyclyl; -Cι-20 alkoxycarbonyl; -S(O)o-2 -Cι-2o alkyl; -S(O)o-2-(Cι-20 alkyl)0-1-aryl; -S(O)0-2-(Cι-2o alkyl)0-ι -heteroaryl;
-S(O)0-2 -(Cι.20 alkyl)0-ι -heterocyclyl; -N(R3)2; -N3; oxo; -halogen;
-NO2; -OH; and -SH; and
-Ci -20 alkyl-NR3-Q-X-R4 or -C2-20 alkenyl-NRs-Q-X-Ri wherein Q is -CO- or -
SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -Cι-2o alkyl or C2-2o alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl; -heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl,
-O-(C1-20alkyι)0-1-aryl;
-O-(C1- oalkyl)0-ι -heteroaryl; -O-(C1-2oalkyl)0-1-heterocyclyl;
-C1-2o alkoxycarbonyl;
-S(O)o-2 -C1-20 alkyl;
-S(O)o-2-(Cι-20 alkyDo-i-aryl;
-S(O)0-2 -(Cι-20 alkyl)0-1 -heteroaryl; -S(O)o-2 -(C1-20 alkyl)0-1 -heterocyclyl;
-N(R3)2;
-NR3-CO-O-C1-20alkyl; -N3; oxo;
-halogen; -NO2; -OH; and -SH; or t is
Figure imgf000010_0001
wherein Y is -N- or -CR-; R2 is selected from the group consisting of: -hydrogen;
-CMO alkyl; -C2-ιo alkenyl; -aryl
-Cj.,0 alkyl -O-Cio-alkyl; -Ci-io alkyl-O-C2-1o alkenyl; and
-Cμio alkyl or C2-10 alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R3)2;
-CO-N(R3)2; -CO-C 0 alkyl; -N3; -aryl; -heteroaryl;
-heterocyclyl; -CO-aryl; and -CO-heteroaryl; each R3 is independently selected from the group consisting of hydrogen and CM O alkyl; and each R is independently selected from the group consisting of hydrogen, Ci-io alkyl, CMO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
As used herein, the terms "alkyl", "alkenyl", and the prefix "-alk" are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. These cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopentyl, cyclohexyl and adamantyl.
The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl .and indenyl. The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, tetrazolyl, imid.azo, .and so on.
"Heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thi-azolidinyl, and imidazolidinyl. The aryl, heteroaryl and heterocyclyl groups may be unsubstituted or substituted by one or more substituents selected from the group consisting of C 1-20 alkyl, hydroxy, halogen, N(R3)2, NO , C1-2o alkoxy, Cι- 0 alkylthio, trihalomethyl, Cι-20 acyl, arylcarbonyl, heteroarylcarbonyl, (Cι-10alkyl)o-ι-aryl, (Cι-ιoalkyl)o-ι-heteroaryl, nitrile, Cι-2o alkoxycarbonyl, oxo, arylalkyl wherein the alkyl group has from 1 to 10 carbon atoms, and heteroarylalkyl wherein the alkyl group has from 1 to 10 carbon atoms.
The invention is inclusive of the compounds described herein in .any of their ph.armaceutically acceptable forms, including isomers such as diastereomers and enantiomers, salts, solvates, polymorphs, and the like. Preparation of the Compounds
Compounds of Formulas I and II wherein A is =N-CR=CR-CR= or B is -NR-C(R)2-C(R)2-C(R)2- and R, Ri and R2 are as defined above can be prepared according to Reaction Scheme I:
Reaction Scheme I
Figure imgf000013_0001
)
Figure imgf000013_0002
VIII VII VI
Figure imgf000013_0003
IX X XI
(9)
Figure imgf000013_0004
(13)
Figure imgf000014_0001
XV
Many 2-aminonicotinic acids of Formula III are known (see, for example, U.S. 3,917,624). The compound where R is hydrogen is commercially available. In step (1) of
Reaction Scheme I a 2-aminonicotinic acid of Formula III is reacted with acetic anhydride by heating to provide a 2-methyl-4H-pyrido[2,3--i][l,3]oxazin-4-one of Formula IV. The compound of Formula IV where R is hydrogen is known and its preparation has been disclosed in U.S. Patent No. 3,314,941 (Littell), the disclosure of which is incorporated herein by reference.
In step (2) of Reaction Scheme I a compound of Formula IV is reacted with sodium .azide in a suitable solvent such as acetic acid to provide a tetrazolyl nicotinic acid of Formula V. The reaction conveniently may be run at ambient conditions.
In step (3) of Reaction Scheme I an acid of Formula V is esterified to provide a compound of Formula VI. The esterification may be carried out using conventional methods. For example, the acid may be esterified in acetone using potassium carbonate and ethyl iodide.
In step (4) of Reaction Scheme I a compound of Formula VI is cyclized to provide a tetrazolo[l,5-α][l,8]naphthyridin-5-ol of Formula VII. The reaction may be carried out by reacting the compound of Formula VI with an alkoxide in a suitable solvent, e.g., potassium ethoxide in N,N-dimethylformamide, at ambient conditions.
In step (5) of Reaction Scheme I a compound of Formula VII is nitrated using a suitable nitrating agent such as nitric acid to provide a 4-nitrotetrazolo[l,5~ α][l,8]naphthyridin-5-ol of Formula VIII. In step (6) of Reaction Scheme I a compound of Formula VIII is converted to a triflate of Formula IX. The reaction is preferably carried out by combining a compound of Formula VIII with a base, preferably a tertiary amine such as triethyl amine, in a suitable solvent such as dichloromethane and then adding trifluoromethanesulfonic anhydride. The addition is preferably carried out in a controlled manner, e.g., adding dropwise at a reduced temperature such as, for example, at about 0°C. The product can be isolated by conventional methods or it can be carried on without isolation as described below in connection with step (7).
In step (7) of Reaction Scheme I a compound of Formula IX is reacted with an amine of formula RιNH2 where Ri is as defined above to provide a 4-nitrotetrazolo[l,5- α][l,8]naphthyridin-5-amine of Formula X. The reaction can be carried out by adding the amine to the reaction mixture resulting from step (6). The reaction can also be carried out by adding the amine to a solution of the compound of Formula IX and a tertiary amine in a suitable solvent such as dichloromethane.
In step (8) of Reaction Scheme I a compound of Formula X is reduced to provide a tetrazolo[l,5-α][l,8]naphthyridin-4,5-diamine of Formula XL Preferably, the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon. The reaction can conveniently be carried out on a Pan apparatus in a suitable solvent such as ethanol.
In step (9) of Reaction Scheme I a compound of Formula XI is reacted with a carboxylic acid or an equivalent thereof to provide a 7H-tetrazolo[l,5-α]imidazo[4,5- c][l,8]naphthyridine of Formula XII. Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R2 substituent in a compound of Formula XII. For example, diethoxymethylacetate will provide a compound where R2 is hydrogen and valeryl chloride will provide a compound where R2 is butyl. The reaction can be run in the absence of solvent, in a carboxylic acid such as acetic acid, or in an inert solvent in the presence of a carboxylic acid. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
In step (10) of Reaction Scheme I a compound of Formula XII is reacted with triphenylphosphine to provide a N-triphenylphosphinyl-iH-imidazo[4,5- c][l,8]naphthyridin-4- .amine of Formula XIII. The reaction can be carried out by combining a compound of Formula XII with triphenylphosphine in a suitable solvent such as 1 ,2-dichlorobenzene and heating. In step (11) of Reaction Scheme I a compound of Formula XIII is hydro lyzed to provide a 7H-imidazo[4,5-c][l,8]naphthyridin-4-amine of Formula XIV which is a subgenus of Formula I. The hydrolysis can be carried out by conventional methods such as by heating in a lower alkanol in the presence of an acid. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (12) of Reaction Scheme I a compound of Formula XIV is reduced to provide a 6,7,8,9-tetrahydro-77J-imidazo[4,5-c][l,8]naphthyridin-4-amine of Formula XV which is a subgenus of Formula II. The reduction is carried out by suspending or dissolving a compound of Formula XIV in trifluoroacetic acid, adding a catalytic amount of platinum (IV)oxide, and then subjecting the mixture to hydrogen pressure. The reaction can be conveniently carried out in a Pan apparatus. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Alternatively, as illustrated in step (13) of Reaction Scheme I, a 6,7,8,9-tetrahydro- 7H-imidazo[4,5-c][l,8]naphthyridin-4- .amine of Formula XV can be prepared by reduction of a compound of Formula XII. The reduction is carried out by suspending or dissolving a compound of Formula XII in trifluoroacetic acid, adding a catalytic amount of platinum (IV)oxide, and then subjecting the mixture to hydrogen pressure. The reaction can be conveniently carried out in a Pan apparatus. As above, the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Compounds of Formulas I and II wherein A is =CR-N=CR-CR= or B is
-C(R)2-NR-C(R)2-C(R)2-; R, R\ and R2 are as defined above can be prepared according to Reaction Scheme II.
Reaction Scheme II
Figure imgf000016_0001
(3)
Figure imgf000017_0001
XXI XX XLX
Figure imgf000017_0002
XXII XXIII XXTV
(9)
Figure imgf000017_0003
2)
(13)
Figure imgf000017_0004
In step (1) of Reaction Scheme II a 3-aminoisonicotinic acid of Formula XVI is reacted with acetic anhydride by heating to provide a 2-methyl- H-pyrido[3,4- £tj[l,3]oxazin-4-one of Formula XVII. The compound of Formula XVII where R is hydrogen is known and its preparation has been disclosed in Littell cited above.
In step (2) of Reaction Scheme II a compound of Formula XVII is reacted with sodium azide in a suitable solvent such as acetic acid to provide a tetrazolyl isonicotinic acid of Formula XVIII. The reaction conveniently may be run at ambient conditions.
In step (3) of Reaction Scheme II an acid of Formula XVIII is esterified to provide a compound of Formula XIX. The esterification may be carried out using conventional methods. For example, the acid may be esterified in acetone using potassium carbonate and ethyl iodide or by reacting with dimethylformamide diethyl acetal in a suitable solvent such as dichloromethane.
In step (4) of Reaction Scheme II a compound of Formula XIX is cyclized to provide a tetrazolo[l,5-α][l,7]naphthyridin-5-ol of Formula XX. The reaction may be carried out by reacting the compound of Formula XIX with an alkoxide in a suitable solvent, e.g., potassium ethoxide in N,N-dimethylformamide, at ambient conditions. In step (5) of Reaction Scheme II a compound of Formula XX is chlorinated using a suitable chlorinating agent such as thionyl chloride, oxalyl chloride, phosphorus pentachloride or preferably phosphorus oxychloride to provide a 5-chlorotetrazolo[l,5- fl][l,7]naphthyridine of Formula XXI. The reaction can be carried out in an inert solvent or if appropriate in neat chlorinating agent. Preferred reaction conditions involve reaction in neat phosphorus oxychloride with heating at about 90°C.
In step (6) of Reaction Scheme II a compound of Formula XXI is reacted with an amine of formula R1NH2 where Rj is as defined above to provide a tetrazolo[l,5- α][l,7]naphthyridin-5-amine of Formula XXII. The reaction can be carried out by heating with an excess of the amine. In step (7) of Reaction Scheme II a compound of Formula XXII is nitrated using a suitable nitrating agent such as nitric acid to provide a 4-nitrotetrazolo[l,5- α][l,7]naphthyridin-5-amine of Formula XXIII. Preferably the reaction is carried out in acetic acid with mild heating and .an excess of nitric acid.
In step (8) of Reaction Scheme II a compound of Formula XXIII is reduced to provide a tetrazolo[ 1 ,5-a] [ 1 ,7]naphthyridin-4,5-diamine of Formula XXIV. Preferably the reduction is carried out using an excess of sodium hydrogensulfide in a suitable solvent such as acetic acid. In step (9) of Reaction Scheme II a compound of Formula XXIV is reacted with a carboxylic acid or an equivalent thereof to provide a 7H-tetrazolo[l,5-α]imidazo[4,5- c][l,7]naphthyridine of Formula XXV. Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R substituent in a compound of
Formula XXV. For example, diethoxymethylacetate will provide a compound where R2 is hydrogen and valeryl chloride will provide a compound where R2 is butyl. The reaction can be run in the absence of solvent, in a carboxylic acid such as acetic acid, or in an inert solvent in the presence of a carboxylic acid. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
In step (10) of Reaction Scheme II a compound of Formula XXV is reacted with triphenylphosphine to provide a N-triphenylphosphinyl-7H-imidazo[4,5- c][l,7]naphthyridin-4-amine of Formula XXVI. The reaction can be carried out by combining a compound of Formula XXV with triphenylphosphine in a suitable solvent such as 1 ,2-dichlorobenzene and heating.
In step (11) of Reaction Scheme II a compound of Formula XXVI is hydro lyzed to provide a 7H-imidazo[4,5-c][l,7]naphthyridin-4-amine of Formula XXVII which is a subgenus of Formula I. The hydrolysis can be carried out by conventional methods such as by heating in a lower alkanol in the presence of an acid. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
In step (12) of Reaction Scheme II a compound of Formula XXVII is reduced to provide a 6,7,8,9-tetrahydro-77J-imidazo[4,5-c][l,7]naphthyridin-4- .amine of Formula XXVIII which is a subgenus of Formula II. The reduction is carried out by suspending or dissolving a compound of Formula XXVII in trifluoroacetic acid, adding a catalytic amount of platinum (IV)oxide, and then subjecting the mixture to hydrogen pressure. The reaction can be conveniently carried out in a Pan apparatus. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Alternatively, as illustrated in step (13) of Reaction Scheme II, a 6,7,8,9- tetrahydro-77/-imidazo[4,5-c][l,7]naphthyridin-4-amine of Formula XXVIII can be prepared by reduction of a compound of Formula XXV. The reduction is carried out by suspending or dissolving a compound of Formula XXV in trifluoroacetic acid, adding a catalytic amount of platinum (IV)oxide, and then subjecting the mixture to hydrogen pressure. The reaction can be conveniently carried out in a Parr apparatus. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Compounds of Formulas I and II wherein A is =CR-CR-CR-N= or B is -C(R)2-C(R)2-C(R)2-NR- and R, R\ and R2 are as defined above can be prepared according to Reaction Scheme III.
Reaction Scheme III
Figure imgf000020_0001
(3)
Figure imgf000020_0002
XXXIV XXXIII
(6)
Figure imgf000020_0003
XXXV XXXVI
In step (1) of Reaction Scheme III a 3-nitro[l,5]naphthyridin-4-ol of Formula XXIX is chlorinated using a suitable chlorinating agent such as phosphorus oxychloride to provide a 4-chloro-3-nitro[l,5]naphthyridine of Formula XXX. The reaction can be carried out by reacting a compound of Formula XXIX with phosphorus oxychloride in a suitable solvent such as N,N-dimethylformamide with mild heating (-55° C). The compound may be isolated by conventional methods or it can be carried on without isolation as described below in connection with step (2). The compound of Formula XXIX where R is hydrogen is known and its preparation has been disclosed in Hart,
Journal of the Chemical Society pp. 212-214, (1956).
In step (2) of Reaction Scheme III a 4-chloro-3-nitro[l,5]naphthyridine of Formula
XXX is reacted with an amine of Formula R1NH2 where Ri is as defined above to provide a 3-nitro[l ,5]naphthyridin-4-amine of Formula XXXI. The reaction can be carried out by adding water then excess amine to the reaction mixture resulting from step (1) then heating on a steam bath. The reaction can also be carried out by adding excess amine to a solution of a compound of Formula XXX in a suitable solvent such as dichloromethane and optionally heating. The compound of Formula XXXI where Rj is hydrogen is known and its preparation has been disclosed in Wozniak et al, J. R. Neth. Chem. Soc. 102 (12), pp. 511-13 (1983).
In step (3) of Reaction Scheme III a 3-nitro[l,5]naphthyridin-4-amine of Formula
XXXI is reduced to provide a [l,5]naphthyridine-3,4-diamine of Formula XXXII. Preferably, the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as ethyl acetate.
In step (4) of Reaction Scheme III a compound of Formula XXXII is reacted with a carboxylic acid or an equivalent thereof to provide a IH- imidazo[4,5-c][l,5]naphthyridine of Formula XXXIII. Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R2 substituent in a compound of Formula
XXXIII. For example, diethoxymethylacetate will provide a compound where R2 is hydrogen and trimethylorthovalerate will provide a compound where R2 is butyl. The reaction can be run in the absence of solvent, in a carboxylic acid such as acetic acid, or in an inert solvent in the presence of an acid. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
Alternatively, step (4) may be carried out by (i) reacting a compound of Formula
XXXII with an acylating agent; and then (ii) cyclizing the product. Part (i) involves reacting a compound of Formula XXXII with an acyl halide of formula R2C(O)X wherein R2 is as defined above and X is chloro or bromo. The reaction can be carried out by adding the acyl halide in a controlled fashion (e.g. dropwise) to a solution of a compound of Formula XXXII in a suitable solvent such as dichloromethane at a reduced temperature (e.g., 0°C). The resulting amide intermediate can be isolated by removal of the solvent.
Part (ii) involves cyclizing the product of part (i) by reacting it with methanolic ammonia at an elevated temperature (e.g. 150°C) and pressure.
In step (5) of Reaction Scheme III a compound of Formula XXXIII is oxidized to provide a IH- imidazo[4,5-c][l,5]naphthyridine-5N-oxide of Formula XXXIV using a conventional oxidizing agent that is capable of forming N-oxides. Prefened reaction conditions involve reacting a solution of a compound of Formula XXXIII in chloroform with 3-chloroperoxybenzoic acid at ambient conditions.
In step (6) of Reaction Scheme III a compound of Formula XXXIV is aminated to provide a IH- imidazo[4,5-c][l,5]naphthyridin-4-amine of Formula XXXV which is a subgenus of Formula I. Step (6) involves (i) reacting a compound of formula XXXIV with an acylating agent; and then (ii) reacting the product with an aminating agent. Part (i) of step (6) involves reacting an N-oxide with an acylating agent. Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benzenesulfonyl chloride, methanesulfonyl choride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are prefened. p- Toluenesulfonyl chloride is most prefened. Part (ii) of step (6) involves reacting the product of part (i) with an excess of an aminating agent. Suitable aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate). Ammonium hydroxide is prefened. The reaction is preferably carried out by dissolving the N-oxide of Formula XXXIV in an inert solvent such as dichloromethane, adding the aminating agent to the solution, and then adding the acylating agent. Preferred conditions involve cooling to about 0°C to about 5°C during the addition of the acylating agent. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
Alternatively step (6) may be carried out by (i) reacting a compound of Formula XXXFV with an isocyanate; and then (ii) hydrolyzing the product. Part (i) involves reacting the N-oxide with an isocyanate wherein the isocyanato group is bonded to a carbonyl group. Prefened isocyanates include trichloroacetyl isocyanate and aroyl isocyanates such as benzoyl isocyanate. The reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as dichloromethane. The resulting product can be isolated by removal of the solvent. Part (ii) involves hydrolysis of the product from part (i). The reaction can be carried out by conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide.
In step (7) of Reaction Scheme III a compound of Formula XXXV is reduced to provide a 6,7,8,9-tetrahydro-777- imidazo[4,5-c][l,5]naphthyridin-4-amine of Formula XXXVI which is a subgenus of Formula II. The reduction is carried out by suspending or dissolving a compound of Formula XXXV in trifluoroacetic acid, adding a catalytic amount of platinum (IV) oxide, and then subjecting the mixture to hydrogen pressure. The reaction can be conveniently carried out in a Pan apparatus. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Certain functional groups recited in connection with Ri and R2 may be incompatible with some of the reagents of Reaction Schemes I, II and III. Compounds containing such functional groups can be prepared by those skilled in the art using well known methods of functional group protection and manipulation. For example, amine groups may be protected when necessary by derivatizing with di-tert-butyl dicarbonate. Some compounds of Formula I or Formula II containing certain functional groups may be readily prepared from other compounds of Formula I or Formula II. For example, compounds wherein the Ri substituent contains an amide group may conveniently be prepared by reacting an acid chloride with a compound of Formula I or Formula II wherein the R] substituent contains a primary amine. Likewise, compounds wherein the Ri substituent contains a urea group may be prepared by reacting an isocyanate with a compound of Formula I or Formula II wherein the Ri substituent contains a primary amine. Further, compounds wherein the R] substituent contains a carbamate group may be prepared by reacting a chloro formate with a compound of Formula I or Formula II wherein the Ri substituent contains a primary amine. Certain of the intermediate compounds useful in the preparation of compounds of
Formula I and Formula II have not been previously described. Therefore, the invention also provides intermediate compounds useful in the preparation of compounds of Formula I and Formula II. The structural formulas of these novel intermediates are set forth below. These compounds have the following structural formulas:
Intermediate Compound 1
Figure imgf000024_0001
wherein R1 } R2 and A are as defined above for compounds of Formula I and Formula II.
Intermediate Compound 2
Figure imgf000024_0002
wherein R, Ri, and R2 are as defined above for compounds of Formula I and Formula II.
Intermediate Compound 3
Figure imgf000025_0001
wherein R, Ri and R2 are as defined above for compounds of Formula I and Formula II.
Intermediate Compound 4
Figure imgf000025_0002
wherein R7 is OH, halogen or NHRt (.and A and Ri are as defined above for compounds of Formula I) and R8 is H, NO2 or NH2.
Intermediate Compound 5
Figure imgf000026_0001
wherein A is as defined above for compounds of Formula I and R is H or Ci-io alkyl.
Intermediate Compound 6
Figure imgf000026_0002
wherein R and Ri are as defined above for compounds of Formula I and Formula II with the proviso that Ri is other than hydrogen, and R10 is NO2 or NH2.
Pharmaceutical Compositions and Biological Activity
Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound of Formula I or Formula II as defined above in combination with a pharmaceutically acceptable carrier. As used herein, the term "a therapeutically effective amount" means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction or antiviral activity. Although the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound as well as the nature of the carrier and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about lOOng/kg to about 50mg/kg, preferably about lOμg/kg to about 5mg/kg of the compound to the subject. Any of the conventional dosage forms may be used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and so on.
The compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the Test Method set forth below. This ability indicates that the compounds are useful as immune response modifiers that can modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders.
Cytokines that are induced by the administration of compounds according to the invention generally include interferon (IFN) and tumor necrosis factor (TNF) as well as certain interleukins (IL). In particular, the compounds induce IFN-α, TNF-α, IL-1, 6, 10 .and 12, and a variety of other cytokines. Among other effects, cytokines inhibit virus production and tumor cell growth, making the compounds useful in the treatment of tumors and viral diseases.
In addition to the ability to induce the production of cytokines, the compounds affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes.
Compounds of the invention also have an effect on the acquired immune response. For example, although there is not believed to be any direct effect on T cells or direct induction of T cell cytokines, the production of the T helper type 1 (Thl) cytokine LFN-γ is induced indirectly and the production of the Th2 cytokine IL-5 is inhibited upon administration of the compounds. This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl response and/or downregulation of the Th2 response is desired. In view of the ability of compounds of Formula I and
Formula II to inhibit T-helper-type 2 immune response, the compounds are expected to be useful in the treatment of atopy, e.g., atopic dermatitis, asthma, allergy, allergic rhinitis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia.
The immune response modifying effects of the compounds make them useful in the treatment of a wide variety of conditions. Because of their ability to induce cytokines such as IFN-α and TNF-α, the compounds are particularly useful in the treatment of viral diseases and tumors. This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to viral diseases e.g. genital warts, common warts, plantar warts, Hepatitis B, Hepatitis C, Herpes Simplex Type I and Type II, molluscum contagiosm, HIV, CMV, VZV, cervical intraepithelial neoplasia, human papillomavirus and associated neoplasias; fungal diseases, e.g. Candida, aspergillus, cryptococcal meningitis; neoplastic diseases, e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers; parasitic diseases, e.g. pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, leishmaniasis; bacterial infections, e.g., tuberculosis, mycobacterium avium. Additional diseases or conditions that can be treated using the compounds of the invention include eczema, eosinophilia, essential thrombocythaemia, leprosy, multiple sclerosis, Ommen's syndrome, rheumatoid arthritis, systemic lupus erythematosis, discoid lupus, Bowen's disease and Bowenoid papulosis.
Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective .amount of a compound of Formula I or Formula II to the animal. An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, INF- , TNF-α, IL-1,6,10 and 12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of about lOOng/kg to about 50mg/kg, preferably about lOμg/kg to about 5mg/kg. The invention further provides a method of treating a viral infection in .an animal comprising administering an effective amount of a compound of Formula I or Formula II to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise amount will vary according to factors known in the art but is expected to be a dose of lOOng/kg to about 50mg/kg, preferably about lOμg/kg to about 5mg/kg. The invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way.
Example 1 Compound of Formula V 2-(5-Methyl-ii/-tetrazol-l -yl)nicotinic Acid
Part A:
2-Aminonicotinic acid (5 g, 36 mmole) was suspended in acetic anhydride (25 mL) then heated at reflux for 2 hours. The reaction mixture was concentrated under vacuum.
The resulting residue was slurried with ethyl acetate and hexane then filtered to provide 5 g of 2-methyl-^77-pyrido[2,3--7][l,3]oxazin-4-one.
Part B:
The material from Part A was covered with acetic acid (75 mL), sodium azide (2 g) was added and the reaction mixture was stined at ambient temperature over the weekend.
The resulting precipitate was isolated by filtration then dried to provide 5.6 g of 2-(5- methyl-7H-tetrazol-l-yl)nicotinic acid as a white solid, .p. 178-180°C (gas evolution).
Analysis: Calculated for C8Η7N5O2: %C, 46.83; %H, 3.44; %N, 34.13; Found: %C, 46.38;
%H, 3.36; %N, 34.01.
Example 2
Compound of Formula VI
Ethyl 2-(5-Methyl-7/7-tetrazol-l -yl)nicotinate
2-(5-Methyl-7H-tetrazol-l-yl)nicotinic acid (5.6 g, 27 mmole) was suspended in acetone (250 mL), potassium carbonate (5 g) and ethyl iodide (5 mL) were added and the reaction mixture was heated at reflux for 2 hours. The acetone was removed under vacuum. The residue was partitioned between water and dichloromethane. The dichloromethane layer was separated, dried, then concentrated under vacuum to provide 6.3 g of ethyl 2-(5 -methyl- lH-tetrazol-l-yl)nicotinate.
Example 3
Compound of Formula VII
Tetrazolo [ 1 ,5-a] [1 ,8] naphthyridin-5-ol
Ethyl 2-(5-methyl-7H-tetrazol-l-yl)nicotinate (6.3 g, 27 mmole) was covered with N,N-dimethylformamide (50 mL), potassium ethoxide (4.5 g, 54 mmole) was added and the reaction mixture was stined at ambient temperature for 2 hours. The reaction mixture was poured into ice water containing about 17 mL of acetic acid. The resulting precipitate was isolated by filtration, washed with water then dried to provide 4.5 g of tetrazolo[l,5- fl][l,8]naphthyridin-5-ol as an off white solid, m.p. 236° (decomposition). Analysis: Calculated for C8Η5N5O: %C, 51.34; %H, 2.69; %N, 37.42; Found: %C, 51.23 ; %H,
2.77; %N, 37.25.
Example 4 5-Chlorotetrazolo [1 ,5-α] [1 ,8] naphthyridine Tetrazolo[l,5-a][l,8]naphthyridin-5-ol (0.5 g, 2.67 mmole) was suspended in phosphorous oxychloride (10 mL) and heated at reflux for 4 hours. The reaction mixture was concentrated under vacuum and the residue was poured into water. Dichloromethane was added and the aqueous layer was made basic with sodium bicarbonate. The dichloromethane layer was separated, dried over magnesium sulfate, filtered and then concentrated under vacuum. The resulting solid was recrystallized from toluene to provide 0.3 g of 5-chlorotetrazolo[l,5-α][l,8]naphthyridine as a solid, m.p. 229-230°C (decomposition). Analysis: Calculated for C8H4C1N5: %C, 46.73; %H, 1.96; %N, 34.06; Found: %C, 46.87; %H 1.54; %N, 33.93.
Example 5 Compound of Formula VIII
4-Nitrotetrazolo [ 1 ,5-α] [ 1 ,8] n aphth ryidin-5-ol
Nitric acid (1.33 mL of 16M) was added to a suspension of tetrazolo[l,5- α][l,8]naphthyridin-5-ol (4 g, 21 mmole) in acetic acid (50 mL). The reaction mixture was heated on a steam bath for 5 minutes then cooled to ambient temperature. Sodium acetate (0.3 eq) in a small amount of water was added to the reaction mixture. The resulting solid was isolated by filtration and dried to provide 5 g of 4-nitrotetrazolo[l,5- α][l,8]naphthryidin-5-ol as a solid, m.p. 278°C (decomposition). Analysis: Calculated for C8H4N6O3 + 1.1 H2O: %C, 38.12; %H, 2.48; %N, 33.35; Found: %C, 37.99; %H, 2.41; %N, 32.82.
Example 6 Compound of Formula X N5-(2-Methylpropyl)-4-nitrotetrazolo [1 ,5-α] [1 ,8] naphthyridin-5-amine 4-Nitrotetrazolo[l,5-α][l,8]naphthryidin-5-ol (3 g, 13 mmole) was suspended in dichloromethane (3.8 mL), triethylamine (1.8 mL) was added, and the reaction mixture was cooled in an ice bath. Trifiuoromethanesulfonic anhydride (2.2 mL) was added dropwise. Isobutylamine (3.8 mL) was added in a single aliquot and the reaction mixture exothermed. The reaction mixture was partitioned between dichloromethane and aqueous sodium bicarbonate. The dichloromethane layer was separated, dried over magnesium sulfate then filtered through a layer of silica gel. The silica gel was eluted first with dichloromethane then with 5% methanol in dichloromethane. The eluant was evaporated to provide N5-(2-methylpropyl)-4-nitrotetrazolo[l,5- ][l,8]naphthyridine-5-amine as a yellow solid, m.p. 171°C (decomposition). Analysis: Calculated for Ci2Hi3N O2: %C, 50.17; %H 4.56; %N, 34.13; Found: %C, 49.84; %H, 4.51; %N, 33.88. Example 7
Compound of Formula XI
N5-(2-Methylpropyl)tetrazolo[l,5-α][l,8]naphthyridin-4,5-diamine
A catalytic amount of 5% platinum on carbon was added to a suspension of N5-(2- methylpropyl)-4-nitrotetrazolo[l,5-β][l,8]naphthyridine-5-amine (2.45 g, 8.5 mmoles) in ethanol (120 mL). The reaction mixture was reduced on a Pan apparatus at 50 psi (3.5 Kg/cm2) hydrogen for 2 hours. The reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under vacuum to provide N5-(2-methylpropyl)tetrazolo[l,5- α][l,8]naphthyridin-4,5-diamine as an oil.
Example 8
Compound of Formula XII
1 -(2-Methy lpropy l)-7/7-tetrazoIo [ 1 ,5-α] imidazo [4,5-c] [ 1 ,8] n aphthyridin e
The N5-(2-methylpropyl)tetrazolo[ 1 ,5-a] [ 1 ,8]naphthyridin-4,5-diamine from Example 7 was combined with diethoxymethylacetate (2 mL) and heated on a steam bath for 3 hours. The reaction mixture was allowed to stand at ambient temperature overnight and then it was diluted with dichloromethane and methanol. The resulting solution was heated to remove the dichloromethane and reduce the volume of methanol to 50 mL and then cooled. The resulting precipitate was isolated by filtration to provide 1.2 g of l-(2- methylpropyl)-7H-tetrazolo[ 1 ,5-α]imidazo[4,5-c] [ 1 ,8]naphthyridine as a solid, m.p. 248-
250°C (decomposition). Analysis: Calculated for CBH13N7: %C, 58.42; %H, 4.90; %N, 36.68; Found: %C, 58.04; %H, 4.79; %N, 36.23.
Example 9
Compound of Formula I l-(2-Methylpropyl)-2/y-imidazo[4,5-c][l,8]naphthyridin-4-amine hydrate
Figure imgf000033_0001
Part A:
Triphenylphosphine (1.0 g, 3.7 mmole) was added to a solution of l-(2- methylpropyl)-7H-tetrazolo[l,5-α]imid^o[4,5-c][l,8]naphthyridine (0.5 g, 1.87 mmole) in 1 ,2-dichlorobenzene (15 mL). The reaction mixture was heated at reflux for 2 hours then concentrated under vacuum to remove the majority of the 1 ,2-dichlorobenzene. The residue was slurried with hexanes for 30 minutes. The resulting solid l-(2-methylpropyl)- N-triphenylphosphinyl-7H-imid.azo[4,5-c][l,8]naphthyridin-4- amine was isolated by filtration and dried. Part B:
The 1 -(2-methylpropyl)-N-triphenylphosphinyl-7H-imidazo[4,5- c][l,8]naphthyridin-4- .amine from P-art A was dissolved in methanol (15 mL). Hydrochloric acid (10 mL of 0.6N) was added and the reaction mixture was heated at reflux for 1 hour. The reaction mixture was concentrated under vacuum. The residue was diluted with water then made basic with sodium bicarbonate. The resulting solid was isolated by filtration, slurried with ether and then isolated by filtration. The solid was suspended in toluene (25 mL). The suspension was heated to reflux then diluted with methanol (10 mL) to dissolve the solid. The solution was refluxed to remove the methanol then cooled to ambient temperature. The resulting precipitate was isolated by filtration then coated onto silica gel. The silica gel was eluted with 10-20% methanol in ethyl acetate. The eluant was concentrated to dryness. The resulting material was recrystallized from methanol and water to provide 0.35 g l-(2-methylpropyl)-7H-imidazo[4,5- c][l,8]naphthyridin-4-amine hydrate as a solid, m.p. 325-330°C (decomposition). Analysis: Calculated for Cι35N5 + Y4 H2O: %C, 63.52; %H, 6.35; %N, 28.49; Found: %C, 64.02; %H, 5.87; %N, 28.23.
Example 10
Compound of Formula II
6,7,8,9-Tetrahydro-l-(2-methylpropyl)-
7/7-imidazo[4,5-c] [l,8]naphthyridin-4- amine
Figure imgf000034_0001
Platinum oxide catalyst was added to a solution of l-(2-methylpropyl)-777- tetrazolo[l,5-α]imidazo[4,5-c][l,8]naphthyridine in trifluoroacetic acid (30 mL). The reaction mixture was reduced on a Parr apparatus at 50 psi (3.5 Kg/cm ) hydrogen pressure for 5 hours. The reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under vacuum. The residue was combined with water and sodium bicarbonate. The resulting precipitate was isolated by filtration. The solid was dissolved in IN hydrochloric acid and charcoal filtered. The filtrate was treated with 10% sodium hydroxide. The resulting precipitate was isolated by filtration then recrystallized from ethyl acetate/methanol. The recrystallized material was dissolved in dichloromethane/methanol and placed on a silica gel column. The column was eluted with 10% methanol in ethyl acetate. The eluant was concentrated under vacuum and the residue was recrystallized from methanol/water to provide 0.9 g of 6,7,8,9-tetrahydro-l- (2-methylpropyl)-77f-imidazo[4,5-c][l,8]naphthyridin-4-amine as a solid, m.p. 231- 233°C. Analysis: Calculated for Cι39N5: %C, 63.65; %H, 7.81 ; %N, 28.55; Found: %C,
62.99; %H, 7.74; %N, 28.33. Example 11
Compound of Formula XII
2-Butyl-l-(2-methylpropyl)-lJH-tetrazolo[l,5-α]imidazo[4,5-c][l,8]naphthyridine A catalytic amount of 5% platinum on carbon was added to a suspension of N^^- methylpropyl^-nitrotetrazolofl^-αJfljSjnaphώ^ (5g, 17.4 mmoles) in ethanol (300 mL). The reaction mixture was reduced on a Pan apparatus at 50 psi (3.5 Kg/cm2) hydrogen for 2 hours. The reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under vacuum to provide N5-(2-methylpropyl)tetrazolo[l,5- α][l,8]naphthyridin-4,5-diamine as an oil.
The oil was covered with acetic acid (300 mL), valeryl chloride (2.1 mL, 17.4 mmole) was added and the resulting mixture was heated at reflux overnight. The reaction mixture was concentrated under vacuum. The resulting residue was taken up in dichloromethane, washed with sodium bicarbonate, dried over magnesium sulfate then concentrated under vacuum. The residue was purified using flash chromatography (silica gel; eluting with 2-3% methanol in dichloromethane). The isolated product was purified further using preparatory high performance liquid chromatography eluting with 2% methanol in dichloromethane to provide 2-butyl-l-(2-methylpropyl)-7H-tetrazolo[l,5- α]imid.azo[4,5-c][l,8]naphthyridine as a solid, m.p. 182-184°C. Analysis: Calculated for C17Η21N7: %C, 63.14; %H, 6.55; %N, 30.32; Found: %C, 63.45; %H, 6.60; %N, 30.40.
Example 12
Compound of Formula I
2-Butyl-l-(2-methylpropyl)- Jlϊ-imidazo[4,5-c][l,8]naphthyridin-4-amine
Figure imgf000036_0001
Triphenylphosphine (0.9 g, 3.7 mmole) was added to a solution of 2-butyl-l-(2- methylpropyl)-7H-tetrazolo[l,5-α]imid^o[4,5-c][l,8]naphthyridine (0.6 g, 1.8 mmole) in 1,2-dichlorobenzene (15 mL). The resulting mixture was heated at reflux for 2 hours then concentrated under vacuum to remove most of the 1,2-dichlorobenzene. The residue was slurred with hexanes then taken up in dichloromethane and filtered through a layer of silica gel. The silica gel was eluted initially with dichloromethane to remove the 1,2- dichlorobenzene and then with 10% methanol in dichloromethane to recover 2-butyl-l-(2- methylpropyl)-N-triphenylphosphinyl-7H-imid.azo[4,5-c] [ 1 ,8]naphthyridin-4- amine.
The 2-butyl-l-(2-methylpropyl)-N-triphenylphosphinyl-7H-imidazo[4,5- c][l,8]naphthyridin-4- amine was taken up in methanol (15 mL), combined with hydrochloric acid (10 mL of 0.6N), and then heated at reflux for 1 hour. The methanol was removed under vacuum. The residue was combined with water and 10% hydrochloric acid then filtered. The filtrate was neutralized with 10% sodium hydroxide. The resulting precipitate was isolated by filtration and dried. The resulting solid was refluxed in toluene. The volume of toluene was reduced and the product was allowed to crystallize out under an argon atmosphere to provide 0.25 g of 2-butyl-l-(2-methylpropyl)-7H- imidazo[4,5-c][l,8]naphthyridin-4-amine hemihydrate, m.p. 237-240°C. Analysis: Calculated for Cι7H23N5 + Vi H2O: %C, 68.66; %H, 7.79; %N, 23.55; Found: %C, 66.80;
%H, 7.62; %N, 23.46. Example 13
Compound of Formula II
2-ButyI-6,7,8,9-tetrahydro-l-(2-methylpropyl)-
7 -imidazo[4,5-c][l,8]naphthyridin-4-amine
Figure imgf000037_0001
A catalytic amount of platinum oxide was added to a solution of 2-butyl-l-(2- methylpropyl)-7H-imid^o[4,5-c][l,8]naphthyridin-4-amine (2.0 g, 6.2 mmole) in trifluoroacetic acid (30 mL). The reaction mixture was reduced on a Pan apparatus under
50 psi (3.5 Kg/cm2) hydrogen pressure. The reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under vacuum. The residue was combined with water, sodium bicarbonate and 10% sodium hydroxide. An oil was recovered and purified using reverse phase high performance liquid chromatography eluting with 30:70 buffer (7.68 g potassium phosphate, monobasic; 1.69 g of sodium hydroxide, 1 L of water) :methanol to provide 2-butyl-6,7,8,9-tetrahydro-l-(2-methylpropyl)-7H- imidazo[4,5-c][l,8]naphthyridin-4-amine hemihydrate as a solid, m.p. 81-84°C. Calculated for C17H27N5 + '/J^O: %C, 65.77; %H, 9.09; %N, 22.56; Found: %C, 65.57; %H, 9.15; %N, 22.53.
Example 14 Compound of Formula XVIII 3-(5-Methyl-2 -tetrazol-l-yl)pyridine-4-carboxylic acid 3-Aminopyridine-4-carboxylic acid (50.0 g, 0.36 mol) was suspended in acetic anhydride (250 mL) then heated at reflux for 2 hours. The reaction mixture was concentrated under vacuum. The solid residue was slurried with heptane then concentrated under vacuum. The resulting solid was covered with acetic acid (300 mL), then sodium azide (23.5 g, 0.36 mol) was added. The reaction exothermed to 50°C. The reaction mixture was allowed to stir at ambient temperature overnight. The precipitate was isolated by filtration then slurried with methanol and filtered. The solid was dissolved in 10% sodium hydroxide. The solution was heated on a steam bath for 30 minutes, allowed to cool to ambient temperature then neutralized with 6N hydrochloric acid. The resulting precipitate was isolated by filtration, washed with water and dried to provide
64.5 g of 3-(5-methyl-7H-tetrazol-l-yl)pyridine-4-carboxylic acid as an off white solid, m.p. 214-215°C (decomposition).
Example 15 Compound of Formula XIX
Ethyl 3-(5-Methyl-i/7-tetrazol-l-yl)pyridine-4-carboxylate
Dimethylformamide diethyl acetal (46 mL) was added to a suspension of 3-(5- methyl-7H-tetrazol-l-yl)pyridine-4-carboxylic acid (36 g) in dichloromethane (800 mL). The reaction mixture was stined at ambient temperature overnight then washed six times with water (500 mL), dried over magnesium sulfated, and concentrated under vacuum.
The residue was recrystallized from ethyl acetate/hexanes to provide 40 g of ethyl 3-(5- methyl-77J-tetrazol-l-yl)pyridine-4-carboxylate as a solid.
Example 16 Compound of Formula XX
Tetrazolo[l,5-α] [l,7]naphthyridin-5-ol hydrate
Potassium ethoxide (20.2 g) was added to a mixture of ethyl 3-(5-methyl-7H- tetrazol-l-yl)pyridine-4-carboxylate (28 g) and dimethylformamide (280 mL). The reaction mixture was allowed to stir at ambient temperature overnight then poured into cold dilute acetic acid. The resulting precipitate was collected, washed with water and dried to provide 22.4 g of tetrazolo[l,5- ][l,7]naphthyridin-5-ol hydrate as a solid, m.p. 247-248°C (decomposition). Analysis: Calculated for C8H5N5O: %C, 46.83; %H, 3.44; %N, 34.13; Found: %C, 46.48; %H, 3.42; %N, 34.03. Example 17
Compound of Formula XXI
5-Chlorotetrazolo[l,5-α][l,7]naphthyridine A suspension of tetrazolo[l,5-α][l,7]naphthyridin-5-ol (3.5 g) in phosphorous oxychloride (15 mL) was heated at 90°C for 2 hours. The reaction mixture was concentrated under vacuum. The residue was poured into ice water, dichloromethane was added followed by the addition of 10% sodium hydroxide to neutral pH. The product was partitioned into dichloromethane. The dichloromethane layer was separated, dried over magnesium sulfate then concentrated under vacuum to provide 3.8 g of 5- chlorotetrazolo[l,5-α][l,7]naphthyridine as a solid, m.p. 176-177°C. Analysis: Calculated for C8H4C1N5: %C, 46.73; %H, 1.96; %N, 34.06; Found: %C, 46.80; %H, 2.16; %N, 34.45.
Example 18
Compound of Formula XXII N5-(2-Methylpropyl)tetrazolo[l,5-α][l,7]naphthyridin-5-amine
A suspension of 5-chlorotetrazolo[l,5-α][l,7]naphthyridine (20 g) in isobutylamine (100 mL) was heated at reflux for several hours. The reaction mixture was concentrated under vacuum. The residue was taken up in dichloromethane, washed with water, dried over magnesium sulfate then concentrated under vacuum. The residue was recrystallized from toluene to give a material that was a mixture by thin layer chromatography. The material was purified by flash chromatography, silica gel eluting with dichloromethane, 5- 20% ethyl acetate in dichloromethane, and 10% methanol in dichloromethane. The fractions with the slower moving material were concentrated to provide N5-(2- methylpropyl)tetr^olo[l,5-α][l,7]naphthyridin-5-amine as a solid, m.p. 220-221°C. Analysis: Calculated for Cι2H14N6: %C, 59.49; %H, 5.82; %N, 34.69; Found: %C, 59.35; %H, 5.89; %N, 34.88. Example 19
Compound of Formula XXIII
N5-(2-Methy lpropy l)-4-nitrotetr azolo [ 1 ,5-α] [ 1 ,7] n aphthy ridin-5-amin e
Nitric acid (2 equivalents of 16M) was added to a solution of N5-(2- methylpropyl)tetrazolo[l,5-α][l,7]naphthyridin-5-amine (2.0 g, 8.26 mmol) in acetic acid.
The reaction mixture was heated on a steam bath for about an hour then concentrated under vacuum. The residue was poured into ice water and the resulting mixture was neutralized with sodium bicarbonate. The resulting precipitate was extracted with dichloromethane. The dichloromethane extracts were combined, washed with water, and dried over magnesium sulfate. Thin layer chromatography indicated a mixture so the material was filtered through a layer of silica gel eluting with 5% ethyl acetate in dichloromethane. The reaction was rerun on 4 g of starting material but using only one equivalent of nitric acid. The resulting material was also a mixture. The material from both reactions was combined then purified by flash chromatography eluting with mixtures of hexanes/ethyl acetate. The fractions containing the slower moving material were combined to provide about 0.3 g of N5-(2-methylpropyl)-4-nitrotetrazolo[l,5- α][l,7]naphthyridin-5-amine as a yellow solid, m.p. 173-174°C. Analysis: Calculated for C12H13N7O2: %C, 50.17; %H, 4.56; %N, 34.13; Found: %C, 49.85; %H, 4.53; %N, 34.26.
Example 20
Compound of Formula XXIV N5-(2-Methylpropyl)tetrazolo [1 ,5-α] [1 ,7] naphthyridin-4,5-diamine
N5-(2-Methylpropyl)-4-nitrotetrazolo[l,5-α][l,7]naphthyridin-5-amine (1.5 g, 5.22 mmol) was suspended in acetic acid (75 mL). An excess of sodium hydrogen sulfide was dissolved in a minimum of water and added to the suspension. The reaction mixture turned red and all of the material went into solution. The reaction mixture was extracted twice with dichloromethane (150 mL). The extracts were combined, washed with water, dried over magnesium sulfate, filtered and concentrated under vacuum to provide 1.22 g of N5-(2-methylpropyl)tetrazolo[l,5-α][l,7]naphthyridin-4,5-diamine as a light yellow solid, m.p. 203-204.5°C. Analysis: Calculated for: C12H15N7: %C, 56.02; %H, 5.88; %N, 38.11;
Found: %C, 55.68; %H, 5.81; %N, 37.74. Example 21
Compound of Formula XXV l-(2-Methylpropyl)-7/ -tetrazolo[l,5-α]imidazo[4,5-c][l,7]naphthyridine
N5-(2-Methylpropyl)tetrazolo[l,5-α][l,7]naphthyridin-4,5-diamine (1.1 g, 4.3 mmol) was combined with diethoxymethylacetate (2 mL) and heated on a steam bath overnight. The reaction mixture was partitioned between dichloromethane and ammonium hydroxide. The dichloromethane layer was separated, washed with water, dried over magnesium sulfate and concentrated under vacuum. The residue was recrystallized from ethyl acetate/hexane to provide 0.85 g of l-(2-methylpropyl)-77J-tetrazolo[l,5- α]imidazo[4,5-c][l,7]naphthyridine as a solid, m.p. 181-182.5°C. Analysis: Calculated for
C133N7: %C, 58.42; %H, 4.90; %N, 36.68; Found: %C, 58.87; %H, 5.04; %N, 36.13.
Example 22 Compound of Formula I l-(2-Methylpropyl)-7/ -imidazo[4,5-c] [l,7]naphthyridin-4-amine
Figure imgf000041_0001
Part A: Triphenylphosphine (0.49 g, 1.8 mmol) was added to a suspension of l-(2- methylpropyl)-777-tetrazolo[l,5-α]imidazo[4,5-c][l,7]naphthyridine (0.24 g, 0.9 mmol) in dichlorobenzene (15 mL). The reaction mixture was heated at reflux overnight then concentrated under vacuum. The residue was slurried with hexane and the resulting solid 1 -(2-methylpropyl)-N-triphenylphosphinyl-7H-imidazo[4,5-c] [ 1 ,7]naphthyridin-4-amine was isolated by filtration.
Part B: The 1 -(2-methylpropyl)-N-triphenylphosphinyl-7H-imidazo[4,5- c][l,7]naphthyridin-4-amine from Part A was dissolved in methanol (30 mL). Hydrochloric acid (3 mL of 3N) was added to the solution and the reaction mixture was heated at reflux overnight before being concentrated under vacuum to remove the methanol. The aqueous residue was neutralized with sodium bicarbonate then extracted with dichloromethane. The extract was dried over magnesium sulfate then concentrated under vacuum. The residue was purified by flash chromatography (silica gel eluting with 5-10% methanol in dichloromethane) to provide 0.15 g of l-(2-methylpropyl)-7H- imidazo[4,5-c][l,7]naphthyridin-4-amine as a solid, m.p. 306-307°C. Analysis: Calculated for C135N5: %C, 64.71; %H, 6.27; %N, 29.02; Found: %C, 65.10; %H, 6.28;
%N, 28.70.
Example 23 Compound of Formula II 6,7,8,9-Tetrahydro-l -(2-methylpropyl)-
7/7-imidazo[4,5-c][l,7]naphthyridin-4-amine
Figure imgf000042_0001
A catalytic amount of platinum oxide was added to a solution of l-(2- methylpropyl)-7H-imid^o[4,5-c][l,7]naphthyridin-4-amine (0.4 g, 1.66 mol)) in trifluoroacetic acid. The reaction mixture was reduced on a Parr apparatus at 50 psi (3.5 Kg/cm2) hydrogen pressure overnight. The reaction mixture was filtered and washed with methanol to remove the catalyst. The filtrate was concentrated under vacuum. The residue was combined with dichloromethane and aqueous sodium bicarbonate was added until the mixture was basic. The dichloromethane layer was separated. The aqueous layer was extracted five times with dichloromethane (100 mL). The dichloromethane extracts were combined, dried over magnesium sulfate and concentrated under vacuum. The resulting residue was recrystallized from toluene to provide 0.34 g of 6,7,8,9-tetrahydro-l- (2-methylpropyl)-7H-imidazo[4,5-c][l,7]naphthyridin-4-amine as a solid, m.p. 220- 223°C. Analysis: Calculated for C139N5 + % H2O: %C, 62.50 %H, 7.87; %N, 28.03; Found: %C, 62.50; %H, 7.72; %N, 27.46.
Example 24
Compound of Formula XXV
2-Methyl-l -(2-methylpropyl)-7//-tetrazolo [ 1 ,5-α] imidazo [4,5-c] [ 1 ,7] naphthyridine Acetic anhydride (2-3 L) was added to a solution of N-(2- methylpropyl)tetrazolo[l,5-α][l,7]naphthyridin-4,5-diamine (0.8 g, 3.1 mmole) in acetic acid. The reaction mixture was heated on a steam bath for several hours then concentrated under vacuum. The residue was partitioned between dichloromethane and water. The aqueous layer was made basic with 10% sodium hydroxide then the dichloromethane layer was separated, dried over magnesium sulfate and concentrated under vacuum. The residue was purified by flash chromatography (silica gel eluting with 2-5% methanol in dichloromethane) to provide 0.25 g of 2-methyl-l-(2-methylpropyl)- 7H-tetrazolo[l,5-α]imidazo[4,5-c][l,7]naphthyridine as a solid, m.p. 157-158°C. Analysis: Calculated for Cι45N7: %C, 59.77; %H, 5.37; %N, 34.85; Found: %C, 59.64; %H, 5.48; %N, 34.98.
Example 25
Compound of Formula I
2-Methyl-l-(2-methylpropyl)-77^-imidazo[4,5-c][l,7]naphthyridin-4-amine
Figure imgf000044_0001
Part A:
Triphenylphosphine (2.5 g, 9.6 mmol) was added to a suspension of 2-methyl-l- (2-methylpropyl)-777-tetrazolo[l,5-α]imidazo[4,5-c][l,7]naphthyridine (1 g, 4 mmol) in dichlorobenzene. The reaction mixture was heated at reflux overnight then concentrated under vacuum. The residue was slurried with hexane and the
resulting solid 2-methyl-l-(2-methylpropyl)-N-triphenylphosphinyl-7H-imidazo[4,5- c][l,7]naphthyridin-4-amine was isolated by filtration.
Part B:
The 2-methyl-l-(2-methylpropyl)-N-triphenylphosphinyl-7H-imidazo[4,5- c][l,7]naphthyridin-4-amine from Part A was dissolved in methanol (100 mL).
Hydrochloric acid (10 mL of 3N) was added to the solution and the reaction mixture was heated at reflux overnight before being concentrated under vacuum to remove the methanol. The residue was purified by flash chromatography ( silica gel eluting with dichloromethane and gradually increasing the polarity to 5% methanol in dichloromethane) to provide 2-methyl- 1 -(2-methylpropyl)-777-imidazo[4,5- c][l,7]naphthyridin-4-amine as a solid, m.p. 322-324°C. Analysis: Calculated for C1 H17N5: %C, 65.86; %H, 6.71; %N, 27.43; Found: %C, 65.81; %H, 6.64; %N, 27.41.
Example 26 Compound of Formula II
6,7,8,9-Tetrahydro-2-methyl-l-(2-methylpropyl)- 7H-imidazo[4,5-c][l,7]naphthyridin-4-amine
Figure imgf000045_0001
A catalytic amount of platinum oxide was added to a solution of 2-methyl- 1 -(2- methylpropyl)-777-imidazo[4,5-c][l,7]naphthyridin-4-amine (0.1 g, 0.4 mol) in trifluoroacetic acid. The reaction mixture was reduced on a Parr apparatus at 50 psi (3.5 Kg/cm2) hydrogen pressure overnight. The reaction mixture was filtered and washed with methanol to remove the catalyst, and the filtrate was concentrated under vacuum. The residue was combined with dichloromethane and aqueous sodium bicarbonate was added until the mixture was basic. The dichloromethane layer was separated, and the aqueous layer was extracted three times with dichloromethane (100 mL). The combined dichloromethane extracts were dried over magnesium sulfate and concentrated under vacuum. The resulting residue was recrystallized from toluene to provide 6,7,8,9- tetrahydro-2-methyl-l-(2-methylpropyl)-7H-imidazo[4,5-c][l,7]naphthyridin-4-amine as a solid, m.p. 226-230°C. Analysis: Calculated for C,4H2iN5 + 1.75 H20: %C, 57.81; %H, 8.49; %N, 24.07; Found: %C, 57.89; %H, 8.04; %N, 23.45.
Example 27
Compound of Formula I
2-ButyI-l-(2-methylpropyI)-7//-imidazo[4,5-c][l,7]naphthyridin-4-amine
Figure imgf000046_0001
Part A:
Valeryl chloride (0.76 mL, 6.4 mmol) was added to a solution of N5-(2- methylpropyl)tetrazolo[l,5-β][l,7]naphthyridin-4,5-diamine (1.5 g, 5.8 mmol) in acetonitrile (15 mL). The reaction mixture was allowed to stir at ambient temperature for several hours. The resulting precipitate was isolated by filtration. Thin layer chromatography indicated that the material contained two components. The solid was dissolved in acetic acid and heated at reflux overnight. The reaction mixture was concentrated under vacuum, and the residue extracted with dichloromethane. The dichloromethane extract was washed with water, dried over magnesium sulfate and concentrated under vacuum to provide a mixture of 2-butyl -l-(2-methylpropyl)-7H- tetrazolo[l,5-α]imidazo[4,5-c][l,7]naphthyridine and the acylated, but uncyclized intermediate. Part B: Triphenylphosphine (2.4 g) was added to a suspension of the material from Part A in dichlorobenzene. The reaction mixture was heated at reflux overnight then concentrated under vacuum. The residue was slurried with hexane and the resulting solid 2-butyl- 1 -(2-methylpropyl)-N-triphenylphosphinyl-777-imidazo[4,5- c][l,7]naphthyridin-4-amine was isolated by filtration.
Part C:
The 2-butyl-l-(2-methylpropyl)-N-triphenylphosphinyl-777-imidazo[4,5- c][l,7]naphthyridin-4-amine from Part B was dissolved in methanol. Hydrochloric acid
(3N) was added to the solution and the reaction mixture was heated at reflux overnight before being concentrated under vacuum to remove the methanol. The aqueous residue was mixed with dichloromethane then neutralized with aqueous sodium bicarbonate. The dichloromethane layer was separated, dried over magnesium sulfate and concentrated under vacuum. The residue was purified by flash chromatography (silica gel eluting with dichloromethane and gradually increasing the polarity to 5% methanol in dichloromethane) to provide 2-butyl- 1 -(2 -methylpropyl)-7H-imidazo[4,5- c][l,7]naphthyridin-4-amine as a solid, m.p 213-214°C. Analysis: Calculated for Cι7H23N5: %C, 68.66; %H, 7.80; %N, 23.55; Found: %C, 68.26; %H, 7.69; %N, 23.41.
Ex-ample 28
Compound of Formula II
2-Butyl-6,7,8,9-tetrahydro -1 -(2-methylpropyl)- l//-imidazo [4,5-c] [1 ,7] naphthyridin-4-amine
Figure imgf000047_0001
A catalytic amount of platinum oxide was added to a solution of 2-butyl -l-(2- methylpropyl)-7H-imidazo[4,5-c][l,7]naphthyridin-4-amine (0.5g, 1.68 mol)) in trifluoroacetic acid (20 mL). The reaction mixture was reduced on a Pan apparatus at 50 psi (3.5 Kg/cm ) hydrogen pressure overnight. The reaction mixture was filtered and washed with methanol to remove the catalyst. The filtrate was concentrated under vacuum. The residue was combined with dichloromethane and aqueous sodium bicarbonate was added until the mixture was basic. The dichloromethane layer was separated. The aqueous layer was extracted three times with dichloromethane (100 mL). The dichloromethane extracts were combined, dried over magnesium sulfate and concentrated under vacuum. The resulting residue was recrystallized from toluene then purified by flash chromatography (silica gel eluting with 20% methanol in dichloromethane with a trace of ammonium hydroxide) to provide 6,7,8,9-tetrahydro-2- butyl-l-(2-methylpropyl)-7H-imidazo[4,5-c][l,7]naphthyridin-4-amine as a solid, m.p. 164-166°C. Analysis: Calculated for C H27N5 + 0.5 H2O: %C, 65.77; %H, 9.09; %N, 22.56; Found: %C, 65.99; %H, 8.71; %N, 22.23.
Example 29
Compound of Formula XXXI
N4-(2-Methylpropyl)-3-nitro[l,5]naphthyridin-4-amine
Phosphorous oxychloride (0.6 mL, 6.44 mmol) was reacted with N,N- dimethylformamide then added to a solution of 3-nitro[ 1 ,5]naphthyridin-4-ol (l.O g, 5.23 mmol) in N,N-dimethylformamide (20 mL). The reaction mixture was warmed using a jacketed flask with refluxing acetone as a heat source. After 3 hours the reaction mixture was poured into ice water, isobutylamine (2.0 mL, 20.1 mmol) was added and the mixture was heated on a steam bath. After several hours the reaction mixture was cooled to ambient temperature, filtered and washed with water. The aqueous layer was extracted with dichloromethane. The dichloromethane extract was washed with aqueous sodium bicarbonate, washed with water, dried over magnesium filtrate then loaded onto a layer of silica gel. The silica gel was eluted initially with dichloromethane to remove an impurity then with 5% methanol in dichloromethane to recover the product. The eluant was concentrated to dryness to provide N4-(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine as a solid, m.p. 97-99°C. Example 30
Compound of Formula XXXIII l-(2-Methylpropyl)-7/7-imidazo[4,5-c][l,5]naphthyridine Part A:
A catalytic amount of 5% platinum on carbon was added to a solution of N4-(2- methylpropyl)-3-nitro[l,5]naphthyridin-4-amine (1.0 g, 4.1 mmol) in ethyl acetate (50 mL). The reaction mixture was reduced on a Pan apparatus at 50 psi (3.5 Kg/cm ) hydrogen for four hours. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated under vacuum to provide N4-(2-methylpropyl)[ 1 ,5]naphthyridin-
3,4-diamine as a crude solid. Part B:
The crude solid from Part A was combined with diethoxymethylacetate (2 mL) then heated on a steam bath overnight. The reaction mixture was taken up in dichloromethane, washed with water, dried over magnesium sulfate then filtered through a layer of silica gel. The silica gel was eluted with dichloromethane to remove excess diethoxymethylacetate then with 5% methanol in dichloromethane to recover the product. The eluant was concentrated to provide an oil which was purified by flash chromatography (silica gel eluting with 50% ethyl acetate/hexane then with ethyl acetate) to provide 0.25 g of 1 -(2-methylpropyl)-77/-imidazo[4,5-c] [ 1 ,5]naphthyridine as a solid m.p. 82-84°C.
Analysis: Calculated for C13H14N4: %C, 69.00; %H, 6.24; %N, 24.76; Found: %C, 68.79; %H, 6.44; %N, 24.73.
Example 31 Compound of Formula XXXIV l-(2-Methylpropyl)-ifi-imidazo[4,5-c][l,5]naphthyridine-5N-oxide
3-Chloroperoxybenzoic acid (3.7 g of 50%) was added in small portions over a period of 30 minutes to a solution of l-(2-methylpropyl)-7H-imidazo[4,5- c][l,5]naphthyridine (1.5 g) in chloroform at ambient temperature. After 3 hours the reaction mixture was diluted with chloroform, washed twice with 2.0 M sodium hydroxide and once with water, dried over magnesium sulfate then concentrated under vacuum. The residue was recrystallized from ethyl acetate/hexane to provide 1.2 g of l-(2- methylpropyl)-7H-imidazo[4,5-c][l,5]naphthyridine-5N-oxide as a solid, m.p. 183-185°C. Analysis: Calculated for Cι3H14N4O: %C, 64.45; %H, 5.82; %N, 23.12; Found: %C, 64.15; %H, 5.92; %N, 23.02.
Ex.ample 32
Compound of Formula I l-(2-Methylpropyl)-7^-imidazo[4,5-c][l,5]naphthyridin-4-amine
Figure imgf000050_0001
Ammonium hydroxide (10 mL) was added to a solution of l-(2-methylpropyl)-7H- imidazo[4,5-c][l,5]naphthyridine-5N-oxide (0.6 g) in dichloromethane (30mL). The reaction mixture was cooled in an ice bath then tosyl chloride (0.5 g) in dichloromethane was added while the reaction was being rapidly stined. The reaction mixture was stined at ambient temperature overnight. The dichloromethane layer was separated, washed with aqueous sodium bicarbonate, dried over magnesium sulfate then concentrated under vacuum. The residue was recrystallized from ethyl acetate/hexane to provide 0.2 g of 1- (2-methylpropyl)-7H-imidazo[4,5-c][l,5]naphthyridin-4-amine as a solid, m.p. 230- 231.5°C. Analysis: Calculated for C13Ηι5N5: %C, 64.71; %H, 6.27; %N, 29.02; Found: %C, 64.70; %H, 6.01; %N, 29.08.
Example 33
Compound of Formula II
6,7,8,9-Tetrahydro-l-(2-methylpropyl)-
7 -imidazo[4,5-c][l,5]naphthyridin-4-amine
Figure imgf000051_0001
A catalytic amount of platinum oxide was added to a solution of l-(2- methylpropyl)-777-imidazo[4,5-c][l,5]naphthyridin-4-amine (0.46 g) in trifluoroacetic acid (10 mL). The reaction mixture was reduced on a Parr apparatus under 45 psi (3.15 Kg/cm2) hydrogen pressure for 4 hours. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated under vacuum. The residue was combined with aqueous sodium bicarbonate then a small amount of 10% sodium hydroxide was added. The resulting precipitate was extracted with dichloromethane. The dichloromethane extract was dried over magnesium sulfate then concentrated under vacuum. The residue was purified by flash chromatography (silica gel eluting with 5% methanol in dichloromethane containing 0.5% ammonium hydroxide). The eluant was concentrated under vacuum. The residue was recrystallized from ethyl acetate to provide 6,7,8,9- tetrahydro- 1 -(2-methylpropyl)-7H-imidazo[4,5-c] [ 1 ,5]naphthyridin-4-amine as a solid, m.p. 222-226°C. Analysis: Calculated for C13H19N5: %C, 63.65; %H, 7.81; %N, 28.55; Found: %C, 63.07; %H, 7.51; %N, 28.00. Example 34
Compound of Formula XXXIII
2- MethyI-l-(2-methylpropyl)-7 -imidazo[4,5-c][l,5]naphthyridine Part A:
Magnesium sulfate (3 g) and a catalytic amount of 5% platinum on carbon were added to a solution of N4-(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine (4.0 g, 16.2 mmol) in ethyl acetate (250 mL). The reaction mixture was reduced on a Parr apparatus at 50 psi (3.5 Kg/cm2) hydrogen for four hours. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated under vacuum to provide N4-(2- methylpropyl)[l,5]naphthyridin-3,4-diamine as a crude solid. Part B:
The crude solid from Part A was taken up in acetic acid, combined with acetic anhydride then heated at reflux overnight. The reaction mixture was concentrated under vacuum. The resulting residue was combined with methanol to decompose excess acetic anhydride then concentrated under vacuum. The resulting residue was combined with cyclohexane then concentrated under vacuum to remove the acetic acid. The resulting residue was recrystallized from hexanes to provide 2.2 g of 2- methyl- 1 -(2 -methylpropyl)- 77J-imidazo[4,5-c][l,5]naphthyridine as off-white needles, m.p. 118-119°C. Analysis: Calculated for C14H16N4: %C, 69.97; %H, 6.71 ; % , 23.31 ; Found: %C, 69.24; %H, 6.67;
%N, 23.23.
Example 35 Compound of Formula XXXIV 2-Methyl-l-(2-methylpropyl)-i T-imidazo[4,5-c][l,5]naphthyridine-5N-oxide
3-Chloroperoxybenzoic acid (4.5 g of 50%, 13.1 mmol) was added in small portions over a period of 30 minutes to a solution of 2-methyl- 1 -(2-methylpropyl)-7H- imidazo[4,5-c][l,5]naphthyridine (2.1 g, 8.7 mmole) in chloroform at ambient temperature. After 3 hours the reaction mixture was diluted with chloroform, washed twice with 2.0 M sodium hydroxide, once with water, and once with brine, dried over magnesium sulfate then concentrated under vacuum. The residue was purified by flash chromatography (silica gel eluting with 5% methanol in dichloromethane) to provide 2- methyl-l-(2-methylpropyl)-77J-imidazo[4,5-c][l,5]naphthyridine-5N-oxide as a solid, m.p. 228-230°C. Analysis: Calculated for C,4H16N4O: %C, 65.61; %H, 6.29; %N, 21.86; Found: %C, 65.73; %H, 6.31; %N, 21.95.
Example 36
Compound of Formula I
2-Methyl-l-(2-methylpropyl)-l -imidazo[4,5-c][l,5]naphthyridin-4-amine
Figure imgf000053_0001
Ammonium hydroxide (10 mL) was added to a solution of 2-methyl- 1 -(2- methylpropyl)-777-imidazo[4,5-c][l,5]naphthyridine-5N-oxide (1.1 g, 4.29 mmol) in dichloromethane (50mL). The reaction mixture was cooled in an ice bath then tosyl chloride (0.82 g, 4.29 mmol) in dichloromemane was added. The reaction was warmed to about 30°C while being rapidly stirred. The reaction mixture was stined at ambient temperature overnight. The dichloromethane layer was separated, washed with 10% sodium hydroxide, water and brine, dried over magnesium sulfate then concentrated under vacuum. The residue was recrystallized from ethyl acetate to provide 0.8 g of 2-methyl- 1- (2-methylpropyl)-7H-imidazo[4,5-c][l,5]naphthyridin-4-amine as a solid, m.p. 228- 230°C. Analysis: Calculated for C14H17N5: %C, 65.86; %H, 6.71; %N, 27.43; Found: %C, 65.65; %H, 6.69; %N, 27.59. Example 37
Compound of Formula XXXIII
2- Butyl-l-(2-methylpropyl)-7.ff-imidazo[4,5-c] [l,5]naphthyridine Part A:
Magnesium sulfate (3 g) and a catalytic amount of 5% platinum on carbon were added to a solution of N4-(2-methylpropyl)-3-nitro[l,5]naphthyridin-4-amine (3.0 g, 12.2 mmol) in ethyl acetate (150 mL). The reaction mixture was reduced on a Parr apparatus at 50 psi (3.5 Kg cm2) hydrogen for four hours. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated under vacuum to provide N4-(2- methylpropyl)[l,5]naphthyridin-3,4-diamine as a crude solid. Part B:
The crude solid from Part A was taken up in acetonitrile then combined with valeryl chloride (1.5 mL, 12.2 mmol). The mixture was stined at ambient temperature for 30 minutes. The resulting precipitate was isolated by filtration, washed with a small amount of acetonitrile and air dried to provide 2.75 g of N-(4-(2- methylpropylamino)[l,5]naphthyridin-3-yl)valeramide hydrochloride as a solid. Part C:
The solid from Part B was suspended in acetic acid and heated at reflux overnight. The reaction mixture was concentrated under vacuum and the resulting residue was partitioned between dichloromethane and aqueous sodium bicarbonate. The dichloromethane layer was separated, dried over magnesium sulfate and concentrated under vacuum to provide 2.3 g of 2-butyl- 1 -(2 -methylpropyl)-7H-imidazo[4,5- c][l,5]naphthyridine as an oil.
Example 38
Compound of Formula XXXIV
2-Butyl-l-(2-methylpropyl)-77^-imidazo[4,5-c][l,5]naphthyridine-5N-oxide 3-Chloroperoxybenzoic acid (5.3 g of 50%, 15.2 mmol) was added in small portions over a period of 30 minutes to a solution of 2-butyl- l-(2-methylpropyl)-7H- imidazo[4,5-c][l,5]naphthyridine (2.3 g, 10.2 mmole) in chloroform at ambient temperature. After 3 hours the reaction mixture was diluted with chloroform, washed twice with 2.0 M sodium hydroxide, once with water, and once with brine, dried over magnesium sulfate then concentrated under vacuum. The residue was purified by flash chromatography (silica gel eluting with 5% methanol in dichloromethane) to provide 2- butyl-l-(2-methylpropyl)-7H-imidazo[4,5-c][l,5]naphthyridine-5N-oxide. Analysis: Calculated for C17H22N4O: %C, 68.43; %H, 7.43; %N, 18.78; Found: %C, 67.67; %H, 6.73; %N, 18.13
Example 39
Compound of Formula I
2-Butyl-l-(2-methylpropyl)-7^-imidazo[4,5-c][l,5]naphthyridin-4-amine
Figure imgf000055_0001
Ammonium hydroxide (25 mL) was added to a solution of 2-butyl- 1 -(2- methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridine-5N-oxide (2.0 g, 6.7 mmol) in dichloromethane (lOOmL). The reaction mixture was cooled in an ice bath then tosyl chloride (1.3 g, 6.7 mmol) in dichloromethane was added. The reaction was warmed to about 30°C while being rapidly stined. The reaction mixture was stined at ambient temperature overnight. The dichloromethane layer was separated, washed with 10% sodium hydroxide, water and brine, dried over magnesium sulfate then concentrated under vacuum. The residue was recrystallized from hexane to provide 1.55 g of 2-butyl- 1 -(2- methylpropyl)-7H-imidazo[4,5-c][l,5]naphthyridin-4-amine as a solid, m.p. 115-116°C. Analysis: Calculated for Cι7H23N5: %C, 68.66; %H, 7.80; %N, 23.55; Found: %C, 69.52; %H, 7.72; %N, 21.72
Ex-ample 40
Compound of Formula II
6,7,8,9-Tetrahydro-2-butyl-l-(2-methylpropyl)-
77 -imidazo[4,5-c][l,5]naphthyridin-4-amine
Figure imgf000056_0001
A catalytic amount of platinum oxide was added to a solution of 2-butyl- 1 -(2- methylpropyl)-7H-imidazo[4,5-c][l,5]naphthyridin-4-.amine (0.5 g) in trifluoroacetic acid (15 mL). The reaction mixture was reduced on a Pan apparatus under 50 psi (3.5 Kg/cm2) hydrogen pressure overnight. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated under vacuum. The residue was combined with aqueous sodium bicarbonate then a small amount of 10% sodium hydroxide was added. The resulting precipitate was extracted with dichloromethane. The dichloromethane extract was dried over magnesium sulfate then concentrated under vacuum. The residue was purified by flash chromatography (silica gel eluting with 1-5% methanol in dichloromethane containing 0.5% ammonium hydroxide). The eluant was concentrated under vacuum. The residue was recrystallized from hexane/ethyl acetate to provide 6,7,8,9-tetrahydro-2-butyl- 1 -(2-methylpropyl)-77J-imid.azo[4,5-c] [ 1 ,5]naphthyridin-4- amine as a solid, m.p. 143-147°C. Analysis: Calculated for C17H27N5: %C, 67.74; %H,
9.03; %N, 23.23; Found: %C, 61.90; %H, 7.51; %N, 19.91. Example 41 Compound of Formula XXXI 1,1-Dimethylethyl N-{4-[(3-Nitro[l,5]naphthyridin-4-yl)amino]butyl}carbamate
Phosphorus oxychloride (4 mL, 0.31 mole) was combined with N,N- dimethylform.amide (100 mL) while cooling in .an ice bath. The resulting mixture was added to a solution of 3-nitro[l,5]naphthyridin-4-ol (50 g, 0.26 mole) in N,N- dimethylformamide (500 mL). The reaction mixture was stined at ambient temperature for 6 hours. The reaction mixture was poured into ice water and then extracted with dichloromethane (1800 mL). The organic layer was separated and then combined with triethylamine (45 mL). 7ert-butyl N-(4-aminobutyl)carbamate was added and the reaction mixture was stined overnight. The reaction mixture was concentrated under vacuum and the residue was treated with water (-1500 mL). The resulting solid was isolated by filtration, washed with water and dried to provide 76 g of 1 , 1 -dimethylethyl N- {4-[(3- nitro[l,5]naphthyridin-4-yl)amino]butyl} carbamate as a solid. A small sample was recrystallized from isopropyl alcohol to provide a pure sample, m.p. 137-138°C. Analysis: Calculated for C17H23N5O4: %C, 56.50; %H, 6.41; %N, 19.38; Found: %C, 56.26; %H, 6.30; %N, 19.53.
Ex-ample 42 Compound of Formula XXXII 1,1-Dimethylethyl N-{4-[(3-Amino[l,5]naphthyridin-4-yl)amino]butyl}carbamate 1,1 -Dimethylethyl N- {4-[(3-nitro[ 1 ,5]naphthyridin-4-yl)amino]butyl} carbamate
(42.7 g, 0.12 mole), platinum on carbon (2 g) and ethyl acetate (500 mL) were combined and then hydrogenated on a Pan apparatus at 30 psi (2.1 Kg/cm ) hydrogen pressure for 1 hour. The catalyst was removed by filtration and rinsed with ethyl acetate. The filtrate was concentrated under vacuum to provide 1,1 -dimethylethyl N-{4-[(3- amino[ 1 ,5]naphthyridin-4-yl)amino]butyl} carb.amate as a bright yellow-orange solid. Example 43 Compound of Formula XXXIII 1,1-Dimethylethyl N-[4-(2-Butyl-l/J-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate
Freshly distilled trimethyl orthovalerate (41 mL, 0.24 mole) was added to a mixture of 1,1 -dimethylethyl N-{4-[(3-amino[l,5]naphthyridin-4- yl)amino]butyl} carbamate (39 g, 0.12 mole) in warm xylene (500 mL). The reaction mixture was heated at reflux overnight. Thin layer chromatography showed that at least half of the starting material was still present. p-Toluenesulfonic anhydride monohydrate (6 g) was added. After a short time thin layer chromatography showed that the reaction was complete. The reaction mixture was allowed to cool to ambient temperature and then it was diluted with ethyl acetate and washed with aqueous sodium bicarbonate. The organic layer was concentrated under vacuum to provide an oily residue. The residue was triturated with hexane to provide a dark pink solid. This solid was recrystallized from acetonitrile to provide 1,1 -dimethylethyl N-[4-(2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)butyl]carbamate as a pale peach solid, m.p. 96.0-98.0°C. Analysis: Calculated for C22H31N5O2: %C, 66.47; %H, 7.86; %N, 17.62; Found: %C, 66.29; %H, 7.78; %N, 17.76.
Example 44
Compound of Formula XXXIV l-{4-[(l,l-Dimethylethylcarbonyl)amino]butyl}-2-butyl-
177-imidazo [4,5-c] [ 1 ,5] n aphthy ridine-5N-oxide 3-Chloroperbenzoic acid (1 eq at 57%) was added in portions to a solution of 1,1- dimethylethyl N-[4-(2-butyl-l/7-imid^o[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate in chloroform (50 mL). The reaction mixture was allowed to stir at ambient temperature for 2 hours at which time thin layer chromatography showed that no starting material remained. The reaction mixture was diluted with dichloromethane and then washed twice with 1M sodium hydroxide. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under vacuum to provide l-{4-[(l,l- dimethylethylcarbonyl)amino]butyl}-2-butyl-177-imidazo[4,5-c][l,5]naphthyridine-5N- oxide as an orange oil which solidified on standing.
Example 45
Compound of Formula I
1 ,1 -Dimethylethyl N- [4-(4-Amino-2-butyl-l H-imidazo [4,5-c]
[l,5]naphthyridin-l-yl)butyl]carbamate
Figure imgf000059_0001
Ammonium hydroxide (20 mL) was added to a solution of l-{4-[(l,l- dimethylethylcarbonyl)amino]butyl} -2-butyl- 177-imidazo[4,5-c] [ 1 ,5 ]naphthyridine-5N- oxide (19.4 g) in chloroform. Tosyl chloride (9 g) was slowly added. Thin layer chromatography indicated that the reaction was proceeding slowly. Additional tosyl chloride was added twice. After thin layer chromatography indicated that the reaction was complete, the layers were separated. The organic layer was washed with dilute aqueous sodium carbonate, dried over magnesium sulfate and then concentrated under vacuum. The residue was covered with methyl acetate (10 mL), hexane (5 mL) was added and the mixture was allowed to stand overnight. The resulting crystalline solid was isolated by filtration, washed with hexane and then dried to provide 15.1 g of 1,1 -dimethylethyl N-[4- (4-amino-2-butyl-lH-imidazo[4,5-c][l ,5]naphthyridin-l-yl)butyl]carbamate, m.p. 148.5- 149.5°C. Analysis: Calculated for C22Η32N6O2: %C, 64.05; %H, 7.82; %N, 20.37; Found: %C, 64.15; %H, 7.82; %N, 20.55. Example 46 Compound of Formula I 4-(4-Amino-2-butyl-l/J-imidazo[4,5-c][l,5]naphthyridin-l-yl)butaneamine
Figure imgf000060_0001
A suspension of 1,1 -dimethylethyl N-[4-(4-amino-2 -butyl- lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)butyl]carbamate (13.8g) in IN hydrochloric acid (140 mL) was heated on a steam bath for 1.5 hours. The reaction mixture was allowed to cool to ambient temperature and then it was made basic (pH>l 1) with 50% sodium hydroxide. The resulting precipitate was isolated by filtration, washed with water and then dried to provide 9.5g of 4-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l-yl)butaneamine as a white solid, m.p. 212-213°C. Analysis: Calculated for C17H24N6: %C, 65.36; %H, 7.74; %N, 26.90; Found: %C, 65.16; %H, 7.65; %N, 27.29.
Example 47
Compound of Formula I
N-[4-(4-Amino-2-butyl-liy-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
N'-phenylurea
Figure imgf000060_0002
Under a nitrogen atmosphere, phenyl isocyanate (52 μL, 0.48 mmol) was added to a suspension of 4-(4-amino-2-butyl- lH-imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)butaneamine (0.15 g, 0.48 mmole) in anhydrous tetrahydrofuran (60 mL). The reaction mixture was stined for 20 minutes at which time it had turned homogeneous and thin layer chromatography indicated no starting material remained. Aminomethyl resin (280 mg of 1% cross linked, 100-200 mesh available from BACHEM, Torrance, California) was added and the reaction mixture was allowed to stir for 0.5 hr. Silica gel (0.4 g) was added and the mixture was concentrated under vacuum to provide a solid. The solid was purified by flash chromatography eluting with 95/5 dichloromethane/methanol to give a white solid which was dried under vacuum at 60°C to provide 0.12 g of N-[4-(4-amino-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]- N'-phenylurea. Analysis: Calculated for C24H29N7O + 1/5 H2O: %C, 66.25; %H, 6.81; %N, 22.53; Found: %C, 66.27; %H, 6.63; %N, 22.83
Ex-ample 48
Compound of Formula I
N-[4-(4-Amino-2-butyl-lflr-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
N'-cyclohexylurea
Figure imgf000061_0001
Using the general method of Example 47, cyclohexyl isocyanate (61 μL, 0.48 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.15 g, 0.48 mmole) to provide 0.14 g of N-[4-(4-amino-2 -butyl- 177- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]- N'- cyclohexylurea as a white solid. Analysis: Calculated for C24H35N7O: %C, 65.88; %H, 8.06; %N, 22.41. 1H NMR (300 MHz, CDC13) δ 8.60 (dd, J = 4.4, 1.4 Hz, 1 H), 8.08 (d, J = 8.5 Hz, 1 H), 7.44 (dd, J = 8.5, 4.4 Hz, 1 H), 5.55 (br s, 2 H), 4.92 (t, J = 5.8 Hz, 1 H), 4.82 (apparent t, J = 7.8 Hz, 2 H), 4.13 (d, J = 8.6 Hz, 1 H), 3.48 (m, 1 H), 3.35 (apparent q, J = 6.4 Hz, 2 H), 2.93 (apparent t, J = 7.8 Hz, 2 H), 1.80-2.05 (m, 4 H), 1.45-1.75 ( , 6 H), 1.2-1.4 (m 2 H), 1.0-1.2 (m, 2 H), 1.03 (t, 7.4 Hz, 3 H); HRMS (El) calcd for C24H35N7O (M+) 437.2903, found 437.2903.
Example 49
Compound of Formula I
N-[4-(4-Amino-2-butyI-l -imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
N'-butylurea
Figure imgf000062_0001
Using the general method of Example 47, butyl isocyanate (54 μL, 0.48 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.15 g, 0.48 mmole) to provide 0.13 g of N-[4-(4-amino-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]- N'-butylurea as a white solid. Analysis: Calculated for C22Η33N7O: %C, 64.21; %H, 8.08; %N, 23.82; Found: %C, 64.05; %H, 7.97; %N, 24.00.
Ex.ample 50
Compound of Formula I
Phenyl N-[4-(4-Amino-2-butyl-
1/7-imidazo [4,5-c] [ 1 ,5] naphthy ridin-1 -yl)butyl] carb amate
Figure imgf000062_0002
Using the general method of Example 47, phenyl chloro formate (61 μL, 0.48 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.15 g, 0.48 mmole) to provide 0.12 g of phenyl N-[4-(4-amino-2-butyl- lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate as a solid. Analysis: Calculated for C2 H28N6O2: %C, 66.65; %H, 6.53; %N, 19.43; Found: %C, 66.49; %H, 6.59; %N, 19.32.
Example 51
Compound of Formula I
N- [4-(4- Amino-2-butyl-li7-imidazo [4,5-c] [ 1 ,5] naphthy ridin-1 -yl)butyl]-
2-furamide
Figure imgf000063_0001
Using the general method of Example 47, furoyl chloride (15.8 μL, 0.16 mmol) was reacted with 4-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l- yljbut-aneaniine (0.05 g, 0.16 mmole) to provide 0.019 g of N-[4-(4-amino-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-2-furamide as a white solid. 1H NMR (300 MHz, CDC13) δ 8.58 (dd, J = 4.4, 1.5 Hz, 1 H), 8.06 (dd, J = 8.6, 1.6 Hz, 1 H), 7.41 (dd, J = 8.5, 4.4 Hz, 1 H), 7.33 (m, 1 H), 7.08 (dd, J - 3.5, 0.6 Hz, 1 H), 6.84 (m, 1 H), 6.47 (dd, J = 3.5, 1.7 Hz, 1 H), 4.86 (apparent t, J - 7.7 Hz, 2 H), 3.59 (apparent q, J = 6.5 Hz, 2 H), 2.92 (apparent t, J = 7.8 Hz, 2 H), 1.7-2.1(m, 6 H), 1.51 (m, 2 H); 1.00 (t, J = 7.3 Hz, 3 H);
HRMS (El) calcd for C22H26N6O2 (M+) 406.2117, found 406.2121. Example 52
Compound of Formula I
N- [4-(4-Amino-2-butyl- lH-imidazo [4,5-c] [1 ,5] naphthyridin-l-yl)butyl] benzamide
Figure imgf000064_0001
Using the general method of Example 47, benzoyl chloride (56 μL, 0.48 mmol) was reacted with 4-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.15 g, 0.48 mmole) to provide 0.11 g of N-[4-(4-amino-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]benzamide as a white solid. Analysis: Calculated for C24H28N6O + V* H2O: %C, 68.47; %H, 6.82; %N, 19.96: Found: %C, 68.24; %H, 6.76; %N, 19.90.
Example 53
Compound of Formula I
N-[4-(4-Amino-2-butyl-l -imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
N'-benzylurea
Figure imgf000064_0002
Benzyl isocyanate (59 μL, 0.48 mmol) was added at ambient temperature to a suspension of 4-(4-amino-2-butyl-177-imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)but.aneamine (0.15 g, 0.48 mmol) in tetrahydrofuran (60 mL). A solution was obtained in less than 30 minutes and thin layer chromatography (9:1 dichloromethane:methanol) showed one major new spot with a higher Rf and only a trace of starting material. Aminomethyl resin (280 mg) was added and the reaction mixture was stined for 15 minutes. The solvent was removed under vacuum. The residue was purified by column chromatography to provide 0.16 g of N-[4-(4-amino-2-butyl- 177-imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)butyl]-N'- benzylurea as a white solid. Analysis: Calculated for C25H3ιN O: %C, 67.39; %H, 7.01; %N, 22.00; Found: %C, 67.43; %H, 6.92; %N, 22.02.
Example 54
Compound of Formula I
N3-[4-(4-Amino-2-butyI-
1 /7-imidazo [4,5-c] [1 ,5] naphthyridin-1 -yl)butyl] nicotinamide
Figure imgf000065_0001
4-(4-Amino-2-butyl- lH-imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)butaneamine (0.050 g, 0.16 mmol) was suspended in tetrahydrofuran (30 mL). N.N-diisopropylethylamine (28 μL, 0.16 mmol) was added to the suspension and then nicotinoyl chloride hydrochloride (0.028 g, 0.16 mmol) was added. The reaction mixture was stined at ambient temperature for 1 hour by which time a solution was obtained. Thin layer chromatography (9:1 dichloromethane :methanol) showed one major new spot with a higher Rf and only a trace of starting material. Aminomethyl resin (100 mg) was added and the reaction mixture was stined for 5 minutes. The solvent was removed under vacuum. The residue was dissolved in dichloromethane and placed on a layer of silica gel. The silica gel was eluted first with dichloromethane and then with 9:1 dichloromethane:methanol. The cle.anest fractions were combined and then concentrated under vacuum to provide N -[4-(4-amino-2-butyl- 177-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]nicotinamide as a white powder. Η NMR (300 MHz, CDC13) δ 8.91 (m, 1 H), 8.68 (d, J = 4.5 Hz, 1 H), 8.45 (d, J = 4.3 Hz, 1 H), 8.03 (m, 2 H), 7.30-7.40 (m, 2 H), 6.98 (s, 2 H), 5.51 (s, 1 H), 4.86 (apparent t, J = 7.9 Hz, 2 H), 3.66 (q, J - 6.5 Hz, 2 H), 2.92 (apparent t, J = 7.7 Hz, 2 H), 2.05 (m, 2 H), 1.75-1.95 (m, 4 H), 1.51 (m, 2 H), 1.00 (t, J = 7.3 Hz, 3 H); HRMS (El) calcd for C23H27N7O (M+) 417.2277, found 417.2276.
Example 55
Compound of Formula I
N-[4-(4-Amino-2-butyl- l//-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]phenylaceatamide
Figure imgf000066_0001
Phenylacetyl chloride (21 μL, 0.16 mmol) was added to a suspension of 4-(4- amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butaneamine (0.050 g, 0.16 mmol) in tetrahydrofuran (30 L). The reaction mixture was stirred at ambient temperature for 1 hour by which time a solution was obtained. Thin layer chromatography (9:1 dichloromethane :methanol) showed one major new spot with a higher Rf and only a trace of starting material. Aminomethyl resin (100 mg) was added and the reaction mixture was stined for 5 minutes. The solvent was removed under vacuum to provide a white powder. This material was placed on a short column of silica gel and purified by eluting first with dichloromethane and then with 9:1 dichloromethane :methanol. The cleanest fractions were combined and then concentrated under vacuum to provide a colorless oil. The oil was dissolved in dichloromethane, hexane was added just until the solution started to become cloudy, and then the solvent was removed to provide N-[4-(4- amino-2 -butyl- 177-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]phenylacetamide as a white powder. Analysis: Calculated for C25H30N6O2: %C, 67.24; %H, 6.77; %N, 18.82; Found: %C, 67.52; %H, 6.85; %N, 18.38. Η NMR (300 MHz, CDC13) δ 8.51 (dd, J = 4.4, 1.5 Hz, 1 H), 8.11 (dd, J = 8.4, 1.4 Hz, 1 H), 7.43 (dd, J = 8.4, 4.4 Hz, 1 H), 7.10-7.20 (m, 5 H), 6.30 (br s, 2 H), 5.83 (m, 1 H), 4.72 (apparent t, J = 7.8 Hz, 2 H), 3.54 (s, 2 H), 3.35 (apparent q, J = 6.5 Hz, 2 H), 2.88 (apparent t, J = 7.8 Hz, 2 H), 1.80-1.90 (m, 4 H), 1.45- 1.65 (m, 4 H), 1.00 (t, J = 7.3 Hz, 3 H); HRMS (El) calcd for C25H30N6O (M+) 430.2481, found 430.2490.
Example 56
Compound of Formula I
Benzyl N-[4-(4-Amino-2-butyl- l/7-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate
Figure imgf000067_0001
Using the general method of Example 55, benzyl chloroformate (83 μL, 0.58 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.15 g, 0.48 mmol) to provide 0.18 g of benzyl N-[4-(4-amino-2-butyl- lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate as a white powder.
Example 57
Compound of Formula I
9H-9-Fluorenylmethyl N-[4-(4-Amino-2-butyl-
177-imidazo [4,5-c] [1 ,5] naphthy ridin-1 -yl)butyl] carbamate
Figure imgf000068_0001
Using the general method of Example 55, 9-fluorenylmethyl chloroformate (0.085 g, 0.33 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin- l-yl)butaneamine (0.105 g, 0.33 mmol) to provide 0.125 g of 9H-9-fluorenylmethyl N-[4- (4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate as a white powder. Analysis: Calculated for C32H34N6O2 + VA H2O: %C, 71.29; %H, 6.45; %N, 15.59; Found: %C, 70.99; %H, 6.35; %N, 15.55.
Ex.ample 58
Compound of Formula I
Ethyl N-[4-(4-Amino-2-butyl-
1 7-imidazo [4,5-c] [1 ,5] naphthyridin-1 -yl)butyl] carbamate
Figure imgf000068_0002
Using the general method of Example 55, ethyl chloroformate (46 μL, 0.48 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.15 g, 0.48 mmol) to provide 0.15 g of ethyl N-[4-(4-amino-2-butyl-177- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate as a white powder. Analysis: Calculated for C2oH28N6O2: %C, 62.48; %H, 7.34; %N, 21.86; Found: %C, 61.73; %H, 7.28; %N, 21.62.
Example 59
Compound of Formula XXXI l,l-Dimethyl-2-[(3-nitro[l,5]naphthyridin-4-yl)amino]ethanol
Phosphorus oxychloride (4 mL, 43 mmol) was reacted with N,N- dimethylformamide (15 mL) while chilling in an ice bath. This mixture was added to a solution of 3-nitro[l,5]naphthyridin-4-ol (6.9 g, 36.1 mmol) in N,N-dimethylformamide
(60 mL). The reaction mixture was warmed in an oil bath to 60°C. After 3 hours the reaction mixture was poured into ice water. The resulting precipitate was isolated by filtration and then washed with water. The wet crude 5-chloro-3-nitro[l,5]naphthyridine was suspended in dichloromethane (150 mL). Diisopropylethylamme was added followed by the slow addition of hydroxyisobutylamine (3.4 g, 40 mmol). The reaction mixture was refluxed for 2 hours and then combined with water (-100 mL). The resulting precipitate was isolated by filtration to provide 7.2 g of l,l-dimethyl-2-[(3-nitro[l,5]naphthyridin-4- yl)amino]ethanol. A small sample was recrystallized from isopropanol to provide a pure sample, m.p. 184.5-186°C. Analysis: Calculated for C124N4O3: %C, 54.96; %H, 5.38; %N, 21.36; Found: %C, 54.63; %H, 5.36: %N, 21.51.
Example 60
Compound of Formula XXXIII l,l-Dimethyl-2-(2-butyl[l,5]napthyridin-l-yl)ethanol
Part A A catalytic amount of 5% platinum on carbon was added to a suspension of 1 , 1 - dimethyl-2-[(3-nitro[l,5]naphthyridin-4-yl)amino]ethanol (7 g, 26 mmol) in isopropanol
(300 mL). The mixture was hydrogenated on a Parr apparatus at 50 psi (3.5 Kg/cm2) hydrogen pressure for 3 hours. The reaction mixture was fileted to remove the catalyst.
The filtrate was concentrated under vacuum. Toluene was added to the residue and the mixture was concentrated under vacuum to remove all of the alcohol and provide crudel,l-dimethyl-2-[(3-amino[l,5]naphthyridin-4-yl)amino]ethanol.
Part B
Trimethylorthovalerate (3.6 mL, 20 mmol) was added to a suspension of 1,1 - dimethyl-2-[(3-amino[l,5]naphthyridin-4-yl)amino]ethanol 3.5 g, 13 mmol) in xylene (100 mL). The reaction mixture was heated at reflux for two days. The mixture was diluted with methanolic ammonia, placed in a Pan vessel and then heated at 110°C for 4 hours. The reaction mixture was concentrated under vacuum. The residue was partitioned between dichloromethane and water. The layers were separated. The organic layer was washed with water, dried over magnesium sulfate and then concentrated under vacuum to provide an oil. The oil was recrystallized from methyl acetate/faenzene to provide 2.8 g of l,l-dimethyl-2-(2-butyl[l,5]napthyridin-l-yl)ethanol as a solid, m.p. 85-88.5°C. Analysis:
Calculated for Cι7H22N4O: %C, 68.43; %H, 7.43; %N, 18.78; Found: %C, 68.04; %H,
7.18; %N, 19.09.
Example 61
Compound of Formula XXXIV 2-Butyl-l-(2-hydroxy-2-methylpropyl)-l/ -imidazo[4,5-c][l,5]naphthyridine-5N- oxide
3-Chloroperbenzoic acid (2.6 g, 9.5 mmol) was added in 3 portions to a solution of l,l-dimethyl-2-(2-butyl[l,5]napthyridin-l-yl)ethanol (2.6 g, 8.7 mmol) in chloroform (50 mL) in a flask covered with aluminum foil. The reaction mixture was stined at ambient temperature for 4 hours; then it was washed twice with dilute aqueous sodium bicarbonate, washed with brine, dried over magnesium sulfate and then concentrated under vacuum. The residue was recrystallized from methyl acetate to provide 2.25 g of 2-butyl- 1 -(2- hydroxy-2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridine-5N-oxide, m.p. 156- 158°C. Analysis: Calculated for: C17H22N4O2 + % H2O: %C, 64.03; %H, 7.11; %N, 17.57; Found: %C, 63.96; %H, 6.84; %N, 17.71.
Ex.ample 62
Compound of Formula I l,l-Dimethyl-2-(4-amino-2-butyl[l,5]napthyridin-l-yl)ethanol
Figure imgf000071_0001
Ammonium hydroxide (15 mL) was added to a solution of 2-butyl- 1 -(2 -hydroxy-2- methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridine-5N-oxide (1.9 g, 6.0 mmol)in dichlorometh.ane (40 mL). Tosyl chloride (1.2 g, 6.4 mmol) was slowly added. Thin layer chromatography indicated that the reaction was proceeding slowly. Additional tosyl chloride was added twice. After thin layer chromatography indicated that the reaction was complete, the layers were separated. The organic layer was washed with dilute aqueous sodium carbonate, dried over magnesium sulfate and then concentrated under vacuum. The residue was covered with methyl acetate (10 mL), hexane (5 mL) was added and the mixture was allowed to stand overnight. The resulting crystalline solid was isolated by filtration to provide 0.9 g of l,l-dimethyl-2-(4-amino-2-butyl[l,5]napthyridin-l- yl)ethanol, m.p. 177-179°C. Analysis: Calculated for Cι7H23N5O: %C, 65.15; %H, 7.40;
%N, 22.35; Found: %C, 64.97; %H, 7.33; %N, 22.71. Example 63
Compound of Formula XXXIII l,l-Dimethyl-2-(2-phenylemethyl[l,5]napthyridin-l-yl)ethanol Part A
Phenylacetyl chloride (2.0 mL, 20 mmol) was added to a suspension of 1,1- dimethyl-2-[(3-amino[l,5]naphthyridin-4-yl)amino]ethanol 3.5 g, 13 mmol) in dichlorometha. ne (100 mL). The reaction mixture was heated at reflux until thin layer chromatography indicated that the reaction was complete. The reaction mixture was taken on to the next step.
Part B
The material from Part A was combined with 7% ammonia in methanol (100 mL), placed in a sealed vessel, and then heated at 150°C for 6 hours. The reaction mixture was concentrated under vacuum. The residue was combined with water (100 mL) and then extracted with dichloromethane (2 X 75 mL). The extracts were combined, washed with water (100 mL), dried over magnesium sulfate and then concentrated under vacuum. The residue was recrystallized from methyl acetate to provide 2.1 g of l,l-dimethyl-2-(2- phenylmethyl[l,5]napthyridin-l-yl)ethanol as a solid, m.p. 150-152°C. Analysis: Calculated for C2oH2oN4O: %C, 72.27; %H, 6.06; %N, 16.85; Found: %C, 72.11; %H, 6.01; %N, 17.00.
Ex-ample 64 Compound of Formula XXXIV 2-Phenylmethyl-l-(2-hydroxy-2-methylpropyl)- l/7-imidazo[4,5-c] [l,5]naphthyridine-5N-oxide
3-Chloroperbenzoic acid (1.8 g, 6.6 mmol) was added in 3 portions to a solution of l,l-dimethyl-2-(2-phenylmethyl[l,5]napthyridin-l-yl)ethanol (2 g, 6 mmol) in chloroform (50 mL) in a flask covered with aluminum foil. The reaction mixture was stirred at ambient temperature overnight; then it was washed twice with dilute aqueous sodium bicarbonate, washed with brine, dried over magnesium sulfate and then concentrated under vacuum. The residue was recrystallized from isopropanol to provide 2.25 g of 2- phenylmethyl- 1 -(2-hydroxy-2-methylpropyl)- lH-imidazo[4,5-c] [ 1 ,5]naphthyridine-5N- oxide, m.p. 204-206°C. Analysis: Calculated for: C2oH20N4O2 + Vi H2O: %C, 67.21; %H, 5.92; %N, 15.68; Found: %C, 67.05; %H, 5.65; %N, 15.39.
Ex-ample 65
Compound of Formula I l,l-Dimethyl-2-(4-amino-2-phenylmethyl[l,5]napthyridin-l-yl)ethanol
Figure imgf000073_0001
Ammonium hydroxide (10 mL) was added to a solution of 2-phenylmethyl-l-(2- hydroxy-2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridine-5N-oxide (1.5 g, 4.3 mmol) in dichloromethane (40 mL). Tosyl chloride (0.8 g, 4.3 mmol) was slowly added.
Thin layer chromatography indicated that the reaction was proceeding slowly. Additional tosyl chloride was added twice. After thin layer chromatography indicated that the reaction was complete, the layers were separated. The organic layer was washed with dilute aqueous sodium carbonate, dried over magnesium sulfate and then concentrated under vacuum. The residue was covered with methyl acetate (10 mL), hexane (5 mL) was added and the mixture was allowed to stand overnight. The resulting crystalline solid was isolated by filtration to provide l,l-dimethyl-2-(4-amino-2-phenylmethyl[l,5]napthyridin- l-yl)ethanol, m.p. 211-213°C. Analysis: Calculated for C20H2ιN5O: %C, 69.14; %H, 6.09; %N, 20.16; Found: %C, 69.10; %H, 6.12; %N, 20.48.
Example 66 Compound of Formula XXXI N-PhenylmethyI-3-nitro [1 ,5] naphthyridin-4-amine Phosphorus oxychloride (3.5 mL, 37.7 mmol) was reacted with N,N- dimethylformamide (15 mL) while chilling in an ice bath. This mixture was added to a solution of 3-nitro[l,5]naphthyridin-4-ol (6.0 g, 31.4 mmol) in N,N-dimethylformamide (60 mL). The reaction mixture was warmed in an oil bath to 60°C. After 3 hours the reaction mixture was poured into ice water. The resulting precipitate was isolated by filtration and then washed with water. The wet crude 5-chloro-3-nitro[l,5]naphthyridine was suspended in dichloromethane (150 mL). Diisopropylethylamine (1.2 eq) was added followed by the slow addition of benzylamine (4.7 mL g, 40 mmol). The reaction mixture was refluxed for 2 hours and then combined with water (-100 mL). The layers were separated and the organic layer was concentrated under vacuum to provide 5.5 g of N- phenylmethyl-3-nitro[l,5]naphthyridin-4-amine. A small sample was recrystallized from isopropanol to provide a pure sample, m.p. 127-129°C. Analysis: Calculated for Cι5H12N4O2: %C, 64.28; %H, 4.32; %N, 19.99; Found: %C, 63.89; %H, 4.40: %N, 20.35.
Example 67 N-(4-Phenylmethylamino[l,5]naphthyridin-3-yl)-ethoxyacetamide Hydrochloride
A catalytic amount of platinum on carbon was added to a suspension of N- phenylmethyl-3-nitro[l,5]naphthyridin-4-amine (5.1 g, 18.2 mmol) in toluene (300 mL). The reaction mixture was hydrogenated on a Pan apparatus under a hydrogen pressure of
50 psi (3.5Kg/cm2) for 1 hour. The reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under vacuum to a volume of about 200 mL and then reacted with ethoxyacetyl chloride (2.5 g, 20 mmol). The resulting yellow precipitate was isolated by filtration, suspended in diethyl ether, and then isolated by filtration to provide 5.8 g of N-(4-phenylmethylamino[l,5]naphthyridin-3-yl) ethoxyacetamide hydrochloride, m.p.
205-212°C. Analysis: Calculated for C19H20N4O2 HCl: %C, 61.21; %H, 5.68; %N, 15.03; Found: %C, 60.90; %H, 5.38; %N, 15.38.
Ex4 mple 68 Compound of Formula XXXIII
2-Ethoxymethyl-l-phenylmethyl-l//-imidazo[4,5-c][l,5]naphthyridine
N-(4-Phenylmethylamino[l,5]naphthyridin-3-yl)-ethoxyacetamide hydrochloride (5.8 g, 15.5 mmol) was combined with a 7 % solution of ammonia in methanol (100 mL), placed in a sealed Parr vessel and then heated at 150°C for 6 hours. The reaction mixture was concentrated under vacuum. The residue was partitioned between water and dichloromethane. The dichloromethane layer was separated, washed with water, dried over magnesium sulfate and then concentrated under vacuum. The residue was recrystallized from methyl acetate to provide 4.3 g of 2-ethoxym ethyl- 1-phenylmethyl- lH-imidazo[4,5-c][l,5]naphthyridine, m.p. 118-119°C. Analysis: Calculated for Cι9Η18N4O: %C, 71.68; %H, 5.70; %N, 17.60; Found: %C, 71.44; %H, 5.60; %N, 17.66.
Example 69
Compound of Formula XXXIV
2-Ethoxymethyl-l -phenylmethyl- l/7-imidazo[4,5-c][l,5]naphthyridine-5N-oxide
3-Chloroperbenzoic acid (3.7 g, 13.4 mmol) was added in 3 portions to a solution of 2-ethoxymethyl-l-phenylmethyl-177-imidazo[4,5-c][l,5]naphthyridine (3.9 g, 12.2 mmol) in chloroform (100 mL) in a flask covered with aluminum foil. The reaction mixture was stirred at ambient temperature overnight; and then it was washed twice with dilute aqueous sodium bicarbonate and once with brine. The chloroform layer was divided into two portions. One portion was used in the example below. The second portion was concentrated under vacuum. The residue was recrystallized from isopropyl alcohol to provide 2-ethoxymethyl-l-phenylmethyl-lH-imidazo[4,5-c][l,5]naphthyridine- 5N-oxide as a solid, m.p. 187.5-189°C. Analysis: Calculated for Cι98N4O2 + H2O: %C, 67.52; %H, 5.49; %N, 16.58; Found: %C, 67.56; %H, 5.36; %N, 16.77.
Example 70
Compound of Formula I 2-Ethoxymethyl-l-phenylmethyI-l -imidazo[4,5-c][l,5]naphthyridin-4-amine
Figure imgf000075_0001
Ammonium hydroxide (20 mL) was added to the chloroform solution of 2- ethoxymethyl-l-phenylmethyl-177-imidazo[4,5-c][l,5]naphthyridine-5N-oxide from the example above. Tosyl chloride was slowly added. Thin layer chromatography indicated that the reaction was proceeding slowly. Additional tosyl chloride was added twice. After thin layer chromatography indicated that the reaction was complete, the layers were separated. The organic layer was washed with dilute aqueous sodium carbonate, dried over magnesium sulfate and then concentrated under vacuum. The residue was covered with methyl acetate (10 mL), hexane (5 mL) was added and the mixture was allowed to stand overnight. The resulting crystalline solid was isolated by filtration to provide 2- ethoxymethyl-l-phenylmethyl-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, m.p. 173- 174°C. Analysis: Calculated for C]9H19N5O: %C, 68.45; %H, 5.74; %N, 21.01; Found: %C, 68.35; %H, 5.83; %N, 21.27.
Example 71
Compound of Formula XXXI
N4-(3-Isopropoxypropyl)-3-nitro[l,5]naphthyridin-4-amine
Part A Phosphorus oxychloride (3.4 mL, 30 mmol) was added to chilled (ice bath) N,N- dimethylformamide (15 mL). The resulting solution was added dropwise to a solution of 3-nitro[l,5]naphthyridin-4-ol (5.73 g, 30 mmol) in N,N-dimethylformamide (35 mL). The reaction mixture was maintained at ambient temperature for 5 hours and then it was poured onto ice. The resulting yellow precipitate was isolated by filtration and then partitioned between dichloromethane (200 mL) and water (150 mL). The organic layer was separated, dried over magnesium sulfate, filtered, and then concentrated under vacuum to provide 4.2 g of crude 4-chloro-3-nitro[l,5]naphthyridine. Part B
4-Chloro-3-nitro[l,5]naphthyridine (4.1 g), dichloromethane (150 mL), triethylamine (4.1 mL, 29.5 mmol), and 3-isopropoxypropylamine (3.3 mL, 23.8 mmol) were combined. The reaction mixture was maintained at ambient temperature overnight and then quenched with water (100 mL). The phases were separated. The aqueous phase was extracted with dichloromethane (100 mL). The organic phases were combined, dried over magnesium sulfate, filtered and then concentrated under vacuum to provide a yellow oil. The oil was purified by flash chromatography (silica gel eluting with 1 :1 ethyl acetate:hexanes) to provide 4.8 g of N4-(3-isopropoxypropyl)-3-nitro[l,5]naphthyridin-4- amine as a yellow powder, m.p. 62.5-63.5°C. Analysis: Calculated for Cι48N4O : %C, 57.92; %H, 6.25; %N, 19.30; Found: %C, 57.96; %H, 6.19; %N, 19.51. 1H NMR (300 MHz, CDCM: δ 10.08 (broad s, IH), 9.38 (broad s, IH), 8.78 (m, IH), 8.21 (dd, J=8.4,1.6 Hz, IH), 7.64 (dd, J=8.4,4.1 Hz, IH), 4.57 (broad s, 2H), 3.65-3.57 (m, 3H), 2.05 (t, J=5.6 Hz, 2H), 1.19 (d, J=6.0 Hz, 6H); MS (ED: m/e 290.1366 (290.1378 calc'd for C14H18N4O3).
Example 72
Compound of Formula XXXII
N4-(3-Isopropoxypropyl) [1 ,5] naphthy ridine-3,4-diamine N4-(3-Isopropoxypropyl)-3-nitro[l,5]naphthyridin-4-amine (4.2 g, 14.5 mmol), platinum on carbon (1.1 g of 5%), and ethyl acetate (100 mL) were placed in a hydrogenation flask. The mixture was shaken under a hydrogen pressure of 50 psi (3.5 Kg/cm2) for 2.5 hours. The reaction mixture was filtered and the catalyst was washed with ethyl acetate. The filtrate was dried over magnesium sulfate, filtered and then concentrated under vacuum to provide 3.6 g of N4-^- isopropoxypropyl)[l,5]naphthyridine-3,4-diamine as a bright yellow oil. 1H NMR (300 MHz, CDC1 : δ 8.70 (dd, J=4.1,1.6 Hz, IH), 8.39 (s, IH), 8.17 (dd, J=8.4,1.6 Hz, IH), 7.37 (dd, J=8.4,4.1 Hz, IH), 5.99 (broad s, IH), 3.98 (broad s, 2H),3.63-3.55 (m, 5H), 1.87 (pentet, J=6.2 Hz, 2H), 1.17 (d, J=6.1 Hz, 6H); MS (ED: m/e 260.1630 (260.1637 calc'd for C14H20N4O).
Example 73
Compound of Formula XXXIII
2-Butyl-l-(3-isopropoxypropyl)-l -imidazo[4,5-c][l,5]naphthyridine Part A
Valeryl chloride (1.53 mL, 12.9 mmol) was added dropwise over a 15 minute period to a chilled (ice bath) solution of N4-(3-isopropoxypropyl)[l,5]naphthyridine-3,4- diamine (3.2 g, 12.3 mmol) in dichloromethane (40 mL). The cooling bath was removed and the reaction mixture was maintained at ambient temperature for 1 hour. The solvent was removed under vacuum to provide a dark tan solid. Part B
The material from Part A and a 7.5% solution of ammonia in methanol (100 mL) were placed in a pressure vessel. The vessel was sealed and then heated at 150°C for 6 hours. After the mixture was cooled to ambient temperature it was concentrated under vacuum. The residue was partitioned between dichloromethane (150 mL) and water (150 mL). The fractions were separated and the aqueous fraction was extracted with dichloromethane (100 mL). The organic fractions were combined, dried over magnesium sulfate, filtered and then concentrated under vacuum to provide a brown oil. The oil was purified by flash chromatography (silica gel eluting with ethyl acetate) to provide 3.1 g of 2-butyl-l-(3-isopropoxypropyl)-lH-imidazo[4,5-c][l,5]naphthyridine as a colorless oil. 1H
NMR (300 MHz, CDCI : δ 9.32 (s, IH), 8.90 (dd, J=4.3,1.7 Hz, IH), 8.49 (dd, J=8.5,1.7 Hz, IH), 7.57 (dd, J=8.5,4.3 Hz, IH), 4.94 (t, J=7.0 Hz, 2H), 3.56 (pentet, J=6.1 Hz, IH), 3.44 (t, J=5.7 Hz, 2H), 3.05 (t, J=7.9 Hz, 2H), 2.29-2.20 (m, 2H), 2.01-1.90 (m, 2H), 1.60- 1.48 (m, 2H), 1.15 (d, J=6.1 Hz, 6H), 1.03 (t, J=7.3 Hz, 3H); MS (ED: m e 326.2104 (326.2106 calc'd for C19H26N4O).
Example 74 Compound of Formula XXXIV 2-Butyl-l-(3-isopropoxypropyl)-lH-imidazo[4,5-c][l,5]naphthyridine- 5N-oxide
3-Chloroperbenzoic acid (1.2 g of 57-86%) was added in four portions over a period of 20 minutes to 2-butyl-l-(3-isopropoxypropyl)-lH-imidazo[4,5- c][l,5]naphthyridine (1.4 g, 4.3 mmol) in chloroform (20 mL). The reaction mixture was maintained at ambient temperature for 2 hours and then it was washed with saturated sodium bicarbonate (2 x 15 mL) and water (20 mL). The organic fraction was dried over magnesium sulfate, filtered and then concentrated under vacuum to provide a yellow oil. The oil was purified by column chromatography (silica gel eluting with 95:5 ethyl acetate:methanol) to provide 0.95 g of 2-butyl-l-(3-isopropoxypropyl)-lH-imidazo[4,5- c][l,5]naphthyridine-5N-oxide as a yellow solid, m.p. 92.0-93.0°C. Analysis: Calculated for C19H26N4O2: %C, 66.64; %H, 7.65; %N, 16.36; Found: %C, 66.18; %H, 7.39; %N,
16.26. 1H NMR (300 MHz. CDCh : δ 9.24 (dd, J=8.8,1.6 Hz, IH), 9.05 (s, IH), 8.98 (dd, J=4.3,1.6 Hz, IH), 7.65 (dd, J=8.8,4.3 Hz, IH), 4.89 (t, J-7.0 Hz, 2H), 3.56 (pentet, J=6.1 Hz, IH), 3.44 (t, J=5.7 Hz, 2H), 3.02 (t, J=7.9 Hz, 2H), 2.27-2.18 (m, 2H), 1.97-1.87 (m, 2H), 1.59-1.47 (m, 2H), 1.15 (d, J=6.1 Hz, 6H), 1.02 (t, J=7.3 Hz, 3H).
Example 75
Compound of Formula I
2-Butyl-l-(3-isopropoxypropyl)-17Sr-imidazo[4,5-c][l,5]naphthyridine-4-amine
Figure imgf000079_0001
under a nitrogen atmosphere, trichloroacetyl isocyanate (0.42 mL, 3.5 mmol) was added dropwise to a solution of 2-butyl- l-(3-isopropoxypropyl)-177-imidazo[4,5- c][l,5]naphthyridine-5N-oxide (0.8 g, 2.3 mmol) in dichloromethane (25 mL). The reaction mixture was maintained at ambient temperature for 2 hours and then concentrated under vacuum to provide a yellow oil. The oil was dissolved in methanol (15 mL) and then sodium methoxide (0.8 mL of 25% in methanol, 3.5 mmol) was slowly added. The reaction was maintained at ambient temperature overnight. The resulting precipitate was isolated by filtration and then recrystallized from methyl acetate to provide 0.47 g of 2- butyl-l-(3-isopropoxypropyl)-177-imidazo[4,5-c][l,5]naphthyridine-4-amine as a white crystalline solid, m.p. 174-175°C. Analysis: Calculated for Cι9H27N5O: %C, 66.83; %H, 7.97; %N, 20.51; Found: %C, 66.70; %H, 7.81; %N, 20.75. 1H NMR (300 MHz, CDCM: δ 8.50 (dd, J=4.3,1.5 Hz, IH), 7.90 (dd, J=8.4,1.5 Hz, IH), 7.42 (dd, J=8.4,4.3 Hz, IH), 6.75 (s, 2H), 4.77 (t, J=6.8 Hz, 2H), 3.50 (pentet, J=6.1 Hz, IH), 3.35 (m, 2H), 2.95 (t,
J=7.8 Hz, 2H), 2.13-2.04 (m, 2H), 1.86-1.76 (m, 2H), 1.52-1.40 (m, 2H), 1.05 (d, J=6.1 Hz, 6H), 0.97 (t, J=7.3 Hz, 3H). Example 76
Compound of Formula XXXI
N4-(3-Butoxypropyl)-3-nitro[l,5]naphthyridin-4-amine Under a nitrogen atmosphere, 3-butoxypropylamine (4.0 mL, 26 mmol) was added dropwise over a period of 10 minutes to a solution of 4-chloro-3-nitro[l,5]naphthyridine (4.6 g, 22 mmol) and triethylamine (4.6 mL, 33 mmol) in dichloromethane (150 mL). The reaction mixture was maintained at ambient temperature overnight. Water (100 mL) was added and the phases were separated. The aqueous phase was extracted with dichloromethane (100 mL). The organic fractions were combined, dried over magnesium sulfate, filtered and then concentrated under vacuum to provide a yellow oil. The oil was purified by flash chromatography (silica gel eluting with 1 : 1 ethyl acetate:hexanes) to provide 5.3 g of N4-(3-butoxypropyl)-3-mtro[l,5]naphthyridin-4-.amine as a colorless oil. 1H NMR (300 MHz. CDC1 ): δ 10.08 (broad s, IH), 9.38 (broad s, IH), 8.78 (m, IH), 8.22 (dd, J=8.4,1.6 Hz, IH), 7.64 (dd, J=8.4,4.1 Hz, IH), 4.57 (broad s, 2H), 3.63 (t, J=5.8 Hz,
2H), 3.46 (t, J=6.7 Hz, 2H), 2.10-2.03 (m, 2H), 1.65-1.55 (m, 2H), 1.44-1.32 (m, 2H), 0.92 (t, J=7.3 Hz, 3H); MS (ED: m e 304.1535 (304.1535 calc'd for Cι5H2oN4O3).
Example 77 Compound of Formula XXXII
N4-(3-Butoxypropy 1) [ 1 ,5] n aphthy ridin e-3,4-diamin e
Using the method of Example 72, N4-(3-butoxypropyl)-3-nitro[l,5]naphthyridin-4- amine (4.9 g, 16 mmol) was reduced to provide 4.3 g of N4-(3- butoxypropyl)[l,5]naphthyridine-3,4-diamine as a bright yellow oil. Analysis: Calculated for Cι5H22N4O: %C, 65.67; %H, 8.08; %N, 20.42; Found: %C, 65.48; %H, 8.07; %N,
20.41. 1H NMR (300 MHz. CDCh): δ 8.70 (dd, J=4.1,1.6 Hz, IH), 8.39 (s, IH), 8.18 (dd, J=8.4,1.6 Hz, IH), 7.37 (dd, J=8.4,4.1 Hz, IH), 5.97 (broad s, IH), 3.96 (broad s, 2H), 3.63-3.56 (m, 4H), 3.44 (t, J=6.7 Hz, 2H), 1.89 (pentet, J=6.2 Hz, 2H), 1.63-1.53 (m, 2H), 1.44-1.32 (m, 2H), 0.93 (t, J=7.3 Hz, 3H); MS (EIV. m e 274.1799 (274.1793 calc'd for Cι5H22N4O). Example 78
Compound of Formula XXXIII l-(3-Butoxypropyl)-2-butyl-l -imidazo[4,5-c][l,5]naphthyridine
Using the general method of Example 73 Part A and Part B, N4-(3- butoxypropyl)[l,5]naphthyridine-3,4-diamine (3.7 g, 13.5 mmol) was reacted with valeryl chloride (1.7 mL, 14.3 mmol) and the resulting amide intermediate was cyclized to provide 2.9 g of l-(3-butoxypropyl)-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridine as a colorless oil. A small portion was purified by flash chromatography (silica gel eluting with ethyl acetate) to provide a pure sample as a white powder, m.p. 56.5-57.5°C. Analysis: Calculated for C20H28N4O: %C, 70.56; %H, 8.29; %N, 16.46; Found: %C,
70.48; %H, 8.25; %N, 16.61. 1H NMR (300 MHz, CDCh): δ 9.32 (s, IH), 8.90 (dd, J=4.3,1.6 Hz, IH), 8.49 (dd, J=8.5,1.6 Hz, IH), 7.57 (dd, J=8.5,4.3 Hz, IH), 4.94 (t, J=7.0 Hz, 2H), 3.45-3.39 (m, 4H), 3.04 (t, J=7.9 Hz, 2H), 2.26 (pentet, J=6.1 Hz, 2H), 2.01-1.91 (m, 2H), 1.62-1.48 (m, 4H), 1.45-1.33 (m, 2H), 1.03 (t, J=7.3 Hz, 3H), 0.94 (t, J=7.3 Hz, 3H).
Example 79
Compound of Formula XXXIV l-(3-Butoxypropyl)-2-butyl-l-ff-imidazo[4,5-c][l,5]naphthyridine-5N-oxide Using the general method of Example 74, l-(3-butoxypropyl)-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridine (2.2 g, 6.47 mmol) was oxidized to provide 1.6 g of 1- (3-butoxypropyl)-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridine-5N-oxide as a yellow powder, m.p. 126.5-127.5°C. Analysis: Calculated for C2oH28N4O2: %C, 67.39; %H, 7.92; %N, 15.72; Found: %C, 67.13; %H, 7.69; %N, 15.82. 1H NMR (300 MHz, CDCh): δ 9.22 (dd, J=8.8,1.5 Hz, IH), 9.04 (s, IH), 8.99 (dd, J=4.3,1.5 Hz, IH), 7.65 (dd, J=8.8,4.3 Hz,
IH), 4.89 (t, J=7.0 Hz, 2H), 3.46-3.39 (m, 4H), 3.01 (t, J=7.9 Hz, 2H), 2.28-2.20 (m, 2H), 1.97-1.87 (m, 2H), 1.62-1.46 (m, 4H), 1.45-1.33 (m, 2H), 1.03 (t, J=7.3 Hz, 3H), 0.94 (t, J=7.3 Hz, 3H). Example 80
Compound of Formula I l-(3-Butoxypropyl)-2-butyl-l/τT-imidazo[4,5-c][l,5]naphthyridin-4-amine
Figure imgf000082_0001
Using the general method of Example 75, l-(3-butoxypropyι)-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridine-5N-oxide (1.2 g, 3.4 mmol) was reacted with trichloroacetyl isocyanate (0.6 mL, 5.0 mmol) and the resulting intermediate was hydrolyzed to provide 0.86 g of l-(3-butoxypropyl)-2 -butyl- lH-imidazo[4,5- c][l,5]naphthyridin-4-amine as a white powder, m.p. 101.0-101.5°C. Analysis: Calculated for C20H29N5O: %C, 67.58; %H, 8.22; %N, 19.70; Found: %C, 67.55; %H, 7.96; %N, 20.10. Η NMR (300 MHz. DMSO δ 8.50 (dd, J=4.4,1.5 Hz, IH), 7.91 (dd, J=8.4,1.6 Hz, IH), 7.42 (dd, J=8.4,4.4 Hz, IH), 6.77 (s, 2H), 4.78 (t, J=6.9 Hz, 2H), 3.38-3.30 (m, 4H), 2.93 (t, J=7.8 Hz, 2H), 2.11 (pentet, J=6.1 Hz, 2H), 1.82 (pentet, J=7.6 Hz, 2H), 1.51- 1.39 (m, 4H), 1.37-1.25 (m, 2H), 0.96 (t, J=7.3 Hz, 3H), 0.88 (t, J=7.2 Hz, 3H).
Example 81
Compound of Formula XXXI
N4-(2-Phenoxyethyl)-3-nitro[l,5]naphthyridin-4-amine Using the general method of Example 76, 4-chloro-3 -nitro [ 1 ,5]naphthyridine (5.0 g, 24 mmol) was reacted with 2-phenoxyethylamine (3.5 mL, 27 mmol) to provide 6.6 g of N4-(2-phenoxyethyl)-3-nitro[l,5]naphthyridin-4-amine as a yellow solid, m.p. 107-108°C. Analysis: Calculated for C]6H]4N4O3: %C, 61.93; %H, 4.55; %N, 18.05; Found: %C, 61.99; %H, 4.58; %N, 18.42. 1H NMR (300 MHz. DMSO): δ 10.25 (broad s, IH), 9.39 (broad s, IH), 8.81 (dd, J=4.1,1.7 Hz, IH), 8.25 (dd, J=8.5,1.7 Hz, IH), 7.67 (dd, J=8.5,4.1
Hz, IH), 7.34-7.26 (m, 2H), 7.01-6.96 (m, 3H), 4.89 (broad s, 2H), 4.35 (t, J=5.1 Hz, 2H); MS (ED: m e 310.1065 (310.1065 calc'd for C16H14N4O3). Example 82
Compound of Formula XXXII
N4-(2-Phenoxyethyl)[l,5]naphthyridine-3,4-diamine Using the general method of Example 77, N4-(2-phenoxyethyl)-3- nitro[l,5]naphthyridin-4-amine (5.4 g, 17.4 mmol) was reduced to provide 4.6 g of N4-(2- phenoxyethyl)[l,5]naphthyridine-3,4-diamine as a bright yellow oil. 1H NMR (300 MHz, DMSO): δ 8.68 (dd, J=4.1,1.7 Hz, IH), 8.40 (s, IH), 8.10 (dd, J=8.4,1.7 Hz, IH), 7.39 (dd, J=8.4,4.1 Hz, IH), 7.28-7.22 (m, 2H), 6.94-6.90 (m, 3H), 6.12 (t, J=7.0 Hz, IH), 5.15 (s, 2H), 4.13 (t, J=5.5 Hz, 2H), 3.93-3.87 (m, 2H); MS (CD: m e 281 (M+H).
Example 83
Compound of Formula XXXIII
2-(2-Butyl-li/-imidazo [4,5-c] [l,5]naphthyridin-l-yl)ethyl Phenyl Ether Using the general method of Example 73 Part A and Part B, N4-(2- phenoxyethyl)[l,5]naphthyridine-3,4-diamine (4.4 g, 15.7 mmol) was reacted with valeryl chloride (1.95 mL, 16.4 mmol) and the resulting amide intermediate was cyclized to provide 4.0 g of 2-(2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl phenyl ether as a white solid, m.p. 150-150.5°C. Analysis: Calculated for C2ιH22N4O: %C, 72.81; %H, 6.40; %N, 16.17; Found: %C, 72.78; %H, 6.40; %N, 16.31. 1H NMR (300 MHz. DMSOV. δ 9.25 (s, IH), 9.00 (dd, J=4.3,1.7 Hz, IH), 8.52 (dd, J=8.4,1.7 Hz, IH), 7.74 (dd, J=8.4,4.3 Hz, IH), 7.25-7.20 (m, 2H), 6.91-6.84 (m, 3H), 5.22 (t, J=5.2 Hz, 2H), 4.53 (t, J=5.2 Hz, 2H), 3.09 (t, J=7.7 Hz, 2H), 1.91 (pentet, J=7.6 Hz, 2H), 1.55-1.43 (m, 2H), 0.97 (t, J=7.3 Hz, 3H); MS (ED: m/e 346.1794 (346.1793 calc'd for C2iH22N4O).
Example 84 Compound of Formula XXXTV 2-Butyl-l-(2-phenoxyethyl)-li -imidazo[4,5-c][l,5]naphthyridine-5N-oxide Using the general method of Example 74, 2-(2-butyl-17J-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl phenyl ether (0.6 g, 1.7 mmol) was oxidized to provide 0.44 g of 2-butyl-l-(2-phenoxyethyl)-177-imidazo[4,5-c][l,5]naphthyridine-5N-oxide as a yellow powder. 1H NMR (300 MHz. CDCh : δ 9.10-9.03 (m, 3H), 7.81 (dd, J=8.7,4.3 Hz, IH), 7.25-7.20 (m, 2H), 6.92-6.83 (m, 3H), 5.16 (t, J=4.9 Hz, 2H), 4.51 (t, J=4.9 Hz, 2H), 3.06 (t, J=7.7 Hz, 2H), 1.93-1.83 (m, 2H), 1.54-1.41 (m, 2H), 0.96 (t, J=7.3 Hz, 3H); MS (CD: m e 363 (M+H).
Example 85
Compound of Formula I
2-Butyl-l-(2-phenoxyethyl)-177-imidazo[4,5-c][l,5]naphthyridin-4-amine
Figure imgf000084_0001
Using the general method of Example 75, 2-butyl- 1 -(2 -phenoxyethyl)-lH- imidazo[4,5-c][l,5]naphthyridine-5N-oxide (0.38 g, 1.05 mmol) was reacted with trichloroacetyl isocyanate (0.19 mL, 1.6 mmol) and the resulting intermediate was hydrolyzed to provide 0.23 g of 2-butyl- l-(2-phenoxyethyl)- 177-imidazo[4,5- c][l,5]naphthyridin-4-amine as a white powder, m.p. 159.0-159.2°C. 1H NMR (300 MHz. DMSO): δ 8.52 (dd, J=4.4,1.5 Hz, IH), 7.92 (dd, J=8.4,1.5 Hz, IH), 7.45 (dd, J=8.4,4.4 Hz, IH), 7.26-7.21 (m, 2H), 6.92-6.86 (m, 3H), 6.79 (s, 2H) 5.13 (t, J=5.2 Hz, 2H), 4.48 (t,
J=5.2 Hz, 2H), 3.00 (t, J=7.8 Hz, 2H), 1.91-1.81 (pentet, J=7.4 Hz, 2H), 1.52-1.40 (m, 2H), 0.95 (t, J=7.3 Hz, 3H); MS (ED: m/e 361.1899 (361.1902 calc'd for C21H23N5O).
Example 86 Compound of Formula XXXI
1,1-Dimethylethyl N- {2- [(3-Nitro [ 1 ,5] n aphthy ridin-4-y l)amin o] eth l} carb amate
A solution of diisopropylethylamme (13.47 g, 0.10 mole) in dichloromethane (25 mL) was added to a solution of 5-chloro-3-nitro[l,5]naphthyridine (18.2 g, 0.086 mol) in dichloromethane (250 mL). A solution of tert-butyl N-(2-aminoethyl)carbamate (16.7 g,
0.10 mol) in dichloromethane (75 mL) was slowly added to the reaction mixture. The reaction mixture was heated at reflux overnight. Additional tert-butyl N-(2- aminoethyl)carbamate (1 g) was added and the reaction mixture was heated at reflux for an additional 3 hours. The reaction mixture was allowed to cool to ambient temperature and then it was diluted with additional dichloromethane, washed with water and with brine, dried, and then concentrated under vacuum to provide a dark solid. This solid was purified by flash chromatography (silica gel eluting with dichloromethane) to provide 24.8 g of 1,1 -dimethylethyl N-{2-[(3-nitro[l,5]naphthyridin-4-yl)amino]ethylcarbamate as a canary yellow solid. A portion (0.3 g) was recrystallized from toluene (10 mL) and heptane (10 mL) to provide 0.2 g of canary yellow needles, m.p. 149-151°C. Analysis: Calculated for Cι59N5O4: %C, 54.05; %H, 5.75; %N, 21.01; Found: %C, 54.17; %H, 5.73; %N, 20.90.
Example 87 Compound of Formula XXXII 1,1-Dimethylethyl N-{2- [(3- Amino [1 ,5]naphthyridin-4-yl)amino] ethyl} carbamate
1 , 1 -Dimethylethyl N- {2-[(3-nitro[l ,5]naphthyridin-4-yl)amino]ethyl} carbamate (10 g, 0.03 mol), ethyl acetate (800 mL) and platinum on carbon catalyst were combined in a Pan bottle and then the mixture was hydrogenated overnight. The reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under vacuum to provide 9.1 g of 1,1 -dimethylethyl N-{2-[(3-amino[l,5]naphthyridin-4-yl)amino]ethyl}carbamate as a yellow syrup. Analysis: Calculated for C15H21N5O2 + 0.1 CH3CO2C2H5: %C, 59.25; %H, 7.04; %N, 22.43; Found: %C, 58.96; %H, 6.87; %N, 22.46.
Example 88 Compound of Formula XXXIII
1,1-Dimethylethyl N-[2-(B-butyl-l/7-imidazo[4,5-c] 1 ,5]naphthyridin-l -yl)ethyl] carbamate
1 , 1 -Dimethylethyl N- {2-[(3-amino[ 1 ,5]naphthyridin-4-yl)amino]ethyl} carbamate 0.6 g, 2 mmol), trimethyl orthovalerate (0.35 g, 2.1 mmol), and toluene (25 mL) were combined and heated at reflux for 2 hours. Additional trimethyl orthovalerate (1 eq.) was added and the reaction mixture was heated at reflux overnight. Xylene was added and the toluene was distilled off. The reaction was heated at reflux for an additional 8 hours. The bulk of the xylene was distilled off leaving a volume of about 5 mL. The reaction mixture was allowed to cool. The resulting precipitate was isolated by filtration, washed with heptane and dried to provide 0.35 g of 1,1 -dimethyl ethyl N-[2-(2-butyl-177-imidazo[4,5- c]l,5]naphthyridin-l-yl)ethyl]carbamate as an ivory powder, m.p. 198-199°C. Analysis: Calculated for C2oH27N5O2: %C, 65.01 ; %H, 7.36; %N, 18.95; Found: %C, 64.75; %N,
7.57; %N, 19.09.
Example 89 Compound of Formula XXXIII 1 -{2- [(1 ,l-dimethylethoxycarbonyl)amino] ethyl}-2-butyl- l/f-imidazo[4,5-c][l,5]naphthyridine-5N-oxide
3-Chloroperbenzoic acid (0.7 g of 57-86%) was dissolved in chloroform (10 mL). One half of this solution was added to a solution of 1,1 -dimethylethyl N-[2-(2-butyl-177- imidazo[4,5-c]l,5]naphthyridin-l-yl)ethyl]carbamate (1.0 g, 2.7 mmol) in chloroform (10 mL). The reaction mixture was stined at ambient temperature for 30 minutes and then the remaining half of the chloroperbenzoic acid solution was added dropwise to the reaction mixture. The reaction mixture was stirred at ambient temperature for a total of 2.5 hours and then it was diluted with chloroform (50 mL); washed with sodium carbonate, with 10% sodium hydroxide, with water, and with brine; dried and concentrated under vacuum to provide 1.1 g of a yellow solid. This material was recrystallized twice from acetonitrile to provide 1.0 g of l-{2-[(l,l-dimethylethoxycarbonyl)amino]ethyl}-2-butyl-177- imidazo[4,5-c][l,5]naphthyridine-5N-oxide. Analysis: Calculated for C20H27N5O3: %C, 62.32; %H, 7.06; %N, 18.17; Found: %C, 62.03; %H, 6.73; %N, 18.10.
Example 90
Compound of Formula I
1 ,1 -Dimethylethyl N- [2-(4-Amino-2-butyl- l -imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]carbamate
Figure imgf000087_0001
Trichloroacetyl isocyanate (4.8 mL, 40 mmol) was added via a syringe to a solution of l-{2-[(l, l-dimethylethoxycarbonyl)amino]ethyl}-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridine-5N-oxide (10.4 g, 27 mmol) in dichloromethane (75 mL). The reaction mixture was stined at ambient temperature for 1 hour. Sodium methoxide (9 mL of 25% sodium methoxide in methanol) was added and the reaction mixture was stined at ambient temperature overnight. Thin layer chromatography indicated that the reaction was not complete so additional sodium methoxide was added twice with each addition being followed by 2 hours of stirring at ambient temperature. The reaction mixture was diluted with dichloromethane; washed with sodium carbonate, water, and then brine; dried and then concentrated under vacuum to provide 10.4 g of a yellow solid. This material was purified by column chromatography (silica gel eluting with dichloromethane) to provide 8.5 g of a solid. This solid was recrystallized from toluene (20 mL) to provide 6.0 g of 1,1 -dimethylethyl N-[2-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)ethyl] carbamate as ivory crystals, m.p. 118-120°C. Analysis: Calculated for
C2oH28N6O2: %C, 62.48; %H, 7.34; %N, 21.85; Found: %C, 62.31; %H, 7.23; %N, 22.13. HRMS (El) calcd for C2oH28N6O2 (M+) 384.2273, found 384.2273 Example 91
Compound of Formula I
2-(4-Amino-2-butyl-liϊ-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethaneamine
Figure imgf000088_0001
Trifluoroacetic acid (5 mL) was added to a solution of 1,1 -dimethylethyl N-[2-(4- amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]carbamate (5.7 g, 15 mmol) in dichloromethane (10 mL). The reaction mixture was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with dichloromethane and then extracted with 10% hydrochloric acid. The hydrochloric acid extract was washed twice with dichloromethane and then it was made basic with ammonium hydroxide. The resulting precipitate was isolated by filtration and dried to provide 3.7 g of 2-(4-amino-2 -butyl- 1H- imidazo[4,5-c][l,5]naphthyridin-l-yl)ethaneamine as a white powder, m.p. 175-176°C. Analysis: Calculated for Cι5H20N6: %C, 63.36; %H, 7.09; %N, 29.55; Found: %C, 62.98; %H, 6.92; %N, 29.89. HRMS (El) calcd for C15H20N6 (M+) 284.1749, found 284.1748.
Ex-ample 92
Compound of Formula I
N1-[2-(4-Aιιιino-2-butyl- l -imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]acetamide
Figure imgf000088_0002
Under a nitrogen atmosphere, acetyl chloride (50 μL, 0.7 mmole) in dichloromethane (25 mL) was added dropwise to a cooled (ice bath) solution of 2-(4- amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethaneamine (0.2 g, 0.7 mmol) in dichloromethane (50 mL). After the addition was complete, the reaction mixture was allowed to warm to ambient temperature. After 30 minutes thin layer chromatography indicated that the reaction was complete. The reaction mixture was washed with 10% sodium hydroxide, water and brine; dried; and concentrated under vacuum to provide 0.25 g of crude product. This material was purified by column chromatography (silica gel eluting with dichloromethane) to provide 0.2 g of a solid. This solid was recrystallized from acetonitrile (30 mL) to provide 0.18 g of N1-[2-(4-amino-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl]acetamide as a white powder, m.p.228-230°C. Analysis: Calculated for C17H22N6O: %C, 62.56; %H, 6.79; %N, 25.75; Found: %C, 62.50; %H, 6.59; %N, 26.04. HRMS (El) calcd for C22H26N6O2 (M+) 326.1855, found 326.1846
Example 93
Compound of Formula I
N1-[2-(' -Aιιιino-2-bntyl- lJΪ-imidazo^jS-cllljSlnaphthyridin-l-y ethylJ- E^-butenamide
Figure imgf000089_0001
Using the general method of Example 92, crotonyl chloride (68 μL, 0.7 mmol) was reacted with 2-(4-amino-2-butyl-lH-imidazo[4,5-c] [ 1 ,5 jnaphthyridin- 1 -yl)ethaneamine (0.2 g, 0.7 mmol) to provide 0.2 g of N1-[2-(4-amino-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl]-(E)-2-butenamide as a white powder, m.p. 198-200°C. Analysis: Calculated for C19H24N6O: %C, 64.75; %H, 6.86; %N, 23.85; Found: %C, 64.25; %H, 6.68; %N, 23.99. HRMS (El) calcd for C19H24N6O (M+) 352.2011 found 352.1996 Example 94
Compound of Formula I
N1-[2-(4-Amino-2-butyl-li^-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-
1-cyclohexanecarboxamide
Figure imgf000090_0001
Using the general method of Example 92, cyclohexanecarbonyl chloride (94 μL, 0.7 mmol) was reacted with 2-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l- yl)ethaneamine (0.2 g, 0.7 mmol) to provide 0.2 g of N1 -[2-(4-amino-2 -butyl- 1H- imid^o[4,5-c][l,5]naphthyridin-l-yl)ethyl]-l-cyclohexanecarboxamide as a white powder, m.p. 188-190°C. Analysis: Calculated for C22H3oN6O: %C, 66.98; %H, 7.66; %N, 21.30; Found: %C, 66.72; %H, 7.57; %N, 21.48. HRMS (El) calcd for C22H30N6O (M+) 394.2481 found 394.2475.
Example 95
Compound of Formula I
N1- [2-(4-amino-2-butyl-li7-imidazo [4,5-c] [1 ,5] naphthyridin-1 -yl)ethyl] -
3,5-di-(l ,1 -dimethylethyl)-4-hydroxybenzamide
Figure imgf000090_0002
Using the general method of Example 92, 3,5-di-(l,ldimethylethyl)-4- hydroxybenzoyl chloride (0.47 g, 1.7 mmol) was reacted with 2-(4-amino-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridin-l-yl)ethaneamine (0.5 g, 1.7 mmol) to provide 0.5 g of N1-[2-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-3,5-di-(l,l- dimethylethyl)-4-hydroxybenzamide as a white powder, m.p. 248-250°C. Analysis: Calculated for C30H40N6O2: %C, 69.74; %H, 7.80; %N, 16.27; Found: %C, 69.65 %H, 7.69; %N, 16.42. HRMS (El) calcd for C30H40N6O2 (M+) 516.3212 found 516.3226
Example 96
Compound of Formula I
N1-[2-(4-Amino-2-butyl-l/^-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-
3-phenylpropan amide Hydrochloride
Figure imgf000091_0001
Using the general method of Example 92, hydrocinnamoyl chloride (0.1 g, 0.7 mmol) was reacted with 2-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)ethaneamine (0.2 g, 0.7 mmol). After one hour the reaction mixture was poured directly onto a silica gel column and eluted with dichloromethane at first, then 15% methanol / dichloromethane to provide 0.2 g of a solid. This solid was recrystallized from toluene to provide 0.2 g of N1-[2-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]- 3-phenylpropanamide hydrochloride as a white powder, m.p. 183-185°C. Analysis: Calculated for C24Η28N6O HCl: %C, 63.64; %H, 6.45; %N, 18.55; Found: %C, 63.68; %H, 6.43; %N, 18.55. Example 97
Compound of Formula I
N-[2-(4-Amino-2-butyl-l^-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-
5-oxotetrahydro-2-furancarboxamide
Figure imgf000092_0001
A solution of (S)-(+)-5-oxo-2-tetrahydrofurancarboxylic acid (0.23 g, 1.7 mmole in anhydrous dichloromethane (30 mL) was slowly added to a solution of 2-(4-amino-2- butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethaneamine (0.5 g, 1.7 mmol) in anhydrous dichloromethane (100 mL). The reaction mixture was stirred at ambient temperature for 30 minutes and then a solution of l-[3-(dimethoxyamino)propyl]-3- ethylcarbodiimide hydrochloride (0.37 g, 1.9 mmol) in anhydrous dichloromethane (50 mL) was added dropwise. The reaction mixture was stined at ambient temperature overnight and then filtered to remove solids. The filtrate was washed twice with 10% sodium hydroxide and then with brine, dried, and then concentrated under vacuum to provide 0.3g of crude product. This material was purified by column chromatography (silica gel eluting with dichloromethane) followed by recrystallization from acetonitrile to provide 0.1 g of N-[2-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-5- oxotetrahydro-2-furancarboxamide as a white powder, m.p. 153-154°C. Analysis: Calculated for C20Η24N6O3: %C, 60.59; %H, 6.10; %N, 21.19; Found: %C, 60.34; %H,
6.14; %N, 21.13. HRMS (El) calcd for C20H24N6O3 (M+) 396.1909 found 396.1905 Example 98
Compound of Formula I
N1-[2-(4-Amino-2-butyl-17 -imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-
2-(3-hydroxyphenyl)acetamide
Figure imgf000093_0001
Using the general method of Example 97 3-hydroxyphenyl acetic acid (0.26 g, 1.7 mmole) was reacted with 2-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yDethaneamine (0.5 g, 1.7 mmol) to provide 0.13 g of N1-[2-(4-amino-2-butyl-lH- imid^o[4,5-c][l,5]naphthyridin-l-yl)ethyl]-2-(3-hydroxyphenyl)acetamide as a white powder, m.p. 208-210°C. Analysis: Calculated for C23Η26N6O2: %C, 66.01; %H, 6.26; %N, 20.08; Found: %C, 65.63; %H, 6.11; %N, 20.30. HRMS (El) calcd for C23H26N6O2 (M+) 418.2117 found 418.2109.
Example 99
Compound of Formula I
N-[2-(4-Amino-2-butyl-l -imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-
6-hy droxy-2-py ridin ecarb oxamide
Figure imgf000093_0002
Using the general method of Example 97 6-hydroxypicolinic acid (0.24 g, 1.7 mmole) was reacted with 2-(4-amino-2 -butyl- lH-imidazo[4,5-cj[l,5]naphthyridin-l- yl)ethaneamine (0.5 g, 1.7 mmol) to provide 0.15 g of N-[2-(4-amino-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-6-hydroxy-2-pyridinecarboxamide as a white powder, m.p. 258-260°C. Analysis: Calculated for C2ιH23N7O2 + Vτ CH3CN: %C, 62.03; %H, 5.80; %N, 24.66; Found: %C, 61.87; %H, 5.70; %N, 24.60.
Example 100
Compound of Formula I
N1-[2-(4-Amino-2-butyl-l^-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-
3,7-dimethyl-6-octenamide
Figure imgf000094_0001
Using the general method of Example 97 citronellic acid (0.3 g, 1.7 mmole) was reacted with 2-(4-amino-2 -butyl- lH-imidazo[4,5 -c] [ 1 ,5]naphthyridin- 1 -yl)ethaneamine (0.5 g, 1.7 mmol) to provide 0.5 g of N1-[2-(4-amino-2-butyl-177-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl]-3,7-dimethyl-6-octenamide as a white whispy solid, m.p. 163-164°C. Analysis: Calculated for C25H36N6O: %C, 68.77; %H, 8.31; %N, 19.25; Found: %C, 68.84; %H, 8.14; %N, 19.58. HRMS (El) calcd for C25H36N6O (M+) 436.2950 found 436.2952.
Example 101
Compound of Formula I
1,1-Dimethylethyl N-[l-({[2-(4-Amino-2-butyl-li/-imidazo[4,5-c]
[l,5]naphthyridin-l-yI)ethyl]amino}carbonyl)-3-methylbutyl]carbamate
Figure imgf000095_0001
Using the general method of Example 97 N-t-BOC-L-leucine (0.41 g, 1.7 mmole) was reacted with 2-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l- yl)ethaneamine (0.5 g, 1.7 mmol) to provide 0.5 g of 1,1 -dimethylethyl N-[l-({[2-(4- amino-2-butyl- 1 7-imidazo [4,5-c] [ 1 ,5]naphthyridin- 1 -yl)ethyl] amino } carbonyl)-3- methylbutyl]carbamate as a white solid, m.p. 184-185°C. HRMS (El) calcd for C26H39N7O3 (M+) 497.3114 found 497.3093.
Example 102
Compound of Formula I
N1-[2-(4-Amino-2-butyl-l T-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-
2-amino-4-methylpentanamide
Figure imgf000095_0002
1 , 1 -Dimethylethyl N-[ 1 -( { [2-(4-amino-2-butyl- 17J-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl]amino}carbonyl)-3-methylbutyl]carbamate (0.35 g, 0.7 mmol) was combined with 1 N hydrochloric acid (40 mL) and heated on a steam bath for 30 minutes. The reaction mixture was allowed to cool and then it was made basic with 10% sodium hydroxide. The resulting precipitate was isolated by filtration and dried to provide 0.15 g of N1-[2-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]- 2-amino-4-methylpentamide as a white solid, m.p.60-65°C. Analysis: Calculated for C2ιH3,N7O: %C, 63.27; %H, 7.86; %N, 24.66; Found: %C, 62.27; %H, 7.67; %N, 24.77. HRMS (El) calcd for C21H3)N7O (M+) 397.2590 found 397.2582.
Example 103
Compound of Formula I
N-[2-(4-Amino-2-butyl-17 -imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-
3,5-dimethyl-4-isoxazolecarboxamide
Figure imgf000096_0001
Using the general method of Example 97 3,5-dimethylisoxazole-4-carboxylic acid (0.25 g, 1.7 mmole) was reacted with 2-(4-amino-2-butyl-177-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethaneamine (0.5 g, 1.7 mmol) to provide 0.23 g of N-[2-(4- amino-2 -butyl- lH-imidazo[4,5-c] [ 1 ,5 ]naphthyridin- 1 -yl)ethyl]-3,5-dimethyl-4- isoxazolecarboxamide as a white powder, m.p. 188-189°C. Analysis: Calculated for C2iH25N7O2: %C, 61.90; %H, 6.18; %N, 24.06; Found: %C, 61.92; %H, 6.15; %N, 24.28. HRMS (El) calcd for C21H25N7O2 (M+) 407.2069 found 407.2068
Ex.am.ple 104
Compound of Formula II
N1-[2-(4-Amino-2-butyl-6,7,8,9-tetrahydro-17^-imidazo[4,5-c]
[l,5]naphthyridin-l-yl)ethyl]-3,5-di-(l,l-dimethylethyl)-4-hydroxybenzamide
Figure imgf000097_0001
A solution of N1-[2-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)ethyl]-3,5-di-(l,l-dimethylethyl)-4-hydroxybenzamide (0.1 g, 0.19 mmol) in trifluoroacetic acid (15 mL) and platinum oxide (0.1 g) were combined and hydrogenated overnight on a Parr apparatus. The reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under vacuum. The residue was dissolved in dichloromethane. The dichloromethane solution was washed twice with 10% sodium hydroxide and with brine, dried and then concentrated under vacuum to provide crude product. This material was purified by chromatography eluting with 10% methanol in dichloromethane. The resulting oil was triturated with acetonitrile to provide 0.05 g of N1- [2-(4-amino-2-butyl-6,7,8,9-tetrahydro- lH-imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)ethyl]-
3,5-di-(l,l-dimethylethyl)-4-hydroxybenzamide as a white powder, m.p. 208-210°C. Analysis: Calculated for C^H^N^ + 0.1 CF3CO2H: %C, 68.17; %H, 8.35; %N, 15.79; Found: %C, 68.48; %H, 8.29; %N, 16.08. Example 105
Compound of Formula I
N1-[4-(4-Amino-2-butyl -17ar-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
5-(l,3-dimethyl-2,6-oxo-2,3,6,7-tetrahydro-lH-purinyl)pentamide
Figure imgf000098_0001
4-(4-Amino-2-butyl-177-imidazo[4,5-c][l ,5]naphthyridin-l -yl)butaneamine (0.2 g), 5-(l,3-dimethyl-2,6-oxo-2,3,6,7-tetrahydro-lH-purinyl)pentanoic acid (0.18 g) and dichloromethane (100 mL) were combined and stined at ambient temperature for 30 minutes. l-[3-(Dimethylamino)propy]-3-ethylcarbodiimide (0.12 g) was added and the reaction mixture was stined at ambient temperature for 2 hours. The reaction was filtered through a column of silica gel and eluted with 10% methanol in dichloromethane to provide 0.2 g of N'-[4-(4-amino-2-butyl -lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]- 5-(l ,3-dimethyl-2,6-oxo-2,3,6,7-tetrahydro-lH-purinyl)pentamide, m.p. 153.5-155°C. Analysis: Calculated for C29H38N10O3: %C, 60.61 ; %H, 6.66; %N, 24.37; Found: %C,
60.65; %H, 6.66; %N, 24.32.
Example 106
Compound of Formula I
N1-[4-(4-Amino-2-butyl -17 -imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
6-morpholinonicotinamide
Figure imgf000099_0001
Using the general method of Example 105 6-morpholinonicotinic acid (0.12 g, 64 mmol) was reacted with 4-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.2 g, 0.64 mmol) to provide N1-[4-(4-.amino-2 -butyl -lH-imid^o[4,5- c][l,5]naphthyridin-l-yl)butyl]-6-morpholmonicotinamide as a white solid, m.p. 95- 100°C. Calculated for C27H34N8O2 + lA H2O: %C, 63.39; %H, 6.90: %N, 21.90; Found: %C, 63.69; %H, 6.95; %N, 21.52.
Example 107
Compound of Formula I
N1-[4-(4-Amino-2-butyl -l -'-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
6-quinolinecarboxamide
Figure imgf000099_0002
Using the general method of Example 105 6-quinolinecarboxylic acid (0.11 g, 64 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.2 g, 0.64 mmol) to provide N -[4-(4-amino-2-butyl -lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)butyl]-6-quinolinecarboxamide as a white solid, m.p. 190-191°C. Analysis: Calculated for C27Η29N7O + 'ΛHzO: %C, 68.70; %H, 6.30; %N, 20.77; Found: %C, 68.54; %H, 6.21; %N, 20.93.
Example 108
Compound of Formula I
N1-[4-(4-Amino-2-butyl -lJ&-imidazo[4,5-c][l,5]naphthyridin-l-yI)butyI]-
2-(4-hydroxy-5-methyl-2-oxo-l,2-dihydro-l-pyrimidinyl)acetamide
Figure imgf000100_0001
Using the general method of Example 105 2-(4-hydroxy-5-methyl-2-oxo-l,2- dihydro-l-pyrimidinyl)acetic acid (0.12 g, 64 mmol) was reacted with 4-(4-amino-2-butyl- lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butaneamine (0.2 g, 0.64 mmol) to provide 0.06 g of N1 -[4-(4-amino-2-butyl - 1 7-imidazo [4,5-c] [ 1 ,5]naphthyridin- 1 -yl)butyl]-2-(4- hydroxy-5-methyl-2-oxo-l,2-dihydro-l-pyrimidinyl)acetamide as a solid, m.p. 242-244°C.
Example 109
Compound of Formula I
N1-[4-(4-Amino-2-butyl -li -imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
2-(2-pyrimidinylsulfanyl)acetamide
Figure imgf000101_0001
Using the general method of Example 105 (2-pyrimidinylthio)acetic acid (0.11 g, 64 mmol) was reacted with 4-(4-amino-2-butyl-177-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (0.2 g, 0.64 mmol) to provide N1-[4-(4-amino-2 -butyl -177-imidazo[4,5- c][l,5]naphthyridin-l-yl)butyl]-2-(2-pyrimidinylsulfanyl)acetamide as a white solid, m.p. 156-160°C (dec).
Example 110
Compound of Formula I
N1-[4-(4-Amino-2-butyl -liϊ-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
2-(4-pyridylsulfanyl)acetamide
Figure imgf000101_0002
Using the general method of Example 105 (4-pyridylthio)acetic acid (0.11 g, 64 mmol) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yDbutaneamine (0.2 g, 0.64 mmol) to provide 0.1 g of N1-[4-(4-amino-2-butyl -177- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-2-(4-pyridylsulfanyl)acetamide as a solid, m.p. 127.5-129°C.
Example 111
Compound of Formula I
4-(4-amino- 177-imidazo[4,5-c][ 1 ,5]naphthyridin- 1 -yl)butaneamine
Figure imgf000102_0001
Part A Triethylorthoformate (2.8 mL, 16.6 mmol) was added to a solution of 1,1- dimethylethyl N-{4-[(3-.amino[l,5]naphthyridin-4-yl)amino]butyl}carbamate (5.0 g, 15.1 mmol) in toluene (150 mL). The reaction was heated at reflux overnight with ethanol being collected in a Dean Stark trap. The reaction mixture was heated at reflux for an additional 6 hours and then p-toluenesulfonic acid (1.4 g, 7.5 mmol) was added and the reaction was refluxed overnight. A dark orange/brown oil had formed. The toluene supernatant was decanted off and concentrated under vacuum to provide 1.1 g of 1,1- dimethylethyl N-[4-(177-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate. The oil was identified as 4-(177-imidazo[4,5-c][l,5]naphthyridin-l-yl)butaneamine. This material was reacted with 1,1-dimethylethyl-dicarbonate to provide an additional 1 g of 1,1- dimethylethyl N-[4-(17J-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]carbamate. The two lots were combined .and carried on to the next step. Part B
3-Chloroperbenzoic acid (1.86 g of 60%) was added in small portions to a solution of the material from Part A in chloroform (25 mL). The reaction was maintained at ambient temperature overnight and then it was diluted with 5% sodium carbonate solution.
The layers were separated. The organic layer was concentrated under vacuum. The residue was slurried with hot methyl acetate, cooled and then filtered to provide 2.0 g of 1- {4-[( 1 , 1 -dimethylethylcarbonyl)amino]butyl} - lH-imidazo[4,5-c] [ 1 ,5]naphthyridine-5N- oxide.
Part C
Tosyl chloride (0.64 g, 3.37 mmol) was slowly added in small portions to a solution of the material from Part B (1.2 g, 3.37 mmol) in dichloromethane (20 mL).
After 4 hours an additional 100 mg of tosyl chloride was added to drive the reaction to completion. The reaction was quenched with concentrated ammonium hydroxide (5 mL) and water (10 mL) and stirred at ambient temperature over the weekend. The layers were separated. The organic layer was concentrated under vacuum to provide a tan solid. This solid was slurried in hot methyl acetate, cooled and the filtered to provide 0.9 g of l,l-dimethylethyl N-[4-(4-amino-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butyl]carbamate.
Part D
A mixture of the material from Part C and 1 N hydrochloric acid (25 mL) was heated at reflux until thin layer chromatography indicated that the reaction was complete.
The mixture was adjusted to pH 14 with 6 N sodium hydroxide. The resulting precipitate was isolated by filtration to provide 0.2 g of 4-(4-amino-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)butaneamine as a pale yellow solid, m.p. 161-163°C. Mass spec (M + l) = 257.09.
Example 112
Compound of Formula I
N1-[4-(4-Amino-2-butyl-l/^-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
4-{[2-(dimethylamino)ethoxy](phenyl)methyl}benzamide
Figure imgf000104_0001
Part A
Under a nitrogen atmosphere phenyl magnesium bromide (39 mL of 3 M in ether) was added via a syringe over a period of 30 minutes to a solution of methyl 4- formylbenzoate (19.2 g, 117 mmol). The mixture was allowed to stir for an additional 10 minutes and then it was quenched by the addition of 1 M hydrochloric acid (125 mL). The reaction mixture was extracted with diethyl ether (2 X 200 mL). The combined extracts were washed with brine, dried over magnesium sulfate, filtered and then concentrated under vacuum to provide a yellow oil. This material was purified by flash chromatography (silica gel eluting with 6:1 hexanes:ethyl acetate) to provide 6.9 g of methyl 4-( -hydroxybenzyl)benzoate as a clear oil.
Under a nitrogen atmosphere a suspension of p-toluenesulfonic acid monohydrate (10.7 g, 56 mmol) in toluene (70 mL) was heated at reflux. Water (-1 mL) was collected in a Dean Stark trap. The heating mantle was removed. To the warm mixture was added a solution of methyl 4-(α-hydroxybenzyl)benzoate (3.47 g, 14 mmol) and N,N- dimethylethanolamine (2.9 mL, 28 mmol) in a minimal amount of toluene. The mixture was heated at reflux for 20 minutes and then allowed to cool to ambient temperature. The reaction mixture was partitioned between diethyl ether and saturated aqueous sodium bicarbonate (the aqueous layer was basic). The aqueous layer was extracted with an additional lOOmL of diethyl ether. The combined organic layers were dried and then concentrated under vacuum. The residue was purified by flash chromatography (silica gel eluting with 5%, then 10% methanol in dichloromethane) to provide 2.49 g of methyl 4- [ -(2-N,N-dimethylaminoethoxy)benzyl]benzoate as a colorless oil. I N Sodium hydroxide (2.54 mL) was added to a solution of methyl 4-[α-(2-N,N- dimethylaminoethoxy)benzyl]benzoate (0.53 g, 1.7 mmol) in methanol (10 mL). The solution was heated at reflux for 1 hour, allowed to cool to ambient temperature and then neutralized (pH 5-6) with 1 N hydrochloric acid (2.54 mL). The mixture was concentrated under vacuum (bath at 45°C). The resulting residue was extracted into a mixture of dichloromethane (15 mL) and methanol (3 mL). The extract was filtered and the filtrate was concentrated under vacuum to provide a viscous residue. Trituration with several portions of diethyl ether provided 0.39 g of 4-[α-(2-N,N- dimethylaminoethoxy)benzyl]benzoic acid as a white powder. Part B 4-(4-Amino-2-butyl-1 7-imidazo [4,5-c] [ 1 ,5]naphthyridin-l -yl)butaneamine (0.130 g, 0.4175 mmol) .and 4-[α-(2-N,N-dimethyl.aminoethoxy)benzyl]benzoic acid (0.125 g, 0.4175 mmol) were combined in dichloromethane (150 mL) and stined at ambient temperature until a clear solution was obtained. l-[3-(Dimethylamino)propy]-3- ethylcarbodiimide hydrochloride (0.088 g, 0.46 mmol) was added and the reaction was maintained at ambient temperature for 2 days. The volume of dichloromethane was reduced and the concentrate was purified by flash chromatography (silica gel eluting with 10% methanol in dichloromethane) to provide 0.085 g of N1-[4-(4-amino-2-butyl-lH- imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)butyl]-4- { [2- (dimethylamino)ethoxy](phenyl)methyl}benzamide as a solid, m.p. 105-108°C. Mass spec (M + l) = 594.30.
Example 113
Compound of Formula I
N1-[4-(4-Amino-2-butyl-l^-r-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-
4-benzoylbenzamide
Figure imgf000106_0001
Using the general method of Example 112 Part B, 4-benzoylbenzoic acid (72 mg, 0.32 mmole) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)butaneamine (100 mg, 0.32 mmol) to provide 30 mg of N1-[4-(4-amino-2-butyl-lH- imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-4-benzoylbenzamide as a white solid. Mass- spec (M + 1 = 521.31).
Example 114
Compound of Formula I
N1-[4-(4-Amino-2-butyl-lfl-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]-
2-(5-methyl-2,4-dioxo-l,2,3,4-tetrahydro-l-pyrimidinyl)acetamide
Figure imgf000106_0002
Using the general method of Example 112 Part B, thymine-1 -acetic acid (130 mg, 0.70 mmole) was reacted with 4-(4-amino-2 -butyl- 177-imidazo[4,5-c][l,5]naphthyridin-l- yl)eth.aneamine (200 mg, 0.70 mmol) to provide 68 mg of N1-[4-(4-amino-2 -butyl- 177- imidazo[4,5-c][ 1 ,5]naphthyridin-l -yl)ethyl]-2-(5-methyl-2,4-dioxo- 1 ,2,3,4-tetrahydro-l - pyrimidinyl)acetamide as a white solid, m.p. 241-242°C. Mass-spec (M + 1 = 451.24).
Example 115
Compound of Formula I
N1-[4-(4- Amino-2-butyl-177-imidazo [4,5-c] [1,5] naphthyridin-l-yl)ethyl]-
6-(5-methyl-2-oxo-4-imidazoIidinyl)hexamide
Figure imgf000107_0001
Using the general method of Example 112 Part B, D-desthiobiotin (151 mg, 0.70 mmole) was reacted with 4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yDethaneamine (200 mg, 0.70 mmol) to provide 231 mg of N1-[4-(4-amino-2-butyl-lH- imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 -yl)ethyl]-
6-(5-methyl-2-oxo-4-imid.azolidinyl)hexamide as a white solid, m.p. 184-186°C. Mass spec (M + 1 = 481.35).
Example 116
Compound of Formula I
N1-[4-(4-Amino-2-butyl-l^T-imidazo[4,5-c]
[ 1 ,5] n aphthy ridin-1 -yl)ethyl] meth an esu If on amide
Figure imgf000108_0001
Using the method of Examples below, 4-(4-amino-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethaneamine (14 mg, 50 μmol) was reacted with methanesulfonyl chloride (4 μL, 50 μmol) to provide 5.3 mg of N1-[4-(4-amino-2 -butyl- 177-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethyl]methanesulfonamide. 1Η NMR (500 MHz. d6-DMSO δ = 8.49 (dd, J=4.3; 1.5 Hz, 1 H), 7.92 (dd, J=8.0; 1.5 Hz, 1 H), 7.44 (dd, J=8.0; 4.3 Hz, 1 H), 7.30 (t, J=6 Hz, 1 H), 6.76 (s, 2H), 4.77 (t, J=6 Hz, 2 H), 3.50 (q, J=6 Hz, 2 H), 2.98 (t, J=7 Hz, 2 H), 2.85 (s, 3H), 1.82 (quintet, J=7 Hz, 2 H), 1.46 (m, 2 H), 0.96 (t, J=7 Hz, 3 H). Mass spec by APCI (+/-) plug injection gave desired MW.
Example 117
Compound of Formula I
N1-[4-(4-Amino-2-butyl-l -imidazo[4,5-c]
[l,5]naphthyridin-l-yl)ethyl]benzenesulfonamide
Figure imgf000109_0001
Using the method of Examples 118-152 below, 4-(4-amino-2-butyl-177- imidazo[4,5-c][l,5]naphthyridin-l-yl)ethaneamine (14 mg, 50 μmol) was reacted with benzenesulfonyl chloride (6 μL, 50 μmol) to provide 10.9 mg of N'-[4-(4-amino-2-butyl- lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]benzenesulfonamide. IH NMR (500 MHz, d6-DMSO) δ = 8.43 (dd, J=4.4 ; 1.5 Hz, 1 H), 7.94 (t, J=6 Hz, 1 H), 7.89 (dd, J=8.4; 1.5
Hz, 1 H), 7.68 (d, J=8 Hz, 2 H), 7.58 (t, J=8 Hz, 1 H), 7.50 (t, J=8Hz, 2H), 7.41 (dd, J=8.4; 4.4 Hz, 1 H), 4.72 (t, J=6 Hz, 2 H), 3.34 (m, 2 H), 2.97 (t, J=7 Hz, 2 H), 1.81 (quintet, J=7 Hz, 2 H), 1.45 (sextet, J=7 Hz, 2 H), 0.97 (t, J=7 Hz, 3 H). Mass spec by APCI (+/-) plug injection gave desired MW.
Examples 118 - 152
Compounds of Formula I
The compounds of Examples 118-152 shown in the table below were prepared according to the following method. 4-(4-Amino-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)ethaneamine (50 μmol) was dissolved in dichloromethane (5 mL) in a screw-capped test tube and the solution was cooled in an ice-water bath. An acid chloride (50 μmol) of the formula RACOCI was added as a solution in 100 μL of dichloromethane (Acid chlorides that are solids were either dissolved or suspended in -400 μL of dichloromethane and then added). The mixture was vortexed for 15 seconds to 1 minute, becoming cloudy, and then -80 mg of an aminomethyl polystyrene resin (0.62 meq/g, 100-200 mesh, 1% crosslink, Bachem #D-2100, lot # FM507) was added, and the mixture was vortexed for another 30 seconds. The mixture was applied to a short column (3 x 1 cm ) of silica gel conditioned with dichloromethane. The product was eluted with 10:1 dichloromethane:methanol, collecting -2 mL fractions. Thin layer chromatography of the fractions was performed, and fractions with the product spot were pooled and stripped to dryness in a Savant SpeedVac. Purity was checked by reversed phase-HPLC (HPLC conditions refer to using a Hewlett Packard HP 1090 system fitted with a C18 Rainin Microsorb MV column, 4.6 x 50 mm, particle size = 3 microns, pore size = 100 Angstroms. Gradient elution: linear gradient from 100% water +0.1% trifluoroacetic acid to 100% acetonitrile + 0.1% trifluoroacetic acid over 5 min. at 1 mL per minute. Detection is at 220 nm and 254 nm). APCI-mass spectral data confirmed presence of the expected molecular ion, and proton nmr data supported the expected structure.
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Examples 153 - 190
Compounds of Formula I
The compounds of Examples 153-190 shown in the table below were prepared according to the following method. 4-(4-Amino-2-butyl-lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)butaneamine (25 μmol) was dissolved in dichloromethane (10 mL) in a screw-capped test tube and the solution was cooled in an ice-water bath. An acid chloride (25 μmol) of the formula RACOCl was added as a solution in 100 μL of dichloromethane (Acid chlorides that are solids were added directly.). The mixture was vortexed for 15 seconds to 1 minute, becoming cloudy, and then -80 mg of an aminomethyl polystyrene resin (0.62 meq/g, 100-200 mesh, 1% crosslink, Bachem #D- 2100, lot # FM507) was added, and the mixture was vortexed for another 30 seconds. The mixture was applied to a short column (3 x 1 cm ) of silica gel conditioned with dichloromethane. The product was eluted with 10:1 dichloromethane methanol, collecting -2 mL fractions. Thin layer chromatography of the fractions was performed, and fractions with the product spot were pooled and stripped to dryness in a Savant SpeedVac. Purity was checked by reversed phase-HPLC (HPLC conditions refer to using a Hewlett Packard HP 1090 system fitted with a C18 Rainin Microsorb MV column, 4.6 x 50 mm, particle size = 3 microns, pore size = 100 Angstroms. Gradient elution: linear gradient from 100% water +0.1 % trifluoroacetic acid to 100% acetonitrile + 0.1 % trifluoroacetic acid over 5 min. at 1 mL per minute. Detection is at 220 nm and 254 nm). APCI-mass spectral data confirmed presence of the expected molecular ion, and proton nmr data supported the expected structure.
Figure imgf000119_0001
Figure imgf000119_0002
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Examples 191 - 212
Compounds of Formula I
The compounds of Examples 191-212 shown in the table below were prepared according to the following method. 4-(4-Amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)eth.aneamine (50 μmol) was dissolved in 5 mL of dichloromethane in a screw-capped test tube and a carboxylic acid (50 μmol) of formula RACOOH was added at ambient temperature. Within 3 minutes a light suspension typically formed. The coupling agent, l-(3-dimethylaminopropyl)-3- ethyl carbodiimide hydrochloride (-10.5 mg, 55 μmol) was added and the mixture was vortexed at 400 rpm for 1-2 h at ambient temperature, giving a clear solution in most cases. The mixture was applied to a short column (3 x 1 cm ) of silica gel conditioned with dichloromethane. The product was eluted with 10:1 dichloromethane:methanol, collecting -2 mL fractions. Thin layer chromatography of the fractions was performed, and fractions with the product spot were pooled and stripped to dryness in a Savant SpeedVac. Purity was checked by reversed phase-HPLC
(HPLC conditions refer to using a Hewlett Packard HP 1090 system fitted with a C18 Rainin Microsorb MV column, 4.6 x 50 mm, particle size = 3 microns, pore size = 100 Angstroms. Gradient elution: linear gradient from 100% water +0.1% trifluoroacetic acid to 100% acetonitrile + 0.1% trifluoroacetic acid over 5 min. at 1 mL per minute. Detection is at 220 nm and 254 nm). APCI-mass spectral data confirmed presence of the expected molecular ion, and proton nmr data supported the expected structure.
Figure imgf000128_0001
Figure imgf000128_0002
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Example 213
Compound of formula II
N-[2-(4-Amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)ethyl]- 5-oxo-2-pyrrolinecarboxamide
Figure imgf000133_0001
Using the general method of Example 97 L-pyroglutamic acid (0.23 g, 1.7 mmole) was reacted with 2-(4-amino-2 -butyl- lH-imidazo[4,5-c][l,5]naphthyridin-l- yl)ethaneamine (0.5 g, 1.7 mmole) to provide 0.10 g of N-[2-(4-amino-2-butyl-lH- imid^o[4,5-c][l,5]naphthyridin-l-yl)ethyl]-5-oxo-2-pyrrolinecarboxamide as a white powder, m.p. 135-138°C. Analysis: Calculated for C20H25N7O2 !/2 CH3CN: %C, 60.63; %H, 6.42; %N, 25.25; Found: %C, 60.14; %H, 6.41 ; %N, 25.20. HRMS (El) calcd for
C20H25N7O2 (M+) 396.2103 found 396.2112
TEST METHODS
CYTOKINE INDUCTION IN HUMAN CELLS An in vitro human blood cell system was used to assess cytokine induction by compounds of the invention. Activity is based on the measurement of interferon and tumor necrosis factor (<*) (IFN and TNF, respectively) secreted into culture media as described by Testerman et. al. In "Cytokine Induction by the Inimunomodulators
Imiquimod and S-27609", Journal of Leukocyte Biology. 58, 365-372 (September, 1995). Blood Cell Preparation for Culture
Whole blood is collected by venipuncture into EDTA vacutainer tubes from healthy human donors. Peripheral blood mononuclear cells (PBMCs) are separated from whole blood by Histopaque®-1077 (Sigma Chemicals, St. Louis, MO) density gradient centrifugation. The PBMCs are suspended at 1.5-2 x 106 cells/mL in RPMI 1640 medium containing 10 % fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin solution (RPMI complete). 1 mL portions of PBMC suspension are added to 24 well flat bottom sterile tissue culture plates. Compound Preparation
The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO concentration should not exceed a final concentration of 1 % for addition to the culture wells. The compounds are generally tested in a concentration range of from 0.1 to 100 μM. Incubation
The solution of test compound is added to the wells containing 1 mL of PBMCs in media. The plates are covered with plastic lids, mixed gently and then incubated for 18 to
24 hours at 37°C with a 5% carbon dioxide atmosphere. Separation
Following incubation the plates are centrifuged for 5-10 minutes at 1000 rpm
(-200 x g) at 4°C. The cell culture supernatant is removed with a sterile polypropylene pipet and transferred to a 2 mL sterile cryotube. Samples are maintained at -70°C until analysis.
Interferon Analysis/Calculation Interferon is determined by bioassay using A549 human lung carcinoma cells challenged with encephalomyocarditis. The details of the bioassay method have been described by G. L. Brennan and L. H. Kronenberg in "Automated Bioassay of Interferons in Micro-test Plates", Biotechniques, June/July, 78, 1983, incorporated herein by reference. Briefly stated the method is as follows: A549 cells are incubated with samples and standard interferon dilutions at 37°C for 24 hours. The incubated cells are then infected with an inoculum of encephalomyocarditis virus. The infected cells are incubated for an additional 24 hours at 37°C before quantifying for viral cytopathic effect. The viral cytopathic effect is quantified by staining followed by visual scoring of the plates. Results are expressed as alpha reference units/mL based on the value obtained for NTH Human
Leukocyte IFN standard.
Tumor Necrosis Factor (<χ) Analysis Tumor necrosis factor («) (TNF)concentration is determined using an ELISA kit available from Genzyme, Cambridge, MA. The results are expressed as pg/mL. In the table below, a "+" indicates that the compound induced the indicated cytokine at that particular concentration, a "-" indicates that the compound did not induce the indicated cytokine at that particular concentration, and a "±" indicates that the results were equivocal at that particular concentration.
■^
Figure imgf000136_0001
Figure imgf000137_0001
Cytokine Induction in Human Cells
IFN TNF
Example Dose Concentration (μM) Dose Concentration (μM)
Figure imgf000138_0001
0.1 1.0 10.0 100.0 0.1 1.0 10.0 100.0
103 - - + + - - + +
104 - + + - - - + -
105 + + + + - - + +
106 + + + - - + + -
107 + + + + + -
108 + + + + ± - + +
109 + + + + - + + +
110 + + + + - + + +
111 - - + + - - + +
112 + + + + + + - -
113 - + + + - + + +
114 - - + + - - + +
115 - - + + - - + +
116 - + + + - + + +
117 - - + + " - + +
Figure imgf000139_0001
Figure imgf000139_0002
Figure imgf000140_0001
Figure imgf000140_0002
Figure imgf000141_0001
Figure imgf000141_0002
Figure imgf000142_0001
Figure imgf000142_0003
Figure imgf000142_0002
INTERFERON (α) INDUCTION IN HUMAN CELLS
An in vitro human blood cell system was used to assess interferon induction by compounds of the invention. Activity is based on the measurement of interferon secreted into culture media. Interferon is measured by bioassay.
Blood Cell Preparation for Culture
Whole blood was collected by venipuncture into EDTA vacutainer tubes. Peripheral blood mononuclear cells (PBM's) were separated from whole blood by using either LeucoPREP™ Brand Cell Separation Tubes (available from Becton Dickinson) or Ficoll-Paque® solution (available from Pharmacia LKB Biotechnology Inc, Piscataway, NJ). The PBM's were suspended at 1 x 106/mL in RPMI 1640 media (available from GIBCO, Grand Island, NY) containing 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2- eth.anesulfonic acid) and L-glutamine (1% penicillin-streptomycin solution added) with
10% heat inactivated (56°C for 30 minutes) autologous serum added. 200 μL portions of PBM suspension were added to 96 well (flat bottom) MicroTest III sterile tissue culture plates.
Compound Preparation
The compounds were solubilized in ethanol, dimethyl sulfoxide or tissue culture water then diluted with tissue culture water, 0.01N sodium hydroxide or 0.01N hydrochloric acid (The choice of solvent will depend on the chemical characteristics of the compound being tested.). Ethanol or DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells. Compounds were initially tested in a concentration range of from about 0.1 μg/mL to about 5 μg/mL. Compounds which show induction at a concentration of 0.5 μg/mL were then tested in a wider concentration range.
Incubation The solution of test compound was added in a volume (less than or equal to 50 μL) to the wells containing 200 μL of diluted whole blood or of PBM's in media. Solvent and/or media was added to control wells (wells with no test compound) and as needed to adjust the final volume of each well to 250 μL. The plates were covered with plastic lids, vortexed gently and then incubated for 48 hours at 37°C with a 5% carbon dioxide atmosphere.
Separation Following incubation, the plates were covered with parafilm and then centrifuged at 1000 rpm for 10 to 15 minutes at 4°C in a Damon IEC Model CRU-5000 centrifuge. Media (about 200 μL) was removed from 4 to 8 wells and pooled into 2 mL sterile freezing vials. Samples were maintained at -70°C until analysis.
Interferon Analysis/Calculation
Interferon was determined by bioassay using A549 human lung carcinoma cells challenged with encephalomyocarditis. The details of the bioassay method have been described by G. L. Brennan and L. H. Kronenberg in "Automated Bioassay of Interferons in Micro-test Plates", Biotechniques. June/July, 78, 1983, incorporated herein by reference. Briefly stated the method is as follows: interferon dilutions and A549 cells are incubated at 37°C for 12 to 24 hours. The incubated cells are infected with an inoculum of encephalomyocarditis virus. The infected cells are incubated for an additional period at 37°C before quantifying for viral cytopathic effect. The viral cytopathic effect is quantified by staining followed by spectrophotometric absorbance measurements. Results are expressed as alpha reference units/mL based on the value obtained for NTR HU IF-L standard. The interferon was identified as essentially all interferon alpha by testing in checkerboard neutralization assays against rabbit anti-human interferon (beta) and goat anti-human interferon (alpha) using A549 cell monolayers challenged with encephalomyocarditis virus. In the table below, a "+" indicates that the compound induced interferon α at that particular concentration, a "-" indicates that the compound did not induce interferon α at that particular concentration, and a "+" indicates that the results were equivocal at that particular concentration.
Figure imgf000145_0001
The present invention has been described with reference to several embodiments thereof. The foregoing detailed description and examples have been provided for clarity of understanding only, and no unnecessary limitations are to be understood therefrom. It will be apparent to those skilled in the art that many changes can be made to the described embodiments without departing from the spirit and scope of the invention. Thus, the scope of the invention should not be limited to the exact details of the compositions and structures described herein, but rather by the language of the claims that follow.

Claims

The claimed invention is:
1. A compound of the formula I:
Figure imgf000147_0001
I wherein A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or
=CR-CR=CR-N=;
Ri is selected from the group consisting of: - hydrogen;
-C╬╣-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl; -heterocyclyl; -O-C╬╣-20 -alkyl, -O-(C1-2oalkyl)0-╬╣-aryl;
-O-(C ╬╣ -20alkyl)0-╬╣ -heteroaryl; -O-(C ] -2oalkyl)o-╬╣ -heterocyclyl; -C╬╣-20 alkoxycarbonyl; -S(O)0-2 -C1-20 alkyl; -S(O)o-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2 -(C1-20 alkyl)0-╬╣ -heteroaryl; -S(O)0-2 -(C╬╣-20 alkyl)0-╬╣ -heterocyclyl; -N(R3)2; -N3; oxo;
-halogen; -NO2; -OH; and -SH; and
-C1.20 alkyl-NRrQ-X-^ or -C2-20 alkenyl-NR3-Q-X-R4 wherein Q is -CO- or -
SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C╬╣- 0 alkyl or C2-2o alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisiting of:
-aryl; -heteroaryl;
-heterocyclyl;
-O-C,-20 alkyl,
-O-(C1-20alkyl)0-╬╣-aryl;
-O-(C╬╣ -20alkyl)o-1 -heteroaryl; -O-(C 1 -20alkyl)o-1 -heterocyclyl ;
-C1-20 alkoxycarbonyl;
-S(O)0-2 -C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)o-2 -(C1-20 alkyl)0-1-heteroaryl; -S(O)0-2-(C1-2o alkyl)0-1-heterocyclyl;
-N(R3)2;
-NR3-CO-O-C1-20alkyl;
-N3; oxo; -halogen;
-NO2;
-OH; and
-SH; or t is
Figure imgf000149_0001
wherein Y is -N- or -CR-; R2 is selected from the group consisting of: -hydrogen; -Ci-io alkyl;
-C2-10 alkenyl; -aryl;
-Ci.io alkyl -O-Ci-io-alkyl; -d-io alkyl-O-C2-╬╣o alkenyl; and -Ci-io alkyl or C2-╬╣0 alkenyl substituted by one or more substituents selected from the group consisting of:
-OH; -halogen; -N(R3)2; -CO-N(R3)2;
-CO-Cj.io alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and -CO-heteroaryl; each R3 is independently selected from the group consisting of hydrogen and CMO alkyl; and each R is independently selected from the group consisting of hydrogen, CMO alkyl, CMO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
2. A compound according to Claim 1 wherein Ri is selected from the group consisting of C1-6 alkyl and C1-6 hydroxyalkyl.
3. A compound according to Claim 2 wherein R\ is selected from the group consisting of n-butyl, 2-hydroxy-2-methylpropyl, and 2-methylpropyl.
4. A compound according to Claim 1 wherein R2 is selected from the group consisting of C╬╣-6 straight chain alkyl and alkoxyalkyl wherein the alkoxy moiety and the alkyl moiety each independently contain 1 to 4 carbon atoms.
5. A compound according to Claim 4 wherein R2 is selected from the group consisting of methyl, n-butyl, benzyl, ethoxym ethyl, and methoxyethyl.
6. A compound according to Claim 1 wherein each R is hydrogen.
7. A compound according to Claim 1 wherein R\ is -C╬╣-2o alkyl-NR Q-X-Ri.
8. A compound according to Claim 7 wherein Rt is
Figure imgf000150_0001
9. A compound according to Claim 1 wherein A is =CH-CH=CH-N=.
10. A compound of the formula II :
Figure imgf000151_0001
II wherein
B is -NR-C(R)2-C(R)2-C(R)2-; -C(R)2-NR-C(R)2-C(R)2-; -C(R)2-C(R)2-NR-C(R)2- or -C(R)2-C(R)2-C(R)2-NR-; Ri is selected from the group consisting of:
- hydrogen;
-C╬╣-2o alkyl or C2-2o alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -aryl; -heteroaryl;
-heterocyclyl; -O-C╬╣.20 alkyl, -O-(d -20alkyi)0-1 -aryl; -O-(C j -2oalkyl)0- i -hetero -aryl ; -O-(C i .2oalkyl)0-╬╣ -heterocyclyl ;
-C╬╣-20 alkoxycarbonyl; -S(O)0-2 -C1-2o alkyl; -S(O)0-2-(C1-2o alkyl)0-1-aryl; -S(O)o-2 -(C╬╣-2o alkyl)0-1 -heteroaryl; -S(O)o-2 -(Ci -20 alkyl)0-╬╣ -heterocyclyl;
-N(R3)2; -N3; oxo;
-halogen; -NO2;
-OH; and -SH; and
-C╬╣-20 alkyl-NR3-Q-X-R4 or -C2-2o alkenyl-NR3-CO-X-R4 wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR3- and j is aryl; heteroaryl; heterocyclyl; or -C1-20 alkyl or C2. o alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl; -O-C╬╣-20 alkyl,
-O-(C╬╣-20alkyl)0-╬╣-aryl;
-O-(C 1 -2oalkyl)o-╬╣ -heteroaryl;
-O-(C╬╣.20alkyl)0-1-heterocyclyl;
-C╬╣-20 alkoxycarbonyl; -S(O)o-2 -C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2 -(C 1.20 alkyl)0-╬╣ -heteroaryl;
-S(O)0-2 -(Ci-20 alkyl)0-1-heterocyclyl;
-N(R3)2; -NR3-CO-O-C╬╣-20alkyl;
-N3; oxo;
-halogen;
-NO2; -OH; and
-SH; or R_╬╣ is
Figure imgf000152_0001
wherein Y is -N- or -CR-; R2 is selected from the group consisting of: -hydrogen; -CMO alkyl; -C2-╬╣o alkenyl; -aryl;
-CMO alkyl -O-C 0-alkyl; -CMO alkyl-O-C -10 alkenyl; and
-CMO alkyl or C2-10 alkenyl substituted by one or more substituents selected from the group consisting of: -OH;
-halogen; -N(R3)2; -CO-N(R3)2; -CO-CMO alkyl; -N3;
-aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; each R3 is independently selected from the group consisting of hydrogen and CMO alkyl; and each R is independently selected from the group consisting of hydrogen, CMO alkyl, CMO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
11. A compound according to Claim 10 wherein Ri is selected from the group consisting of C╬╣-6 alkyl and C╬╣-6 hydroxyalkyl.
12. A compound according to Claim 11 wherein Rt is selected from the group consisting of n-butyl, 2-hydroxy-2-methylpropyl, and 2-methylpropyl.
13. A compound according to Claim 10 wherein R2 is selected from the group consisting of methyl, n-butyl, benzyl, ethoxymethyl, and methoxyethyl.
14. A compound according to Claim 10 wherein each R is hydrogen.
15. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to Claim 10 and a pharmaceutically acceptable carrier.
17. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound according to Claim 1 to the animal.
18. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound according to Claim 10 to the animal.
19. A method of treating a viral infection in an animal comprising admistering an effective amount of a compound according to claim 1 to the animal.
20. A method of treating a viral infection man animal comprising administering an effective amount of a compounds according to claim 10 to the aminal.
21. A compound of formula
Figure imgf000154_0001
wherein
A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or
=CR-CR=CR-N=;
Ri is selected from the group consisting of: - hydrogen;
-C.-2o alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl; -heteroaryl;
-heterocyclyl;
-O-C20 alkyl,
-O-(C╬╣-2oalkyl)0-╬╣-aryl;
-O-(C╬╣-2oalkyl)o-╬╣-heteroaryl; -O-(Ci-2oalkyl)o-i-heterocyclyl;
-C 1 -20 alkoxycarbonyl ;
-S(O)o-2 -C1-20 alkyl;
-S(O)0-2-(C1-2o alkyl)0-╬╣-aryl;
-S(O)0-2 -(C╬╣-2o alkyl)0-╬╣ -heteroaryl; -S(O)o-2-(C╬╣-2o alkyl)0-╬╣ -heterocyclyl;
-N(R3)2;
-N3; oxo;
-halogen; -NO2;
-OH; and
-SH; and
-C╬╣-20 alkyl-NR^Q-X-R, or -C2- o alkenyl-NR3-Q-X-R4 wherein Q is -CO- or - SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C╬╣-2o alkyl or
C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -aryl;
-heteroaryl; -heterocyclyl;
-O- .20 alkyl, -O-(C╬╣-2oalkyl)0-╬╣-aryl; -O-(C╬╣-2oalkyl)o-╬╣-heteroaryl;
-O-(C╬╣-2oalkyl)0-╬╣-heterocyclyl;
-C╬╣-20 alkoxycarbonyl;
-S(O)o-2 -C 1.20 alkyl; -S(O)o-2-(C1-2o alkyl)0-╬╣-aryl;
-S(O)0-2 -(C╬╣-20 alkyl)0-╬╣ -heteroaryl;
-S(O)o-2 -(C╬╣-2o alkyl)0-╬╣ -heterocyclyl;
-N(R3)2;
-NR3-CO-O-C1-20alkyl; -N3; oxo;
-halogen;
-NO2;
-OH; and -SHj or Rt is
Figure imgf000156_0001
wherein Y is -N- or -CR-; R2 is selected from the group consisting of: -hydrogen; -CMO alkyl;
-C2-╬╣o alkenyl; -aryl
-CMO alkyl -O-C1-10-alkyl; -CMO alkyl-O-C2-1o alkenyl; and -CMO alkyl or C2-10 alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R3)2;
-CO-N(R3)2;
-CO-CMO alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; each R3 is independently selected from the group consisting of hydrogen and CMO alkyl; and each R is independently selected from the group consisting of hydrogen, CM O alkyl, CMO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
22. A compound of formula
Figure imgf000157_0001
wherein
Ri is selected from the group consisting of: - hydrogen;
-C1-2o alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -aryl;
-heteroaryl; -heterocyclyl;
-O-C20 alkyl, -O-(d -2oalkyl)0-╬╣ -aryl; -O-(C╬╣ -2oalkyl)o-╬╣ -heteroaryl;
-O-(C i -2oalkyl)o- 1 -heterocyclyl ;
-C╬╣-20 alkoxycarbonyl;
-S(O)0-2 -C╬╣-2o alkyl; -S(O)0-2-(C1-2o alkyl)0-╬╣-aryl;
-S(O)0-2 -(C╬╣-20 alkyl)0-╬╣ -heteroaryl;
-S(O)o-2 -(C╬╣-20 alkyl)0-╬╣ -heterocyclyl;
-N(R3)2;
-N3; oxo;
-halogen;
-NO2;
-OH; and
-SH; and
-C]-20 alkyl-NR3-Q-X-Rt or -C2- o alkenyl-NR3-Q-X-R4 wherein Q is -CO- or - SO2-; X is a bond, -O- or -NR3- and R_j is aryl; heteroaryl; heterocyclyl; or -CMO alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consiting of: -aryl;
-heteroaryl;
-heterocyclyl;
-O-C╬╣.20 alkyl,
Figure imgf000158_0001
-O-(C1-2oalkyl)o-╬╣-heteroaryl;
-O-(C 1 -2oalkyl)0-╬╣ -heterocyclyl;
-C╬╣-2o alkoxycarbonyl;
-S(O)0-2 -C╬╣.2o alkyl;
-S(O)0-2-(C1-2o alkyl)0-╬╣-aryl; -S(O)o-2-(C1-2o alkyl)0-╬╣-heteroaryl;
-S(O)0-2 -(C 1 -20 alkyl)0-╬╣ -heterocyclyl;
-N(R3)2; -NR3-CO-O-C1-20alkyl;
-N3; oxo;
-halogen;
-NO2;
-OH; and
-SH; or t is
Figure imgf000159_0001
wherein Y is -N- or -CR-; R2 is selected from the group consisting of:
-hydrogen; -CMO alkyl; -C2-╬╣o alkenyl; -aryl; -CMO alkyl -O-C 0-alkyl;
-CMO alkyl-O-C2-╬╣o alkenyl; and
-CMO alkyl or C2-╬╣o alkenyl substituted by one or more substituents selected from the group consiting of:
-OH; -halogen;
-N(R3)2; -CO-N(R3)2; -CO-CMO alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; each R3 is independently selected from the group consisting of hydrogen and CMO alkyl; and each R is independently selected from the group consisting of hydrogen, CMO alkyl, CMO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
23. A compound of formula
Figure imgf000160_0001
wherein
Ri is selected from the group consisting of: - hydrogen;
-C╬╣-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C╬╣.20 alkyl,
-O-(C1-2oalkyl)0-1-aryl;
-O-(C╬╣-2oalkyl)o-╬╣-hetero.aryl;
-O-(C 1 -2oalkyl)o-! -heterocyclyl;
-C╬╣-20 alkoxycarbonyl;
-S(O)o-2 -C1-2o alkyl;
-S(O)0-2-(C1-2o alkyl)0-1-aryl;
-S(O)o-2 -(C╬╣--20 alkyl)0-╬╣ -heteroaryl;
-S(O)0-2 -(C╬╣-20 alkyl)0-╬╣ -heterocyclyl;
-N(R3)2; -N3; oxo;
-halogen; -NO2; -OH; and
-SH;
-C╬╣-20 alkyl-NR3-Q-X-Rt or -C2-2o alkenyl-NR3-Q-X-Rt wherein Q is -CO- or - SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -Q-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl; -O-C╬╣.20 alkyl,
-O-(C1-2oalkyl)0-1-aryl;
Figure imgf000161_0001
-O-(C╬╣-2oalkyl)o-1-heterocyclyl;
-d-20 alkoxycarbonyl; -S(O)0-2 -C1-2o alkyl;
ΓûáS(O)o-2-(C╬╣.2o alkyl)0-1-aryl;
-S(O)o-2 -(C1.20 alkyl)0-1 -heteroaryl;
-S(O)0-2 -(C╬╣-2o alkyl)0-╬╣ -heterocyclyl;
-N(R3)2; -NR3-CO-O-C1-20alkyl;
-N3; oxo;
-halogen;
-NO2; -OH; and
-SH; or t is
Figure imgf000162_0001
wherein Y is -N- or -CR-; R2 is selected from the group consisting of: -hydrogen; -CMO alkyl;
-C2-10 alkenyl; -aryl;
-C╬╣-10 alkyl -O-Cio-alkyl; -CMO alkyl-O-C2- IO alkenyl; and -CMO alkyl or C2-╬╣o alkenyl substituted by one or more substituents selected from the group consisting of:
-OH; -halogen; -N(R3)2; -CO-N(R3)2;
-CO-CMO alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and -CO-heteroaryl; each R3 is independently selected from the group consisting of hydrogen and CMO alkyl; and each R is independently selected from the group consisting of hydrogen, CMO alkyl, CMO alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
24. A compound of formula
Figure imgf000163_0001
wherein A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or
=CR-CR=CR-N=;
R is OH, halogen, or NHRi, Ri is selected from the group consisting of: - hydrogen; -C╬╣-2o alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -aryl;
-heteroaryl; -heterocyclyl; -O-C╬╣-20 alkyl,
-O-(C╬╣-20alkyl)0-╬╣-aryl; -O-(C ╬╣ -2oalkyl)o-╬╣ -heteroaryl ; -O-(C ╬╣ -2oalkyl)o- 1 -heterocyclyl ; -C╬╣-20 alkoxycarbonyl; -S(O)o-2 -C,.2o alkyl;
-S(O)o-2-(C1-20 alkyl)0-╬╣-aryl; -S(O)0-2 -(C╬╣-20 alkyl)0-╬╣ -heteroaryl; -S(O)o-2 -(C╬╣-20 alkyl)0-╬╣ -heterocyclyl; -N(R3)2; -N3; oxo;
-halogen; -NO2; -OH; and -SH; and
-C╬╣-20 alkyl-NRrQ-X-R* or -C -2o alkenyl-NR3-Q-X-Rt wherein Q is -CO- or - SO2-; X is a bond, -O- or -NR3- and R-j is aryl; heteroaryl; heterocyclyl; or -C1-2o alkyl or
C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl; -heterocyclyl;
-O-C╬╣-20 alkyl,
-O-(C╬╣-20alkyl)0-╬╣-aryl;
-O-(C 1 -2oalkyl)0-╬╣ -heteroaryl;
-O-(C -2oalkyl)o-╬╣ -heterocyclyl; -C \ -2o alkoxycarbonyl;
-S(O)o-2 -C╬╣-2o alkyl;
-S(O)0-2-(C╬╣-2o alkyl)o-╬╣-aryl;
-S(O)o-2 -(C╬╣-20 alkyl)0-╬╣ -heteroaryl;
-S(O)0-2 -(C1.20 alkyl)0-╬╣ -heterocyclyl; -N(R3)2;
-NR3-CO-O-C╬╣-20alkyl;
-N3; oxo;
-halogen; -NO2;
-OH; and
-SH; or t is
Figure imgf000164_0001
wherein Y is -N- or -CR-; Rs is H, NO2 or NH2; and each R is independently selected from the group consisting of hydrogen, CMO alkyl, CMO alkoxy, halogen and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
25. A compound of formula
Figure imgf000165_0001
wherein
A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or
=CR-CR=CR-N= and
R is H or CMO alkyl.
26. A compound of formula
Figure imgf000165_0002
wherein
Ri is selected from the group consisting of:
-C╬╣-2o alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -aryl;
-heteroaryl; -heterocyclyl; -O-C╬╣-20 alkyl; -O-(C╬╣-20alkyl)0-╬╣-aryl;
-O-(C╬╣-2oalkyl)0-╬╣-heteroaryl;
-O-(C╬╣-2oalkyl)0-╬╣ -heterocyclyl;
-C╬╣-2o alkoxycarbonyl; -S(O)0-2 -C1-20 alkyl;
-S(O)o-2-(C╬╣-20 alkyl)o.1-aryl;
-S(O)0-2 -(C╬╣-20 alkyl)0-╬╣ -heteroaryl;
-S(O)0-2 -(C╬╣-20 alkyl)0-╬╣ -heterocyclyl;
-N(R3)2; -N3; oxo;
-halogen;
-NO2;
-OH; and -SH;
-C1-20 alkyl-NR3-Q-X-R, or -C2-20 alkenyl-NRrQ-X-^ wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C╬╣-2o alkyl or C2-2o alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -aryl;
-heteroaryl;
-heterocyclyl;
-O-C╬╣-20 alkyl;
-O-(C1-20alkyl)0-╬╣-aryl;
Figure imgf000166_0001
-O-(C 1 -2oalkyl)o-╬╣ -heterocyclyl;
-C╬╣-2o alkoxycarbonyl;
-S(O)o-2 -C1-20 alkyl;
-S(O)o-2-(C1-20 alkyl)0-1-aryl; -S(O)o-2 -(C, -20 alkyl)0-╬╣ -heteroaryl;
-S(O)o-2 -(C╬╣-20 alkyl)0-1 -heterocyclyl;
-N(R3)2; -NR3-CO-O-C╬╣-20alkyl;
-N3; oxo;
-halogen;
-NO2;
-OH; and
-SH; or t is
Figure imgf000167_0001
wherein Y is -N- or -CR-; each R3 is independently selected from the group consisting of hydrogen and CMO alkyl; each R is selected from the group consisting of hydrogen, CMO alkyl, CMO alkoxy, halogen and trifluoromethyl; and R╬╣ois -NO2 or NH2. or a pharmaceutically acceptable salt thereof.
PCT/US1998/026473 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis WO1999029693A1 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
UA2000074070A UA67760C2 (en) 1997-12-11 1998-11-12 Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
DK04022441T DK1512686T3 (en) 1997-12-11 1998-12-11 Imidazonaphtyridines and their use to induce cytokine biosynthesis
PL98341159A PL193915B1 (en) 1997-12-11 1998-12-11 Imidazonaphtyridines and their application in inducing biosynthesis of cytokinins
SK5035-2007A SK286304B6 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
HU0101155A HUP0101155A3 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines, pharmaceutical compositions thereof and intermediates
IL13655698A IL136556A0 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
KR1020037016102A KR100642702B1 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and Their Use in Inducing Cytokine Biosynthesis
JP2000524286A JP4283438B2 (en) 1997-12-11 1998-12-11 Imidazonaphthyridine and its use for induction of cytokine biosynthesis
EEP200000349A EE04314B1 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in induction of cytokine biosynthesis
AU19123/99A AU753864B2 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
AT98963888T ATE277046T1 (en) 1997-12-11 1998-12-11 IMIDAZONAPHTHYRIDINE DERIVATIVES AND USE THEREOF FOR INDUCING CYTOKINE BIOSYTHESIS
KR1020007006369A KR100642703B1 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and Their Use in Inducing Cytokine Biosynthesis
BR9814275-5A BR9814275A (en) 1997-12-11 1998-12-11 Imidazonaftiridines and their use in inducing cytokine biosynthesis
EP98963888A EP1040112B1 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
DE69826518T DE69826518T2 (en) 1997-12-11 1998-12-11 IMIDAZONAPHTHYRIDINE DERIVATIVES AND ITS USE IN THE INDUCTION OF BIOSYTHESIS OF CYTOKIN
NZ504776A NZ504776A (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
DK98963888T DK1040112T3 (en) 1998-12-11 1998-12-11 Imidazonaphthyridines
KR1020037016103A KR100563175B1 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and Their Use in Inducing Cytokine Biosynthesis
SK835-2000A SK285872B6 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
SI9830711T SI1040112T1 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
CA2311456A CA2311456C (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
NO20002663A NO316687B1 (en) 1997-12-11 2000-05-24 Imidazonaphthyridines, pharmaceutical compositions containing imidazone and their use to induce cytokine biosynthesis
HR20000363A HRP20000363B1 (en) 1997-12-11 2000-06-02 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
IL136556A IL136556A (en) 1997-12-11 2000-06-05 1h-imidazo[4,5-c]naphthyridin-4-amines
NO20035719A NO20035719D0 (en) 1997-12-11 2003-12-19 Imidazonaphthyridines and their use to induce cytokine biosynthesis
NO20035718A NO328045B1 (en) 1997-12-11 2003-12-19 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
IL178092A IL178092A (en) 1997-12-11 2006-09-14 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising it or salt thereof
IL178091A IL178091A (en) 1997-12-11 2006-09-14 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising it or salt thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6927697P 1997-12-11 1997-12-11
US60/069,276 1997-12-11

Publications (2)

Publication Number Publication Date
WO1999029693A1 true WO1999029693A1 (en) 1999-06-17
WO1999029693A8 WO1999029693A8 (en) 2004-11-04

Family

ID=22087889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/026473 WO1999029693A1 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis

Country Status (28)

Country Link
US (14) US6194425B1 (en)
EP (1) EP1040112B1 (en)
JP (4) JP4283438B2 (en)
KR (3) KR100642703B1 (en)
CN (1) CN1154647C (en)
AT (3) ATE333456T1 (en)
AU (1) AU753864B2 (en)
BR (1) BR9814275A (en)
CA (1) CA2311456C (en)
CZ (1) CZ307184B6 (en)
DE (3) DE69826518T2 (en)
DK (1) DK1512686T3 (en)
EE (1) EE04314B1 (en)
ES (3) ES2270249T3 (en)
HK (1) HK1070655A1 (en)
HR (1) HRP20000363B1 (en)
HU (1) HUP0101155A3 (en)
IL (4) IL136556A0 (en)
NO (3) NO316687B1 (en)
NZ (1) NZ504776A (en)
PL (1) PL193915B1 (en)
PT (3) PT1512686E (en)
RU (3) RU2312867C2 (en)
SI (1) SI1512686T1 (en)
SK (2) SK286304B6 (en)
TR (1) TR200001705T2 (en)
UA (1) UA67760C2 (en)
WO (1) WO1999029693A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034709A1 (en) * 1999-11-05 2001-05-17 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6245776B1 (en) 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1187613A1 (en) * 1999-06-10 2002-03-20 3M Innovative Properties Company Amide substituted imidazoquinolines
EP1198233A1 (en) * 1999-06-10 2002-04-24 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1198232A1 (en) * 1999-06-10 2002-04-24 3M Innovative Properties Company Urea substituted imidazoquinolines
WO2002046194A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Substituted imidazopyridines
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6706728B2 (en) 1999-01-08 2004-03-16 3M Innovative Properties Company Systems and methods for treating a mucosal surface
EP1438958A1 (en) * 1999-06-10 2004-07-21 3M Innovative Properties Company Carbamate substituted imidazoquinolines
EP1455700A2 (en) * 2001-11-16 2004-09-15 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
EP1542688A2 (en) * 2002-09-26 2005-06-22 3M Innovative Properties Company 1h-imidazo dimers
EP1642580A1 (en) * 1999-06-10 2006-04-05 3M Innovative Properties Company Sulfonamide substituted imidazoquinolines
WO2006080043A2 (en) * 2005-01-27 2006-08-03 Alma Mater Studiorum- Universita' Di Bologna Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
WO2006091568A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
EP1833827A2 (en) * 2004-12-30 2007-09-19 3M Innovative Properties Company Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazoý4,5-c¨ý1,5¨naphthyridin-4-amine
US7393859B2 (en) 1999-06-10 2008-07-01 Coley Pharmaceutical Group, Inc. Amide substituted imidazoquinolines
JP2010031040A (en) * 2000-12-08 2010-02-12 Three M Innovative Properties Co Thioether-substituted imidazoquinoline
US7687628B2 (en) 2003-10-01 2010-03-30 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1H-imidazo(4,5-c)quinolines and acid addition salts thereof
EP2258365A1 (en) 2003-03-28 2010-12-08 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
EP2277595A2 (en) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US7968562B2 (en) 2001-11-29 2011-06-28 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
EP2357184A1 (en) 2006-03-23 2011-08-17 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2468299A2 (en) 2003-04-30 2012-06-27 Novartis Vaccines and Diagnostics, Inc. Compositions for inducing immune responses
EP2583678A2 (en) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10039753B2 (en) 2015-09-14 2018-08-07 Pfizer Inc. Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20040209877A1 (en) * 2000-04-13 2004-10-21 Shelby Nancy J. Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US20020110840A1 (en) * 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
WO2003020889A2 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
PT1478327E (en) * 2002-02-22 2015-08-04 Meda Ab Method of reducing and treating uvb-induced immunosuppression
CN1674894A (en) * 2002-06-07 2005-09-28 3M创新有限公司 Ether substituted imidazopyridines
DK1545597T3 (en) 2002-08-15 2011-01-31 3M Innovative Properties Co Immune Stimulating Compositions and Methods for Stimulating an Immune Response
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
JP2006513212A (en) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP1592302A4 (en) * 2003-02-13 2007-04-25 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor 8
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylactic treatment of uv-induced epidermal neoplasia
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
JP2006519877A (en) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1-amino 1H-imidazoquinoline
WO2004080292A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
ATE556711T1 (en) * 2003-03-13 2012-05-15 3M Innovative Properties Co METHOD FOR IMPROVING SKIN QUALITY
JP2006523212A (en) * 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー Diagnosis method of skin lesion
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP1617871A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co Delivery of immune response modifier compounds using metal-containing particulate support materials
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co Compositions and methods for induction of opioid receptors
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US20080039533A1 (en) * 2003-07-31 2008-02-14 3M Innovative Properties Company Bioactive Compositions Comprising Triazines
CA2534313C (en) * 2003-08-05 2013-03-19 3M Innovative Properties Company Formulations containing an immune response modifier
JP2007502288A (en) * 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー Oxime-substituted imidazo-containing compounds
EP2939693A1 (en) 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
ES2545826T3 (en) * 2003-08-14 2015-09-16 3M Innovative Properties Company Lipid Modified Immune Response Modifiers
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
WO2005020912A2 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co Methods related to the treatment of mucosal associated conditions
JP2007504269A (en) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
KR20060120069A (en) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Pyrazolopyridines and analogs thereof
WO2005041891A2 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
EP1682544A4 (en) 2003-11-14 2009-05-06 3M Innovative Properties Co Hydroxylamine substituted imidazo ring compounds
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
AU2004293096A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
AU2004315771A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
JP2007517035A (en) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Arylalkenyl and arylalkynyl substituted imidazoquinolines
AU2004312510A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
EP1699788A2 (en) * 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co Enhancement of immune responses
ES2665342T3 (en) * 2004-03-15 2018-04-25 Meda Ab Formulations and methods for immune response modifiers
US8697873B2 (en) * 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
CN101426524A (en) * 2004-04-28 2009-05-06 3M创新有限公司 Compositions and methods for mucosal vaccination
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) * 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006028545A2 (en) * 2004-06-18 2006-03-16 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
PL1789042T3 (en) * 2004-09-02 2012-09-28 3M Innovative Properties Co 1-alkoxy 1h-imidazo ring systems and methods
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
US7557211B2 (en) * 2004-11-12 2009-07-07 Bristol-Myers Squibb Company 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2006053120A1 (en) 2004-11-12 2006-05-18 Bristol-Myers Squibb Company IMIDAZO-FUSED THIAZOLO[4,5-b]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
WO2006071997A2 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Treatment for cutaneous metastases
KR20070107685A (en) * 2004-12-30 2007-11-07 다케다 야쿠힌 고교 가부시키가이샤 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
ES2392647T3 (en) * 2004-12-30 2012-12-12 3M Innovative Properties Company Chiral tetracyclic compounds that induce interferon biosynthesis
EP1877056A2 (en) 2005-02-09 2008-01-16 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazoloý4,5-c¨ring compounds and methods
ES2475728T3 (en) 2005-02-09 2014-07-11 3M Innovative Properties Company Thiazoloquinolines and alkoxy substituted thiazolonaphthyridines
JP2008532933A (en) * 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ,インコーポレイテッド Substituted imidazoquinolines and substituted imidazonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1850849A2 (en) * 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006223634A1 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
AU2006216798A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008533148A (en) * 2005-03-14 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー Treatment method for actinic keratosis
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
JP2008535831A (en) * 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ,インコーポレーテッド Ring closure and related methods and intermediates
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
JP2009507795A (en) * 2005-08-31 2009-02-26 スミスクライン ビーチャム コーポレーション Compound
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8476292B2 (en) * 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US8088790B2 (en) * 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
WO2007079086A1 (en) * 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co Immune response modifier conjugates
US8329721B2 (en) * 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2007106852A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
WO2007143526A2 (en) * 2006-06-05 2007-12-13 Coley Pharmaceutical Group, Inc. Substituted tetrahydroimidazonaphthyridines and methods
WO2008008432A2 (en) * 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
AU2007275815A1 (en) * 2006-07-18 2008-01-24 Wirra Ip Pty. Ltd. Immune response modifier formulations
US8124096B2 (en) * 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
EP2121023A1 (en) * 2006-12-22 2009-11-25 3M Innovative Properties Company Controlled release composition and process
WO2008098232A1 (en) * 2007-02-08 2008-08-14 Graceway Pharmaceuticals, Llc Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
AU2009335943A1 (en) 2008-12-19 2013-10-24 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
CN102439153B (en) 2009-03-25 2015-07-22 德克萨斯大学系统董事会 Compositions for stimulation of mammalian innate immune resistance to pathogens
AU2010232731A1 (en) * 2009-03-31 2011-10-20 Arqule, Inc. Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
US8511006B2 (en) * 2009-07-02 2013-08-20 Owens Corning Intellectual Capital, Llc Building-integrated solar-panel roof element systems
WO2011008324A1 (en) * 2009-07-13 2011-01-20 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
TW201129565A (en) * 2010-01-12 2011-09-01 Hoffmann La Roche Tricyclic heterocyclic compounds, compositions and methods of use thereof
US20110319811A1 (en) 2010-06-25 2011-12-29 Nordsiek Michael T Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
MX355623B (en) 2011-06-03 2018-04-25 3M Innovative Properties Co Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom.
US9475804B2 (en) 2011-06-03 2016-10-25 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2013040447A2 (en) 2011-09-14 2013-03-21 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
US9944926B2 (en) 2011-11-30 2018-04-17 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
WO2013162828A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CN103566377A (en) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 Targeted immunotherapy for cancer
AU2014203896B2 (en) 2013-01-07 2018-05-31 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous T cell lymphoma
EP3632458A1 (en) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
JP6446054B2 (en) 2013-11-05 2018-12-26 スリーエム・イノベイティブ・プロパティーズ・カンパニー Sesame oil-based injection formulation
SG11201605449YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for immunotherapy
JP6760919B2 (en) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド Anti-PD-L1 combination for treating tumors
CN112546231A (en) 2014-07-09 2021-03-26 博笛生物科技有限公司 Combination therapeutic compositions and combination therapeutic methods for treating cancer
CN112587672A (en) 2014-09-01 2021-04-02 博笛生物科技有限公司 anti-PD-L1 conjugates for the treatment of tumors
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
US11680244B2 (en) 2015-05-20 2023-06-20 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
JP6956071B2 (en) * 2015-08-31 2021-10-27 スリーエム イノベイティブ プロパティズ カンパニー Imidazo [4,5-c] cyclic compound containing a substituted guanidine group
KR20180041745A (en) 2015-08-31 2018-04-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Guanidine substituted imidazo [4,5-c] cyclic compound
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
CN115252792A (en) 2016-01-07 2022-11-01 博笛生物科技有限公司 anti-EGFR combinations for the treatment of tumors
CN115350279A (en) 2016-01-07 2022-11-18 博笛生物科技有限公司 anti-HER 2 combinations for the treatment of tumors
CN115554406A (en) 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors
WO2017155030A1 (en) * 2016-03-09 2017-09-14 国立大学法人大阪大学 Compound, and organic semiconductor material including same
MX2018013640A (en) 2016-05-16 2019-08-01 Infectious Disease Res Inst Pegylated liposomes and methods of use.
DK3458475T3 (en) 2016-05-16 2022-09-12 Access To Advanced Health Inst FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE
WO2018038877A1 (en) 2016-08-26 2018-03-01 3M Innovative Properties Company FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS
KR102497742B1 (en) 2016-08-30 2023-02-10 다나-파버 캔서 인스티튜트 인크. Drug Delivery Compositions and Uses Thereof
CN110234401B (en) 2016-11-09 2024-03-01 德克萨斯大学系统董事会 Methods and compositions for adaptive immunomodulation
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
TW201834690A (en) 2016-12-14 2018-10-01 美商寶珍那提公司 Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2018112245A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
EP3554345A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
AU2017376807A1 (en) 2016-12-14 2019-06-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
WO2018160552A1 (en) 2017-03-01 2018-09-07 3M Innovative Properties Company IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
JP7080501B2 (en) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド Pharmaceutical composition
JP7386536B2 (en) 2017-08-22 2023-11-27 ダイナヴァックス テクノロジーズ コーポレイション Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
EP3710059A1 (en) 2017-11-14 2020-09-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
CN111511740B (en) 2017-12-20 2023-05-16 3M创新有限公司 Amide substituted imidazo [4,5-C ] quinoline compounds with branched linking groups for use as immune response modifiers
CA3034912A1 (en) 2018-02-28 2019-08-28 Pfizer Inc. Il-15 variants and uses thereof
US11370788B2 (en) 2018-02-28 2022-06-28 3M Innovative Properties Company Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group
US11434292B2 (en) 2018-05-23 2022-09-06 Pfizer Inc. Antibodies specific for CD3 and uses thereof
MX2020012607A (en) 2018-05-23 2021-01-29 Pfizer Antibodies specific for gucy2c and uses thereof.
CA3101277A1 (en) 2018-05-24 2019-11-28 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20210323962A1 (en) 2018-11-26 2021-10-21 3M Innovative Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
EP3980415A1 (en) 2019-06-06 2022-04-13 3M Innovative Properties Company N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20220194935A1 (en) 2019-06-12 2022-06-23 3M Innovative Properties Company Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
BR112022009723A2 (en) 2019-12-17 2022-08-09 Pfizer SPECIFIC ANTIBODIES TO CD47, PD-L1, AND USES THEREOF
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
CN116323668A (en) 2020-07-17 2023-06-23 辉瑞公司 Therapeutic antibodies and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
WO1993009119A1 (en) * 1991-11-06 1993-05-13 Minnesota Mining And Manufacturing Company Antiviral 2-ethyl-1h-imidazo(4,5-c)quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5627281A (en) * 1993-07-15 1997-05-06 Minnesota Mining And Manufacturing Company Intermediate compounds of fused cycloalkylimidazopyridines
WO1997048704A1 (en) * 1996-06-21 1997-12-24 Minnesota Mining And Manufacturing Company Process for preparing imidazoquinolinamines

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3764681A (en) * 1970-07-08 1973-10-09 Lilly Co Eli Certain tetrazolo-(1,5-a) quinoline compounds as fungus control agents
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ES2071340T3 (en) 1990-10-05 1995-06-16 Minnesota Mining & Mfg PROCEDURE FOR THE PREPARATION OF IMIDAZO (4,5-C) QUINOLIN-4-AMINAS.
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5378698A (en) * 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CA2167042A1 (en) 1993-07-15 1995-01-26 Kyle J. Lindstrom Imidazo[4,5-c]pyridin-4-amines
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5585612A (en) 1995-03-20 1996-12-17 Harp Enterprises, Inc. Method and apparatus for voting
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
JPH09255926A (en) 1996-03-26 1997-09-30 Diatex Co Ltd Pressure-sensitive tape
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
ATE367159T1 (en) 1996-10-25 2007-08-15 Minnesota Mining & Mfg COMPOUNDS THAT ALTER THE IMMUNE RESPONSE FOR THE TREATMENT OF TH2-MEDIATED AND RELATED DISEASES
ATE224878T1 (en) * 1996-11-04 2002-10-15 Aventis Cropscience Sa 1-POLYARYLPYRAZOLES AS PESTICIDES
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4101302B2 (en) 1997-01-09 2008-06-18 テルモ株式会社 Novel amide derivatives and synthetic intermediates
UA67760C2 (en) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
JPH11222432A (en) 1998-02-03 1999-08-17 Terumo Corp Preparation for external use containing amide derivative inducing interferon
JPH11255926A (en) 1998-03-13 1999-09-21 Toray Ind Inc Silicone molding and its production
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
EP1140091B1 (en) 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6545485B1 (en) * 1999-01-21 2003-04-08 Radar Engineers Ultrasonic pinpointer for power system sources of interference
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (en) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd Arachidonic acid-induced skin disease-treating agent
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6660260B1 (en) * 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US20020110840A1 (en) 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
CN1523987A (en) 2001-06-15 2004-08-25 3M创新有限公司 Immune response modifiers for the treatment of periodontal disease
WO2003020889A2 (en) 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US6667347B2 (en) * 2001-09-14 2003-12-23 Chevron U.S.A. Inc. Scrubbing CO2 from methane-containing gases using an aqueous stream
WO2003094836A2 (en) 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
EP1450804B9 (en) 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
PT1478327E (en) 2002-02-22 2015-08-04 Meda Ab Method of reducing and treating uvb-induced immunosuppression
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
CN1674894A (en) 2002-06-07 2005-09-28 3M创新有限公司 Ether substituted imidazopyridines
DK1545597T3 (en) 2002-08-15 2011-01-31 3M Innovative Properties Co Immune Stimulating Compositions and Methods for Stimulating an Immune Response
JP2006503068A (en) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1H-Imidazo dimer
WO2004046329A2 (en) * 2002-11-14 2004-06-03 Pintex Pharmaceuticals, Inc. Levels of pin1 in normal and cancerous tissue
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
JP2006513212A (en) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP1592302A4 (en) 2003-02-13 2007-04-25 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor 8
WO2004075865A2 (en) 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylactic treatment of uv-induced epidermal neoplasia
JP2006519877A (en) 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1-amino 1H-imidazoquinoline
ATE556711T1 (en) 2003-03-13 2012-05-15 3M Innovative Properties Co METHOD FOR IMPROVING SKIN QUALITY
JP2006523212A (en) 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー Diagnosis method of skin lesion
WO2004080292A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040191833A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP1617871A4 (en) 2003-04-10 2010-10-06 3M Innovative Properties Co Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (en) 2003-04-28 2006-09-20 3M Innovative Properties Co Compositions and methods for induction of opioid receptors
DE602004026891D1 (en) 2003-09-05 2010-06-10 Anadys Pharmaceuticals Inc TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C
KR20070107685A (en) * 2004-12-30 2007-11-07 다케다 야쿠힌 고교 가부시키가이샤 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5346905A (en) * 1991-09-04 1994-09-13 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo-[4,5-C]quinolin-4-amines
WO1993009119A1 (en) * 1991-11-06 1993-05-13 Minnesota Mining And Manufacturing Company Antiviral 2-ethyl-1h-imidazo(4,5-c)quinolin-4-amines
US5627281A (en) * 1993-07-15 1997-05-06 Minnesota Mining And Manufacturing Company Intermediate compounds of fused cycloalkylimidazopyridines
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
WO1997048704A1 (en) * 1996-06-21 1997-12-24 Minnesota Mining And Manufacturing Company Process for preparing imidazoquinolinamines

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6245776B1 (en) 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6706728B2 (en) 1999-01-08 2004-03-16 3M Innovative Properties Company Systems and methods for treating a mucosal surface
EP1198232A4 (en) * 1999-06-10 2002-07-24 3M Innovative Properties Co Urea substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
EP1198232A1 (en) * 1999-06-10 2002-04-24 3M Innovative Properties Company Urea substituted imidazoquinolines
CZ303287B6 (en) * 1999-06-10 2012-07-18 3M Innovative Properties Company Sulfonamide or sulfamide substituted imidazoquinoline and pharmaceutical composition comprising thereof
EP1642580A1 (en) * 1999-06-10 2006-04-05 3M Innovative Properties Company Sulfonamide substituted imidazoquinolines
EP1187613A4 (en) * 1999-06-10 2002-07-24 3M Innovative Properties Co Amide substituted imidazoquinolines
EP1198233A4 (en) * 1999-06-10 2002-07-24 3M Innovative Properties Co Sulfonamide and sulfamide substituted imidazoquinolines
US7393859B2 (en) 1999-06-10 2008-07-01 Coley Pharmaceutical Group, Inc. Amide substituted imidazoquinolines
EP1198233A1 (en) * 1999-06-10 2002-04-24 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1438958A1 (en) * 1999-06-10 2004-07-21 3M Innovative Properties Company Carbamate substituted imidazoquinolines
EP1187613A1 (en) * 1999-06-10 2002-03-20 3M Innovative Properties Company Amide substituted imidazoquinolines
JP2004500347A (en) * 1999-11-05 2004-01-08 スリーエム イノベイティブ プロパティズ カンパニー Dye-labeled imidazoquinoline compounds
WO2001034709A1 (en) * 1999-11-05 2001-05-17 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
WO2002046194A3 (en) * 2000-12-08 2003-02-06 3M Innovative Properties Co Substituted imidazopyridines
JP2010031040A (en) * 2000-12-08 2010-02-12 Three M Innovative Properties Co Thioether-substituted imidazoquinoline
WO2002046194A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Substituted imidazopyridines
EP1455700A2 (en) * 2001-11-16 2004-09-15 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
EP1455700A4 (en) * 2001-11-16 2007-02-14 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor pathways
US7968562B2 (en) 2001-11-29 2011-06-28 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
EP1542688A4 (en) * 2002-09-26 2010-06-02 3M Innovative Properties Co 1h-imidazo dimers
EP1542688A2 (en) * 2002-09-26 2005-06-22 3M Innovative Properties Company 1h-imidazo dimers
EP2258365A1 (en) 2003-03-28 2010-12-08 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
EP2468299A2 (en) 2003-04-30 2012-06-27 Novartis Vaccines and Diagnostics, Inc. Compositions for inducing immune responses
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US8080662B2 (en) 2003-10-01 2011-12-20 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1H-imidazo (4,5-c) quinolines and acid addition salts thereof
US7687628B2 (en) 2003-10-01 2010-03-30 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1H-imidazo(4,5-c)quinolines and acid addition salts thereof
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
EP2277595A2 (en) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP2583678A2 (en) 2004-06-24 2013-04-24 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
NO339859B1 (en) * 2004-12-30 2017-02-06 Meda Ab Process for the preparation of 2-methyl-1- (2-methylpropyl) -1H-imidazo [4,5-c] [1,5] naphthyridin-4-amine
EP1833827A4 (en) * 2004-12-30 2009-11-11 Meda Ab Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazoý4,5-c¨ý1,5¨naphthyridin-4-amine
EP1833827A2 (en) * 2004-12-30 2007-09-19 3M Innovative Properties Company Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazoý4,5-c¨ý1,5¨naphthyridin-4-amine
US7307083B2 (en) 2005-01-27 2007-12-11 Alma Mater Studiorum-Universita'di Bologna Tetrahydro-acridine and dithiolane derivatives
WO2006080043A2 (en) * 2005-01-27 2006-08-03 Alma Mater Studiorum- Universita' Di Bologna Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
WO2006080043A3 (en) * 2005-01-27 2006-09-08 Univ Bologna Alma Mater Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US8343993B2 (en) 2005-02-23 2013-01-01 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
WO2006091568A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
WO2006091568A3 (en) * 2005-02-23 2007-05-31 3M Innovative Properties Co Hydroxyalkyl substituted imidazonaphthyridines
EP2357184A1 (en) 2006-03-23 2011-08-17 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10039753B2 (en) 2015-09-14 2018-08-07 Pfizer Inc. Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors

Also Published As

Publication number Publication date
US20070167481A1 (en) 2007-07-19
JP4283438B2 (en) 2009-06-24
NO20035719D0 (en) 2003-12-19
US6797716B2 (en) 2004-09-28
US7678918B2 (en) 2010-03-16
JP4203067B2 (en) 2008-12-24
DE69835844D1 (en) 2006-10-19
US20040023932A1 (en) 2004-02-05
HUP0101155A3 (en) 2002-10-28
US20080091010A1 (en) 2008-04-17
US7038051B2 (en) 2006-05-02
DE69835309T2 (en) 2007-07-19
RU2003126258A (en) 2005-03-10
HRP20000363A2 (en) 2001-06-30
US20050288320A1 (en) 2005-12-29
CN1154647C (en) 2004-06-23
PT1040112E (en) 2005-01-31
NO328045B1 (en) 2009-11-16
HRP20000363B1 (en) 2005-06-30
SK285872B6 (en) 2007-10-04
NO316687B1 (en) 2004-04-05
ATE338757T1 (en) 2006-09-15
RU2312867C2 (en) 2007-12-20
HK1070655A1 (en) 2005-06-24
EE200000349A (en) 2001-10-15
US6693113B2 (en) 2004-02-17
US6894165B2 (en) 2005-05-17
CN1284957A (en) 2001-02-21
HUP0101155A2 (en) 2001-12-28
KR20010033016A (en) 2001-04-25
RU2003126259A (en) 2005-02-27
US20030096998A1 (en) 2003-05-22
NO20002663L (en) 2000-08-11
US20050107421A1 (en) 2005-05-19
SK286304B6 (en) 2008-07-07
BR9814275A (en) 2000-10-03
NO20002663D0 (en) 2000-05-24
US20060128674A1 (en) 2006-06-15
DK1512686T3 (en) 2007-01-15
US6699878B2 (en) 2004-03-02
CZ2007268A3 (en) 2016-09-29
KR20040011533A (en) 2004-02-05
US6624172B2 (en) 2003-09-23
ATE333456T1 (en) 2006-08-15
IL178091A (en) 2007-10-31
US6949646B2 (en) 2005-09-27
NO20035718D0 (en) 2003-12-19
US20030212093A1 (en) 2003-11-13
US20020173654A1 (en) 2002-11-21
KR100563175B1 (en) 2006-03-27
US20040204436A1 (en) 2004-10-14
KR100642703B1 (en) 2006-11-10
US6747040B2 (en) 2004-06-08
EP1040112A1 (en) 2000-10-04
EE04314B1 (en) 2004-06-15
CZ307184B6 (en) 2018-02-28
US20040006098A1 (en) 2004-01-08
PL341159A1 (en) 2001-03-26
JP2008115190A (en) 2008-05-22
ES2273138T3 (en) 2007-05-01
DE69826518T2 (en) 2005-09-22
CA2311456C (en) 2010-11-02
AU1912399A (en) 1999-06-28
JP2007262093A (en) 2007-10-11
US20030083500A1 (en) 2003-05-01
DE69826518D1 (en) 2004-10-28
IL136556A (en) 2007-03-08
DE69835844T2 (en) 2007-04-19
JP2006083188A (en) 2006-03-30
CA2311456A1 (en) 1999-06-17
JP2001525411A (en) 2001-12-11
PT1512685E (en) 2006-12-29
PT1512686E (en) 2007-01-31
PL193915B1 (en) 2007-03-30
UA67760C2 (en) 2004-07-15
TR200001705T2 (en) 2001-07-23
WO1999029693A8 (en) 2004-11-04
US6638944B2 (en) 2003-10-28
SK8352000A3 (en) 2001-03-12
ES2270249T3 (en) 2007-04-01
DE69835309D1 (en) 2006-08-31
US6514985B1 (en) 2003-02-04
ATE277046T1 (en) 2004-10-15
EP1040112B1 (en) 2004-09-22
NZ504776A (en) 2002-07-26
IL178092A (en) 2007-10-31
KR100642702B1 (en) 2006-11-10
US7335773B2 (en) 2008-02-26
AU753864B2 (en) 2002-10-31
NO20035718L (en) 2000-08-11
ES2227902T3 (en) 2005-04-01
IL136556A0 (en) 2001-06-14
SI1512686T1 (en) 2007-02-28
KR20040011532A (en) 2004-02-05
US6194425B1 (en) 2001-02-27
RU2221798C2 (en) 2004-01-20
RU2314307C2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
EP1040112B1 (en) Imidazonaphthyridines and their use in inducing cytokine biosynthesis
US6518280B2 (en) Imidazonaphthyridines
EP1512685A1 (en) Imidazonaphthyridines and their use in inducing cytokine biosythesis
AU2002300982B2 (en) Imidazonaphthyridines and their use in inducing cytokine biosynthesis
IL170791A (en) Method of electromagnetically shielding buildings and bitumen panels useful therein
MXPA00005684A (en) Imidazonaphthyridines and their use in inducing cytokine biosynthesis
CZ20002158A3 (en) Imidazonaphthyridines and their use during induction of cytokine biosynthesis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 136556

Country of ref document: IL

Ref document number: 98813563.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2311456

Country of ref document: CA

Ref document number: 2311456

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 504776

Country of ref document: NZ

Ref document number: 19123/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 8352000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: P20000363A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/005684

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1998963888

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2000-2158

Country of ref document: CZ

Ref document number: 2000/01705

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020007006369

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 524286

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1998963888

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-2158

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007006369

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 19123/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998963888

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007006369

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 178092

Country of ref document: IL

Ref document number: 178091

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 50352007

Country of ref document: SK

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2007-268

Country of ref document: CZ